

10/519,722

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 19 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 20 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |
| NEWS X25 | X.25 communication option no longer available |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10/519,722

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:44:50 ON 29 SEP 2006

=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

| | |
|---------------------|------------------|
| SINCE FILE
ENTRY | TOTAL
SESSION |
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:44:58 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7
DICTIONARY FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10519722.str



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom 21:CLASS

22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

10/519,722

18:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 17: Limited
O,00
S,S0
N,N0-3

Node 18: Limited
O,00
S,S0
N,N1-2

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 13:45:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 336 TO ITERATE


100.0% PROCESSED 336 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5621 TO 7819
PROJECTED ANSWERS: 132 TO 668

L2 20 SEA SSS SAM L1

=> d scan
L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[(methyl-3-pyrrolidinylamino)methyl]- (9CI)
MF C29 H31 N7 O

PAGE 1-A



PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):19

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)
 MF C29 H31 N7 O . x C5 H8 O4

CM 1




CM 2

$\text{HO}_2\text{C} - (\text{CH}_2)_3 - \text{CO}_2\text{H}$

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(diethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI)
 MF C32 H35 F3 N8 O
 CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(dimethylamino)-1-piperidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
 MF C31 H33 F3 N8 O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI)
 MF C32 H33 F3 N6 O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monoacetate (9CI)
 MF C30 H33 N7 O . C2 H4 O2


CM 1



CM 2




L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)
 MF C30 H31 Br N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[4-chloro-3-[(1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)-(9CI)
 MF C29 H28 Cl F3 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (1:2)(9CI)
 MF C29 H31 N7 O . 1/2 C5 H8 O4

CM 1




CM 2

HO₂C-(CH₂)₃-CO₂H

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(2R,4S)-
 4-(dimethylamino)-2-methyl-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-
 (9CI)
 MF C31 H33 F3 N8 O
 CI COM


Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-(2-
 hydroxyethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI)
 MF C30 H31 F3 N8 O2
 CI COM


PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-((4,5'-bipyrimidin)-2-ylamino)-4-methylphenyl]-3-ethyl-4-
 [(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI)
 MF C30 H34 N8 O . Cl H



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]aminophenyl]- (9CI)
 MF C29 H31 N7 O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


10/519, 722

IN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI)
MF C26 H24 F3 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI)
MF C30 H31 F3 N8 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI)
MF C29 H31 N7 O . Cl H



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3-(dimethylamino)-1-azetidinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
 MF C29 H29 F3 N8 O . Cl H



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-6-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
 MF C29 H29 F3 N8 O . Cl H



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[(4-[(3-aminopropyl)amino]butyl)amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI)

MF C29 H31 N7 O . C17 H37 N7 O3


CI MXS

CM 1



CM 2


Absolute stereochemistry. Rotation (-).



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-3-nitro- (9CI)

MF C29 H30 N8 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful

FULL SEARCH INITIATED 13:45:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6526 TO ITERATE

100.0% PROCESSED 6526 ITERATIONS
SEARCH TIME: 00.00.01

325 ANSWERS

L3 325 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 13:46:03 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 2002 L3

=> l4 and (pyridine or pyrimidine or pyrazine or pyridazine)
L4 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.

10/519,722


For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 14 and (pyridine or pyridazine or pyrazine or pyrimidine)
211669 PYRIDINE
6728 PYRIDAZINE
12811 PYRAZINE
54368 PYRIMIDINE
L5 106 L4 AND (PYRIDINE OR PYRIDAZINE OR PYRAZINE OR PYRIMIDINE)

=> d 15 1-105 bib hitstr

L5 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:817911 CAPLUS
DN 145:249188
TI Preparation of tetrahydropyridothiophenes as antiproliferative agents for
the treatment of cancer
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,
Bjoern
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 158pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006084904 | A1 | 20060817 | WO 2006-EP50859 | 20060210 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI EP 2005-101007 | A | 20050211 | | |
| EP 2005-104493 | A | 20050525 | | |
| EP 2005-112159 | A | 20051214 | | |
| IT 152459-95-5, Imatinib | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (preparation of tetrahydropyridothiophenes as antiproliferative and
apoptosis-inducing agents useful in treatment of cancer) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



10/519,722


RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:817524 CAPLUS
DN 145:249187
TI Preparation of tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels, Bjoern
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 154pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006084869 | A1 | 20060817 | WO 2006-EP50782 | 20060208 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-100895 | A | 20050209 | | |
| | EP 2005-104488 | A | 20050525 | | |
| | EP 2005-112158 | A | 20051214 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of tetrahydropyridothiophenes with cell-cycle dependent,
antiproliferative and apoptosis-inducing activity useful in treatment
of hyperproliferative diseases such as cancer) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:768666 CAPLUS
DN 145:188880
TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and their preparation, pharmaceutical compositions and antiproliferative and

apoptosis inducing activity

IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra;
Beckers, Thomas; Schmidt, Mathias; Ciossek, Thomas; Nappe, Sandra

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 56pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006079644 | A1 | 20060803 | WO 2006-EP50465 | 20060126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-100594 | A | 20050128 | | |
| | EP 2005-100913 | A | 20050209 | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of indolopyridines, benzofuranopyridines, and
benzothienopyridines with antiproliferative and apoptosis inducing
activity) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768650 CAPLUS

DN 145:211060

TI Preparation of substituted phenylaminopyrimidines as B-Raf inhibitors

IN Aquila, Brian; Lyne, Paul; Pontz, Timothy

PA AstraZeneca AB, Swed.; AstraZeneca UK Limited

SO PCT Int. Appl., 59pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
| | | | | |

10/519,722

PI WO 2006079791 A1 20060803 WO 2006-GB223 20060124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI US 2005-646820P P 20050125

OS MARPAT 145:211060


IT 904326-67-6P 904326-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of substituted phenylaminopyrimidines as B-Raf inhibitors for
treating cancer)


RN 904326-67-6 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-
[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 904326-68-7 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(4-
methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768370 CAPLUS

DN 145:188879

TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and
their preparation, pharmaceutical compositions and antiproliferative and
apoptosis inducing activity

IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra
PA Altana Pharma AG, Germany


10/519,722

SO PCT Int. Appl., 61pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006079645 | A1 | 20060803 | WO 2006-EP50467 | 20060126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-100526 | A | 20050127 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of indolopyridines, benzofuranopyridines, and
benzothienopyridines with antiproliferative and apoptosis inducing
activity) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| L5 | ANSWER 6 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN | | | | |
|-----------|---|------|----------|-----------------|----------|
| AN | 2006:729704 CAPLUS | | | | |
| DN | 145:159791 | | | | |
| TI | 2-Phenylquinoxalines as inhibitors of MPP1 for treatment of proliferative diseases | | | | |
| IN | Nigg, Erich A.; Mayer, Thomas U.; Huemmer, Stefan; Barr, Francis; Bormann, Jenny | | | | |
| PA | Max-Planck-Gesellschaft Zur Foerderung der Wissenschaften e.v., Germany | | | | |
| SO | Eur. Pat. Appl., 20 pp. | | | | |
| | CODEN: EPXXDW | | | | |
| DT | Patent | | | | |
| LA | English | | | | |
| FAN.CNT 1 | | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| PI | EP 1683523 | A1 | 20060726 | EP 2005-1419 | 20050125 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, | | | | |

BA, HR, IS, YU
 WO 2006079478 A1 20060803 WO 2006-EP459 20060119
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM


PRAI EP 2005-1419 A 20050125
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination with; phenylquinoxalines as inhibitors of human
 phosphoprotein MPP1 for treatment of cancer and proliferative diseases)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:657352 CAPLUS
 DN 145:124614
 TI Multi-step process for preparing imatinib
 IN Huang, Anli; Xing, Liu; Zelikovitch, Lior; Kaspi, Joseph
 PA Peop. Rep. China
 SO U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI US 2006149061 | A1 | 20060706 | US 2005-318455 | 20051228 |
| PRAI US 2004-640013P | P | 20041230 | | |
| OS CASREACT 145:124614 | | | | |
| IT 152459-95-5P, Imatinib | | | | |
| RL: SPN (Synthetic preparation); PREP (Preparation)
(multi-step process for preparing imatinib) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:655575 CAPLUS

DN 145:124558

TI Preparation of pyrazolyl phenyl ureas as enzyme modulators

IN Flynn, Daniel L.; Petillo, Peter A.

PA Deciphera Pharmaceuticals, LLC, USA

SO PCT Int. Appl., 974 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006071940 | A2 | 20060706 | WO 2005-US47270 | 20051223 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-638968P | P | 20041223 | | |
| | US 2004-638986P | P | 20041223 | | |
| | US 2004-638987P | P | 20041223 | | |
| | US 2004-639087P | P | 20041223 | | |
| OS | MARPAT 145:124558 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of pyrazolyl Ph ureas as enzyme modulators for
treating cancer and hyperproliferative diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[{4-methyl-1-piperazinyl}methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2


CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:513267 CAPLUS
 DN 145:21160
 TI Methods and compositions for the treatment of graft failure
 IN Sukhatme, Vikas P.
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|--|-----------------|----------|
| PI WO 2006057951 | A2 | 20060601 | WO 2005-US42111 | 20051121 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | |
| PRAI US 2004-630242P | P | 20041122 | | |
| IT 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | |
| | (compns. for treatment of graft failure) | | | |
| RN 220127-57-1 | CAPLUS | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S




L5 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:463553 CAPLUS
DN 144:488677
TI Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2006106023 | A1 | 20060518 | US 2005-272392 | 20051110 |
| | US 2004063715 | A1 | 20040401 | US 2003-665005 | 20030919 |
| | US 6919341 | B2 | 20050719 | | |
| | US 2005130980 | A1 | 20050616 | US 2005-47524 | 20050131 |
| PRAI | US 2002-412997P | P | 20020923 | | |
| | US 2003-665005 | A3 | 20030919 | | |
| | US 2005-47524 | A2 | 20050131 | | |
| OS | MARPAT 144:488677 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O


CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:412038 CAPLUS
 DN 144:450735
 TI Preparation of novel aminopyridine derivatives having selective Aurora-A protein kinase inhibitory effect
 IN Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi;
 Shimomura, Toshiyasu
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006046734 | A2 | 20060504 | WO 2005-JP19957 | 20051025 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006106029 | A1 | 20060518 | US 2005-258447 | 20051025 |
| PRAI | JP 2004-315152 | A | 20041029 | | |
| | JP 2005-161156 | A | 20050601 | | |


US 2005-692537P P 20050621
 OS MARPAT 144:450735
 IT 152459-95-5, Imatinib
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (novel aminopyridine derivs. having selective Aurora-A inhibitory
 effect)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:372184 CAPLUS
 DN 145:34047
 TI Anticancer implant compositions containing vasoinhibitor/
 pyrimidine derivative composite implant
 IN Kong, Qingzhong; Sun, Juan; Liu, Enxiang
 PA Peop. Rep. China
 SO Faming Zhanli Shengqing Gongkai Shuomingshu, 18 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| PI CN 1733300 | A | 20060215 | CN 2005-10044377 | 20050805 |
| PRAI CN 2005-10044377 | | 20050805 | | |
| IT 220127-57-1, Imatinib mesylate | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(vasoinhibitor/pyrimidine derivative antitumor composite implant) | | | | |
| RN 220127-57-1 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:333442 CAPLUS

DN 144:370121

TI Preparation of pyrimidine derivatives as phosphatase and kinase inhibitors for treating a variety of diseases

IN Klebl, Bert; Baumann, Matthias; Hoppe, Edmund; Brehmer, Dirk; Daub, Henrik; Keri, Gyoergy; Varga, Zoltan; Marosfalvi, Jenoe; Oerfi, Laszlo

PA GPC Biotech A.-G., Germany

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006021458 | A2 | 20060302 | WO 2005-EP9291 | 20050829 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2004-604685P P 20040827


OS MARPAT 144:370121

IT 152459-93-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 152459-95-5P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 475587-66-7P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-2-yl)pyrimidin-2-yl)amino]phenyl]benzamide 872672-74-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-2-yl)pyrimidin-2-yl)amino]phenyl]benzamide 881676-19-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-4-yl)pyrimidin-2-yl)amino]phenyl]benzamide 881677-62-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-4-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrimidine derivs. as phosphatase and kinase inhibitors for treating a variety of diseases)

RN 152459-93-3 CAPLUS


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-66-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 872672-74-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 881676-19-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 881677-62-9 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[(4-(4-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:333345 CAPLUS

DN 144:350709

TI Pyrazolopyrimidines as protein kinase B inhibitors, their preparation, pharmaceutical compositions, and use in therapy

IN Maier, Thomas; Zuelch, Armin; Ciossek, Thomas; Baer, Thomas; Beckers, Thomas

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006027346 | A2 | 20060316 | WO 2005-EP54366 | 20050905 |
| | WO 2006027346 | A3 | 20060803 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI EP 2004-104283 A 20040906

OS MARPAT 144:350709


IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel pyrazolopyrimidine compds. useful in therapy of hyper-proliferative diseases and disorders responsive to induction of apoptosis)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318488 CAPLUS

DN 144:369909

TI Preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors

IN Bold, Guido; Caravatti, Giorgio; Floersheimer, Andreas; Furet, Pascal; Manley, Paul W.; Pissot Soldermann, Carole; Vaupel, Andrea

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|-----------------|----------|
| PI | WO 2006034833 | A1 | 20060406 | WO 2005-EP10408 | 20050927 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | GB 2004-21525 | A | 20040928 | | |
| OS | MARPAT | 144:369909 | | | |
| IT | 220127-57-1, Glivec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed drug for co-administration; preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2.


CRN 75-75-2
CMF C H₄ O₃ SRE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:196073 CAPLUS
 DN 144:274310
 TI Preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use
 IN Wrasidlo, Wolfgang; Dneprovskaia, Elena
 PA Targegen, Inc., USA
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006024034 | A1 | 20060302 | WO 2005-US30614 | 20050824 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006079526 | A1 | 20060413 | US 2005-212064 | 20050824 |
| PRAI | US 2004-604298P | P | 20040825 | | |
| | US 2005-696168P | P | 20050701 | | |
| OS | MARPAT 144:274310 | | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use) | | | | |

10/519,722

RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:176834 CAPLUS

DN 144:370108

TI Preparation and application of phenylamino pyrimidine derivatives

IN Chen, Guoqing

PA Chen Guoqing, Peop. Rep. China

SO Faming Zhanli Shenqing Gongkai Shuomingshu, 41 pp.

CODEN: CNXXEV

DT Patent


LA Chinese

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | CN 1560050 | A | 20050105 | CN 2004-10014093 | 20040218 |
| PRAI | CN 2004-10014093 | | 20040218 | | |
| IT | 791609-82-0P 791609-84-2P 791609-85-3P
882166-67-8P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and application of phenylamino pyrimidine derivs.) | | | | |
| RN | 791609-82-0 CAPLUS | | | | |
| CN | Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |

10/519, 722

PAGE 1-A




PAGE 2-A




RN 791609-84-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[[[(1-methyl-3-pyrrolidinyl)amino]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-85-3 CAPLUS


CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



RN 882166-67-8 CAPLUS

CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(methyl-3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

|
Me

L5 ANSWER 18 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:167936 CAPLUS
 DN 144:254145
 TI Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.
 PA Schering Corporation, USA
 SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2006041131 | A1 | 20060223 | US 2005-244772 | 20051006 |
| | US 2004106624 | A1 | 20040603 | US 2003-653776 | 20030903 |
| | US 7067661 | B2 | 20060627 | | |
| | US 2006178371 | A1 | 20060810 | US 2006-395676 | 20060331 |
| PRAI | US 2002-408029P | P | 20020904 | | |
| | US 2003-653776 | A2 | 20030903 | | |
| OS | MARPAT 144:254145 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (preparation of novel pyrazolopyrimidines as cyclin dependent kinase | | | | |

10/519,722

inhibitors for treatment and prevention of diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:167588 CAPLUS

DN 144:254148

TI Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy

IN Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2006018182 | A1 | 20060223 | WO 2005-EP8623 | 20050809 |
| | WO 2006018182 | C1 | 20060608 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, | | | |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 2006058311 A1 20060316 US 2005-189540 20050726

PRAI EP 2004-19361 A 20040814
EP 2004-19448 A 20040817


OS MARPAT 144:254148

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for
treatment of cell proliferative diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:117065 CAPLUS

DN 144:184657

TI Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide

IN Breedveld, Pauline; Cipriani, Greta; Pluim, Dick; Schellens, Johannes Henricus Matthias; Van Tellingen, Olaf; Wielinga, Pieter Roeland

PA The Netherlands Cancer Institute, Neth.

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006012958 | A2 | 20060209 | WO 2005-EP7090 | 20050630 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2004-584825P P 20040701

IT 152459-95-5 220127-57-1


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

10/519,722

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 874946-80-2 874946-81-3 874946-82-4

874946-83-5 874946-84-6 874946-85-7

875128-64-6 875128-67-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)


RN 874946-80-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 102625-70-7
CMF C16 H15 F2 N3 O4 S




RN 874946-81-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with (3S,8aS)-hexahydro-3-[[6-methoxy-2-(3-methyl-2-but enyl)-1H-indol-3-yl]methyl]pyrrolo[1,2-a]pyrazine-1,4-dione (9CI) (CA INDEX NAME)

CM 1


CRN 171864-80-5
CMF C22 H27 N3 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 152459-95-5
CMF C29 H31 N7 O



RN 874946-82-4 CAPLUS
 CN Benzamide, 4-[4-methyl-1-piperazinyl]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with (5aS,12S,14aS)-1,2,3,5a,6,11,12,14a-octahydro-9-methoxy-12-(2-methyl-1-propenyl)-5H,14H-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,14-dione (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 118974-02-0
CMF C22 H25 N3 O3

Absolute stereochemistry.




RN 874946-83-5 CAPLUS
 CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid, 1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxo-, 1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[4-methyl-1-piperazinyl]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 461054-93-3
CMF C26 H35 N3 O5

10/519,722


Absolute stereochemistry. Rotation (-).



CM 2

CRN 152459-95-5

CMF C29 H31 N7 O




RN 874946-84-6 CAPLUS

CN 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 143664-11-3

CMF C34 H33 N3 O5



||
O


RN 874946-85-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 289499-45-2

CMF C₂₄ H₂₅ Cl F N₅ O₃ . 2 Cl H


10/519,722



●2 HCl

CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




RN 875128-64-6 CAPLUS
CN Carbamic acid, [4-[(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl]butyl]-, 1,1-dimethylethyl ester, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 329356-42-5
CMF C27 H38 N4 O4


Absolute stereochemistry.



10/519,722

CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




RN 875128-67-9 CAPLUS

CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid,
1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxo-,
1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-
pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 329356-45-8
CMF C25 H33 N3 O4

Absolute stereochemistry.



CM 2

CRN 152459-95-5
CMF C29 H31 N7 O



L5 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN


AN 2006:87941 CAPLUS

DN 144:331390

TI Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors


AU Asaki, Tetsuo; Sugiyama, Yukiteru; Hamamoto, Taisuke; Higashioka, Masaya;

CS Umehara, Masato; Naito, Haruna; Niwa, Tomoko
 Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Minami-ku,
 Kyoto, Kisshoin, 601-8550, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1421-1425
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:331390
 IT 641614-88-2P 859212-07-0P 859212-16-1P, NS-187
 859212-47-8P 859212-49-0P 859212-51-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation N-[[(bipyrimidinyl)amino](methyl)phenyl](trifluoromethyl)benzamide
 deriva. and study of their activity as Bcr-Abl kinase inhibitors)
 RN 641614-88-2 CAPLUS
 CN Benzamide, N-[3-[(4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-
 methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 859212-07-0 CAPLUS
 CN Benzamide, N-[3-[(4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3R)-3-
 (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 859212-16-1 CAPLUS

10/519,722


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859212-47-8 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(dimethylamino)-1-azetidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 859212-49-0 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3R)-3-[(dimethylamino)methyl]-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 859212-51-4 CAPLUS
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-[(dimethylamino)methyl]-1-pyrrolidinylmethyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 641614-83-7P 641614-84-8P 641614-85-9P


641614-86-0P 641614-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation halo[(piperazinyl)methyl][methyl[(pyridinyl)pyrimidinyl]amino]phenylbenzamide derivs. and study of their activity as Bcr-Abl kinase inhibitors)

10/519,722


RN 641614-83-7 CAPLUS
CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-84-8 CAPLUS
CN Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS
CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-86-0 CAPLUS
CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-87-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 220127-57-1, STI-571

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation substituted benzamide derivs., study of their activity as gene
 Bcr-Abl fusion protein- phosphorylating kinase (Bcr-Abl kinase)
 inhibitors and their activity against STI-571-resistant chronic myeloid
 leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:15086 CAPLUS

DN 144:108347

TI Preparation of pyrimidine urea derivatives as kinase inhibitors
 for use against proliferative diseases

IN Ding, Qiang; Gray, Nathanael Schiander; Li, Bing; Liu, Yi; Sim, Taebo;
 Uno, Tetsuo; Zhang, Guobao; Pissot Soldermann, Carole; Breitenstein,
 Werner; Bold, Guido; Caravatti, Giorgio; Furet, Pascal; Guagnano, Vito;
 Lang, Marc; Manley, Paul W.; Schoepfer, Joseph; Spanka, Carsten

10/519,722

PA Novartis AG, Switz.
SO PCT Int. Appl., 327 pp.
CODEN: PIXXD2

DT Patent
LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006000420 | A1 | 20060105 | WO 2005-EP6815 | 20050623 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-582425P | P | 20040624 | | |
| | GB 2005-12324 | A | 20050616 | | |
| OS | MARPAT 144:108347 | | | | |
| IT | 220127-57-1, Glivec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of pyrimidine urea derivs. as kinase
inhibitors for use against proliferative diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1329776 CAPLUS
DN 144:45462
TI Pharmacologically active substances in combination with radio waves for
the treatment of cancer
IN Kalbe, Jochen; Ludwig, Georg
PA Germany
SO PCT Int. Appl., 30 pp.
CÖDEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|----------------------|----------|
| PI | WO 2005120638 | A1 | 20051222 | WO 2005-DE1028 | 20050609 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | DE 102004028156 | A1 | 20060105 | DE 2004-102004028156 | 20040609 |
| PRAI | DE 2004-102004028156 A | | 20040609 | | |
| | US 2004-585061P | P | 20040706 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug-radio wave combination for treatment of cancer) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1289902 CAPLUS
DN 144:17212
TI Use of c-kit inhibitors for treating fibrodysplasia
IN Moussy, Alain; Kinet, Jean-Pierre
PA Ab Science, Fr.
SO PCT Int. Appl., 66 pp.
CÖDEN: PIXXD2


10/519,722

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|--|-----------------|----------|
| PI | WO 2005115304 | A2 | 20051208 | WO 2005-IB1371 | 20050419 |
| | WO 2005115304 | A3 | 20060406 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| PRAI | US 2004-573345P | P | 20040524 | | |
| OS | MARPAT 144:17212 | | | | |
| IT | 152459-95-5 | | | | |
| | | RL: | PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | |
| | | | (c-kit inhibitors for treating fibrodysplasia) | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1289861 CAPLUS

DN 144:17211

TI Use of c-kit inhibitors for treating acne

IN Moussy, Alain; Kinet, Jean-Pierre

PA Ab Science, Fr.

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|--|-----------------|----------|
| PI | WO 2005115385 | A1 | 20051208 | WO 2005-IB1366 | 20050419 |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | | |

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRAI US 2004-573351P P 20040524

OS MARPAT 144:17211


IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(c-kit inhibitors for treating acne)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1262399 CAPLUS

DN 144:22712

TI Triaryl compounds as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

IN Epple, Robert; Azimioara, Mihai

PA Irm LLC, Bermuda

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005113506 | A1 | 20051201 | WO 2005-US16747 | 20050513 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRAI US 2004-571004P P 20040514

OS MARPAT 144:22712


IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(preparation of triaryl compds. as PPAR modulators and their use for treatment and prevention of diseases associated with PPAR δ activity)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1239173 CAPLUS
 DN 143:477963
 TI Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer
 IN Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|---|----------|
| PI | WO 2005110994 | A2 | 20051124 | WO 2005-US15106 | 20050502 |
| | WO 2005110994 | A3 | 20060202 | | |
| | | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | |
| PRAI | US 2004-566445P | P | 20040430 | | |
| OS | MARPAT 143:477963 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(substituted pyrazolylurea derivs. useful for cancer treatment) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1170688 CAPLUS
 DN 143:432622
 TI Use of c-kit inhibitors for treating HIV-related diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005102318 | A1 | 20051103 | WO 2005-IB1433 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| PRAI | US 2004-563442P | P | 20040420 | | |
| OS | MARPAT 143:432622 | | | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treatment of HIV-related diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170667 CAPLUS

DN 143:432692

TI Use of c-kit inhibitors for treating fibrosis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 67 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------------|----------|---|----------|
| PI | WO 2005102346 | A2 | 20051103 | WO 2005-IB1391 | 20050419 |
| | WO 2005102346 | A3 | 20060330 | | |
| | | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | |
| PRAI | US 2004-564569P | P | 20040423 | | |
| OS | MARPAT | 143:432692 | | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treatment of fibrosis) | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




L5 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1170651 CAPLUS

DN 143:432621
 TI Use of c-kit inhibitors for treating plasmodium-related diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA Ab Science, Fr.
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005102455 | A1 | 20051103 | WO 2005-IB1390 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| PRAI | US 2004-564599P | P | 20040423 | | |
| OS | MARPAT 143:432621 | | | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treating plasmodium-related diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1170633 CAPLUS
 DN 143:432657
 TI Use of c-kit inhibitors for treating renal diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2005102326 | A2 | 20051103 | WO 2005-IB1370 | 20050419 |
| | WO 2005102326 | A3 | 20060330 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
 SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
 ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRAI US 2004-564586P P 20040423


OS MARPAT 143:432657

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (c-kit inhibitors for treatment of renal disease)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170607 CAPLUS

DN 143:432650

TI Use of c-kit inhibitors for treating inflammatory muscle disorders
 including myositis and muscular dystrophy

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005102325 | A1 | 20051103 | WO 2005-IB1367 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | PRAI US 2004-563460P | P | 20040420 | | |
| OS | MARPAT 143:432650 | | | | |


IT 152459-95-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (c-kit inhibitors for treatment of inflammatory muscle disorders
 including myositis and muscular dystrophy)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1006008 CAPLUS
 DN 143:260361
 TI Leptomycin B combination with chemotherapeutic agents for the treatment of proliferative diseases
 IN Santi, Daniel V.; Zhou, Yiqing
 PA Kosan Biosciences, Inc., USA
 SO U.S. Pat. Appl. Publ., 4 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI US 2005203174 | A1 | 20050915 | US 2005-58447 | 20050214 |
| WO 2005086944 | A2 | 20050922 | WO 2005-US8124 | 20050309 |
| WO 2005086944 | A3 | 20051215 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| PRAI US 2004-551970P | P | 20040309 | | |
| US 2005-58447 | A | 20050214 | | |
| IT 152459-95-5, Imatinib | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (leptomycin B combination with chemotherapeutic agents for treatment of proliferative diseases) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:823686 CAPLUS
 DN 143:216705
 TI Preparation of salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide (imatinib)
 IN Buerger, Hans Michael; Manley, Paul William; Mutz, Michael
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|---|----------|-----------------|----------|
| PI | WO 2005075454 | A2 | 20050818 | WO 2005-EP1077 | 20050203 |
| | WO 2005075454 | A3 | 20060727 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | AU 2005211514 | A1 | 20050818 | AU 2005-211514 | 20050203 |
| PRAI | US 2004-541817P | P | 20040204 | | |
| | WO 2005-EP1077 | W | 20050203 | | |
| IT | 152459-95-5DP, Imatinib, salts | 862366-24-3P
862366-25-4P 862366-26-5P 862366-27-6P
862366-28-7P 862366-30-1P 862366-31-2P
862366-32-3P 862366-33-4P 862366-34-5P
862366-35-6P 862366-36-7P 862366-37-8P
862366-38-9P 862366-39-0P 862366-40-3P
862366-41-4P 862366-42-5P 862366-43-6P
862366-44-7P 862366-45-8P 862366-46-9P
862366-47-0P 862366-48-1P 862366-49-2P
862366-50-5P 862366-51-6P | | | |
| | RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of salt forms of imatinib) | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 862366-24-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.

RN 862366-25-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 862366-26-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 862366-27-6 CAPLUS

CN Butanedioic acid, hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 862366-28-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 862366-30-1 CAPLUS

CN Butanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 862366-31-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 862366-32-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 98-11-3
CMF C6 H6 O3 S



RN 862366-33-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-
pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 130-85-8
CMF C23 H16 O6




RN 862366-34-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 69-72-7

CMF C7 H6 O3




RN 862366-35-6 CAPLUS

CN Benzoic acid, 4-hydroxy-3-methoxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 121-34-6
CMF C8 H8 O4




RN 862366-36-7 CAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)
(9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S




RN 862366-37-8 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2)
(9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 110-94-1
CMF C5 H8 O4

HO₂C—(CH₂)₃—CO₂H

RN 862366-38-9 CAPLUS
CN Propanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 141-82-2
CMF C3 H4 O4

HO₂C—CH₂—CO₂H


RN 862366-39-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 862366-40-3 CAPLUS

CN Hexanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 124-04-9

CMF C6 H10 O4

HO₂C—(CH₂)₄—CO₂H


RN 862366-41-4 CAPLUS

CN Benzeneacetic acid, α -hydroxy-, (α R)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

10/519,722


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 611-71-2
CMF C8 H8 O3


Absolute stereochemistry. Rotation (-).



RN 862366-42-5 CAPLUS
CN Butanedioic acid, hydroxy-, (2R)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 636-61-3
CMF C4 H6 O5

Absolute stereochemistry.




RN 862366-43-6 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2S,3S)-2,3-dihydroxybutanedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.




RN 862366-44-7 CAPLUS

CN Formic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-
[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA
INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

10/519,722


RN 862366-45-8 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




RN 862366-46-9 CAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 862366-47-0 CAPLUS

CN Propanoic acid, 2-hydroxy-, (2S)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 79-33-4

CMF C3 H6 O3

Absolute stereochemistry. Rotation (+).




RN 862366-48-1 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

10/519,722


CRN 110-94-1
CMF C5 H8 O4



RN 862366-49-2 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, compd. with 3,4-dihydroxy-3-cyclobutene-1,2-dione (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 2892-51-5
CMF C4 H2 O4



RN 862366-50-5 CAPLUS
CN Butanedioic acid, oxo-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



10/519,722

CM 2


CRN 328-42-7
CMF C4 H4 O5



RN 862366-51-6 CAPLUS
CN L-Ascorbic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O




CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.




IT 152459-95-5, Imatinib
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of salt forms of imatinib)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:729564 CAPLUS
 DN 143:186693
 TI Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
 IN Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene
 PA Emory University, USA
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005072826 | A2 | 20050811 | WO 2005-US1710 | 20050120 |
| | WO 2005072826 | A3 | 20060420 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | AU 2005209231 | A1 | 20050811 | AU 2005-209231 | 20050120 |
| | CA 2554201 | AA | 20050811 | CA 2005-2554201 | 20050120 |
| PRAI | US 2004-537960P | P | 20040121 | | |
| | US 2004-553681P | P | 20040316 | | |
| | US 2004-614203P | P | 20040929 | | |
| | WO 2005-US1710 | W | 20050120 | | |
| OS | MARPAT 143:186693 | | | | |
| IT | 152459-95-5 152459-95-5D, derivs. 220127-57-1,
Imatinib mesylate 220127-57-1D, Imatinib mesylate, derivs.
593281-61-9, STI-X 593281-61-9D, derivs. | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (tyrosine kinase inhibitors for treatment of pathogenic infection) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 593281-61-9 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 593281-61-9 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:567125 CAPLUS
DN 143:90993
TI Combination of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one

hypusination inhibitor for the treatment of proliferative diseases,
including leukemia

IN Bruemmendorf, Tim H.; Balabanov, Stefan; Hartmann, Ulrike; Kammer,
Winfried; Nordheim, Alfred

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.


SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|-----------------------|-------------|-----------------|----------|
| PI | WO 2005058320 | A1 | 20050630 | WO 2004-EP14439 | 20041217 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | AU 2004298761 | A1 | 20050630 | AU 2004-298761 | 20041217 |
| | CA 2547196 | AA | 20050630 | CA 2004-2547196 | 20041217 |
| | EP 1696917 | A1 | 20060906 | EP 2004-804040 | 20041217 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| PRAI | US 2003-531563P | P | 20031219 | | |
| | WO 2004-EP14439 | W | 20041217 | | |
| IT | 152459-95-5 220127-57-1 | 855843-70-8 | | | |
| | 855843-71-9 | 855843-72-0 | 855843-73-1 | | |
| | 855843-74-2 | 855843-75-3 | 855843-76-4 | | |
| | 855843-77-5 | 855843-78-6 | 855843-79-7 | | |
| | 855843-80-0 | 855843-81-1 | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- | (9CI) (CA INDEX NAME) | | | |




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 855843-70-8 CAPLUS
CN Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 70-51-9
CMF C25 H48 N6 O8

PAGE 1-A



— (CH₂)₅—NH₂


RN 855843-71-9 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C₂₉ H₃₁ N₇ O



CM 2

CRN 29342-05-0

CMF C₁₂ H₁₇ N O₂




RN 855843-72-0 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C₂₉ H₃₁ N₇ O



CM 2

CRN 89149-10-0
CMF C17 H37 N7 O3


Absolute stereochemistry. Rotation (-).




RN 855843-73-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 30652-11-0
CMF C7 H9 N O2

10/519,722


RN 855843-74-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 150333-69-0

CMF C8 H20 N4



RN 855843-75-3 CAPLUS


CN Butanediamide, N'-[5-[[4-[(5-acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 70-51-9

CMF C25 H48 N6 O8

PAGE 1-A



PAGE 1-B




CM 2

10/519,722

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4


CRN 75-75-2
CMF C H4 O3 S



RN 855843-76-4 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 29342-05-0
CMF C12 H17 N O2




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S

CM 3


10/519, 722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4

CRN 75-75-2
CMF C H4 O3 S




RN 855843-77-5 CAPLUS

CN Benzamide, 4-[{4-methyl-1-piperazinyl}methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[(4-[(3-aminopropyl)amino]butyl)amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 89149-10-0
CMF C17 H37 N7 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4


CRN 75-75-2
CMF C H4 O3 S



RN 855843-78-6 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 30652-11-0
CMF C7 H9 N O2




CM 2


CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5
CMF C29 H31 N7 O




CM 4

CRN 75-75-2
CMF C H4 O3 S

RN 855843-79-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)


CM 1

CRN 150333-69-0
CMF C8 H20 N4

CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O

CM 4

10/519,722


CRN 75-75-2
CMF C H4 O3 S



RN 855843-80-0 CAPLUS
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 201530-41-8
CMF C21 H15 N3 O4



CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




RN 855843-81-1 CAPLUS
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 201530-41-8
CMF C21 H15 N3 O4




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722


AN 2005:369277 CAPLUS
DN 142:430271
TI Preparation of substituted benzazoles as inhibitors of raf kinase
IN Ramurthy, Savithri; Subramanian, Sharadha; Verhagen, Joelle; Poon, Daniel
J.; Hansen, Teresa; Shafer, Cynthia; McBride, Christopher; Levine, Barry
H.; Costales, Abran; Renhowe, Paul A.

PA Chiron Corporation, USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------------|----------|-----------------|----------|
| PI | WO 2005037273 | A1 | 20050428 | WO 2004-US34179 | 20041015 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004281151 | A1 | 20050428 | AU 2004-281151 | 20041015 |
| | CA 2542653 | AA | 20050428 | CA 2004-2542653 | 20041015 |
| | US 2005192287 | A1 | 20050901 | US 2004-967089 | 20041015 |
| | EP 1682126 | A1 | 20060726 | EP 2004-795357 | 20041015 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-511966P | P | 20031016 | | |
| | WO 2004-US34179 | W | 20041015 | | |
| OS | MARPAT | 142:430271 | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of substituted benzazoles as
inhibitors of raf kinase) | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:369221 CAPLUS
DN 142:430024
TI Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and
analogs as activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc

PA Cytovia, Inc., USA
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005037196 | A2 | 20050428 | WO 2004-US32570 | 20041005 |
| | WO 2005037196 | A3 | 20051013 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| PRAI | US 2003-508290P | P | 20031006 | | |
| OS | MARPAT 142:430024 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 2-arylmethylene-N,N'-diarylmalonamides
and analogs as activators of caspases and inducers of apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2


CMF C H4 O3 S



L5 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:324144 CAPLUS
 DN 142:392431
 TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation
 IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia;
 Liu, Yi; Schoepfer, Joseph; Steensma, Ruu
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005033086 | A1 | 20050414 | WO 2004-US32473 | 20040930 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004278413 | A1 | 20050414 | AU 2004-278413 | 20040930 |
| | CA 2539339 | AA | 20050414 | CA 2004-2539339 | 20040930 |
| | US 2005171105 | A1 | 20050804 | US 2004-956412 | 20040930 |
| | EP 1670771 | A1 | 20060621 | EP 2004-789483 | 20040930 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-507592P | P | 20030930 | | |
| | WO 2004-US32473 | W | 20040930 | | |
| OS | MARPAT 142:392431 | | | | |
| IT | 850087-62-6P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide
850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide
850087-74-0P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-(pyrimidin-4-yl)phenyl]amino]phenyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors) | | | | |
| RN | 850087-62-6 CAPLUS | | | | |
| CN | Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)
(CA INDEX NAME) | | | | |

PAGE 1-A




PAGE 1-B

Me

RN 850087-68-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[(4-trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 850087-74-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-(4-pyrimidinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:323779 CAPLUS
 DN 142:397824
 TI Biocompatibly coated medical implants
 IN Rathenow, Jorg; Ban, Andreas; Kunstmann, Jurgen; Mayer, Bernhard; Asgari, Soheil
 PA Germany
 SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of Appl. No. PCT/EP04/04985.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|--|----------|
| PI | US 2005079200 | A1 | 20050414 | US 2004-938995 | 20040910 |
| | DE 10322182 | A1 | 20041202 | DE 2003-10322182 | 20030516 |
| | DE 10324415 | A1 | 20041216 | DE 2003-10324415 | 20030528 |
| | DE 10333098 | A1 | 20050210 | DE 2003-10333098 | 20030721 |
| | WO 2004101017 | A2 | 20041125 | WO 2004-EP4985 | 20040510 |
| | WO 2004101017 | A3 | 20050303 | | |
| | | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | |
| PRAI | DE 2003-10322182 | A | 20030516 | | |
| | DE 2003-10324415 | A | 20030528 | | |
| | DE 2003-10333098 | A | 20030721 | | |
| | WO 2004-EP4985 | A2 | 20040510 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (biocompatibly coated medical implants) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:158528 CAPLUS

DN 142:254620

TI Use of c-kit inhibitors for treating type II diabetes

IN Moussy, Alain; Kinet, Jean-Pierre

PA Ab Science, Fr.

SO PCT Int. Appl., 126 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005016323 | A2 | 20050224 | WO 2004-IB2934 | 20040816 |
| | WO 2005016323 | A3 | 20050407 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | CA 2535242 | AA | 20050224 | CA 2004-2535242 | 20040816 |
| | EP 1653934 | A2 | 20060510 | EP 2004-769332 | 20040816 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-495088P | P | 20030815 | | |
| | WO 2004-IB2934 | W | 20040816 | | |
| OS | MARPAT 142:254620 | | | | |
| IT | 152459-95-5P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (c-kit inhibitor; use of potent, selective and non-toxic c-kit inhibitors for treating type diabetes, obesity and related diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




L5 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:99470 CAPLUS
 DN 142:197889
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf,
 VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
 IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005009961 | A2 | 20050203 | WO 2004-US23500 | 20040722 |
| | WO 2005009961 | A3 | 20050331 | | |
| | WO 2005009961 | B1 | 20050602 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004259760 | A1 | 20050203 | AU 2004-259760 | 20040722 |
| | CA 2532865 | AA | 20050203 | CA 2004-2532865 | 20040722 |
| | US 2005038080 | A1 | 20050217 | US 2004-895985 | 20040722 |
| | EP 1663978 | A2 | 20060607 | EP 2004-786091 | 20040722 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | NO 2006000870 | A | 20060407 | NO 2006-870 | 20060222 |
| PRAI | US 2003-489102P | P | 20030723 | | |
| | US 2004-540326P | P | 20040202 | | |
| | WO 2004-US23500 | W | 20040722 | | |
| IT | 220127-57-1, STI-571 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph
urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated
diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |


10/519,722

CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S




L5 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:17705 CAPLUS
DN 142:148113
TI Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations
AU Wong, S.; McLaughlin, J.; Cheng, D.; Zhang, C.; Shokat, K. M.; Witte, O. N.
CS Molecular Biology Interdepartmental Ph.D. Program, University of California, Los Angeles, CA, 90095, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2004), 101(50), 17456-17461
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1127387 CAPLUS
 DN 142:74600
 TI Heteroaryl-fused pyrimidinyl compounds, including thieno[3,2-d]pyrimidine derivatives, with KSP-inhibiting activity, and their preparation, pharmaceutical compositions, and use as anticancer agents
 IN Wang, Weibo; Lagniton, Liana M.; Constantine, Ryan N.; Burger, Matthew T.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2004111058 | A1 | 20041223 | WO 2004-US16954 | 20040527 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | US 2005065169 | A1 | 20050324 | US 2004-850429 | 20040521 |
| | AU 2004247650 | A1 | 20041223 | AU 2004-247650 | 20040527 |
| | CA 2526217 | AA | 20041223 | CA 2004-2526217 | 20040527 |
| | EP 1636238 | A1 | 20060322 | EP 2004-753729 | 20040527 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | CN 1798749 | A | 20060705 | CN 2004-80014819 | 20040527 |
| PRAI | US 2003-474684P | P | 20030530 | | |

10/519,722

WO 2004-US16954 W 20040527


OS MARPAT 142:74600

IT 152459-95-5, Imatinib 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic coadministration with; preparation of thieno[3,2-d]pyrimidine derivs. as KSP inhibitors for use as anticancer agents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1080793 CAPLUS

DN 142:32971


TI Methods and compounds for the treatment of vascular stenosis using a combination of N-phenyl-2-pyrimidine derivatives and PI3K

inhibitors
 IN Sukhatme, Vikas P.
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004108130 | A1 | 20041216 | WO 2004-US17273 | 20040601 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | CA 2528032 | AA | 20041216 | CA 2004-2528032 | 20040601 |
| | EP 1635815 | A1 | 20060322 | EP 2004-753981 | 20040601 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-475295P | P | 20030603 | | |
| | WO 2004-US17273 | W | 20040601 | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (Imatinib mesylate; methods and compds. for treatment of vascular
stenosis using combination of N-phenyl-2-pyrimidine derivs.
and PI3K inhibitors) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


- LS ANSWER 46 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1060780 CAPLUS
 DN 142:38275
 TI Preparation of N-phenyl-2-pyrimidine-amine derivatives as anticancer agents and process for the preparation thereof
 IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-Chul; Lee, Sun-Ahe; Han, Byoung-Cheol
 PA Il Yang Pharm. Co., Ltd., S. Korea
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 446,446, abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3
- | | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004248918 | A1 | 20041209 | US 2004-806834 | 20040322 |
| PRAI | KR 2003-28669 | A | 20030506 | | |
| | US 2003-446446 | B2 | 20030528 | | |
| OS | MARPAT 142:38275 | | | | |
| IT | 796738-20-0P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-23-3P, 4-[4-Methylhomopiperazin-1-ylamino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-25-5P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-28-8P, 4-[4-Methylhomopiperazin-1-ylaminomethyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-32-4P
, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P, 4-[4-Methylhomopiperazin-1-ylaminomethyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-40-4P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-42-6P, 4-[4-Methylhomopiperazin-1-ylaminomethyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P
, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,
4-[4-Methylhomopiperazin-1-ylmethyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P, 4-[4-Methylhomopiperazin-1-ylaminomethyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
804554-75-4P, 4-[4-Methylhomopiperazin-1-ylmethyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
804554-76-5P, 4-[(4-Methylhomopiperazin-1-ylamino)methyl]-N-[4-methyl- | | | | |

3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-77-6P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-78-7P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[2-methyl-
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-80-1P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-81-2P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-84-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-85-6P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[4-methoxy-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-86-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-87-8P, 4-[(4-Methylpipеразин-1-ylmethyl)-N-[2-fluoro-5-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-88-9P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[2-fluoro-
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-90-3P, 4-(4-Methylpipеразин-1-ylmethyl)-N-[4-fluoro-3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-91-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-92-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-
 yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-94-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-95-8P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[4-methyl-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-98-1P, 4-[(4-Methylpipеразин-1-ylamino)methyl]-N-[4-methyl-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-
 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-23-3 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-25-5 CAPLUS

CN Benzamide, 4-[{(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl}-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[{(4-methyl-1-piperazinyl)amino}methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-32-4 CAPLUS


CN Benzamide, 4-[{(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl}-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-34-6 CAPLUS


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 796738-44-8 CAPLUS


CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



10/519,722


RN 796738-47-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS


CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

10/519,722

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 804554-75-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-76-5 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O

10/519,722



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-77-6 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl-, monomethanesulfonate
(9CI) (CA INDEX NAME)


CM 1

CRN 796738-25-5
CMF C30 H33 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



10/519,722


RN 804554-78-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-80-1 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4


CMF C29 H31 N7 O



CM 2

10/519,722


CRN 75-75-2
CMF C H4 O3 S



RN 804554-81-2 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6
CMF C28 H30 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-84-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-40-4
CMF C30 H33 N7 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-85-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[[[(4-methyl-1-piperazinyl)amino]methyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-86-7 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-

10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate
(9CI) (CA INDEX NAME)


CM 1

CRN 796738-44-8
CMF C29 H30 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-87-8 CAPLUS
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-47-1
CMF C28 H28 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-88-9 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-
[(4-methyl-1-piperazinyl)amino]methyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)


CM 1

CRN 796738-50-6
CMF C28 H29 F N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-90-3 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-
[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX
NAME)

CM 1


CRN 796738-54-0
CMF C28 H28 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-91-4 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




10/519,722

RN 804554-92-5 CAPLUS
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-58-4
CMF C28 H28 N6 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-94-7 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0
CMF C30 H33 N7 O




CM 2

CRN 64-19-7

10/519, 722


CMF C2 H4 O2



RN 804554-95-8 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 804554-98-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

AN 2004:1036851 CAPLUS
 DN 142:696
 TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
 IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
 PA Hybridon, Inc., USA
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004103301 | A2 | 20041202 | WO 2004-US15313 | 20040514 |
| | WO 2004103301 | A3 | 20051103 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004241093 | A1 | 20041202 | AU 2004-241093 | 20040514 |
| | CA 2526212 | AA | 20041202 | CA 2004-2526212 | 20040514 |
| | US 2005009773 | A1 | 20050113 | US 2004-846167 | 20040514 |
| | EP 1628531 | A2 | 20060301 | EP 2004-752345 | 20040514 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| PRAI | US 2003-471247P | P | 20030516 | | |
| | WO 2004-US15313 | W | 20040514 | | |
| OS | MARPAT 142:696 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (immunostimulatory oligonucleotide and/or immunomer combination with
chemotherapeutic agent for synergistic cancer treatment) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |




CRN 75-75-2
CMF C H4 O3 S




L5 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:996162 CAPLUS
DN 141:424205
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for their preparation
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Cheol
PA Il Yang Pharm. Co. Ltd., S. Korea
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2004099187 | A1 | 20041118 | WO 2004-KR611 | 20040319 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| KR 2004095155 | A | 20041112 | KR 2004-17594 | 20040316 |
| PRAI KR 2003-28669 | A | 20030506 | | |
| OS MARPAT 141:424205 | | | | |
| IT 796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
796738-23-3P, 4-[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents) | | | | |
| RN 796738-20-0 CAPLUS | | | | |
| CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 796738-23-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)

IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
796738-24-4P, 4-[(4-Methylhomopiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-22-2 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-20-0

CMF C30 H33 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-24-4 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 75-75-2
CMF C H4 O3 S




IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-28-8P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P
 , 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,
 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-25-5 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS
 CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS


CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS
 CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-29-9P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-35-7P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-41-5P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-43-7P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-48-2P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-51-7P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-

yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-62-0P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-65-3P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 796738-28-8
CMF C29 H32 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-33-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-32-4
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-35-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6
 CMF C28 H30 N8 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 796738-41-5 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-40-4
 CMF C30 H33 N7 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-

10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 796738-44-8
CMF C29 H30 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-48-2 CAPLUS
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-47-1
CMF C28 H28 F N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-51-7 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-55-1 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-54-0


CMF C28 H28 F N7 O



10/519,722

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-57-3 CAPLUS
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 796738-56-2
CMF C29 H30 F N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-59-5 CAPLUS
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-58-4
CMF C28 H28 N6 O

10/519, 722



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-61-9 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0
CMF C30 H33 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 796738-65-3 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs.
related to imatinib mesylate as antitumor agents)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


10/519,722

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:996161 CAPLUS
DN 141:424204
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for the preparation thereof
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jn; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Ceol
PA Il Yang Pharm Co., Ltd., S. Korea
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004099186 | A1 | 20041118 | WO 2003-KR1029 | 20030526 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003232650 | A1 | 20041126 | AU 2003-232650 | 20030526 |
| | KR 2004095155 | A | 20041112 | KR 2004-17594 | 20040316 |
| PRAI | KR 2003-28669 | A | 20030506 | | |
| | WO 2003-KR1029 | W | 20030526 | | |
| OS | MARPAT 141:424204 | | | | |
| IT | 796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3- | | | | |

[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-23-3P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
 796738-24-4P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-22-2 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-20-0

CMF C30 H33 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-24-4 CAPLUS.
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 796738-28-8P, 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-34-6P
 , 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-40-4P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-42-6P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-44-8P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-47-1P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-50-6P,
 4-[[4-(Methylhomopiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-54-0P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-56-2P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-58-4P,
 4-(Piperidin-1-ylmethyl)-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-32-4 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS
 CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-50-6 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-56-2 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-29-9P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-35-7P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-41-5P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-43-7P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-48-2P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-51-7P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-62-0P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-65-3P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-27-7 CAPPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
 (CA INDEX NAME)


CM 1

CRN 796738-25-5
 CMF C30 H33 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 796738-29-9 CAPPLUS
 CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519, 722


CM 1

CRN 796738-28-8
CMF C29 H32 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-33-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-32-4
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-35-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6


CMF C28 H30 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-41-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-40-4

CMF C30 H33 N7 O2



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 796738-43-7 CAPLUS
 CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-42-6
 CMF C29 H32 N8 O2



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 796738-45-9 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-44-8
 CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-48-2 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1


CMF C28 H28 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




10/519,722

RN 796738-51-7 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-50-6
CMF C28 H29 F N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-55-1 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-54-0
CMF C28 H28 F N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-57-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)
(CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-59-5 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-58-4

CMF C28 H28 N6 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-61-9 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0
CMF C30 H33 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS
CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 796738-65-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

IT 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:995984 CAPLUS
 DN 141:389290
 TI New calcitriol analogs and therapeutic use in treating mast cell associated diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|---|--|----------|-----------------|----------|--|
| PI | WO 2004098612 | A2 | 20041118 | WO 2004-IB1871 | 20040507 | |
| | WO 2004098612 | A3 | 20050210 | | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 2003-468295P | P | 20030507 | | | |
| | US 2003-480224P | P | 20030623 | | | |
| OS | MARPAT 141:389290 | | | | | |
| IT | 152459-95-5 | | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | | |

(new calcitriol analogs and therapeutic use in treating mast cell associated diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965068 CAPLUS

DN 141:406114

TI Use of tyrosine kinase inhibitors for treating cerebral ischemia

IN Kinet, Jean-Pierre; Moussy, Alain

PA AB Science, Fr.

SO PCT Int. Appl., 117 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------------|----------|-----------------|----------|
| PI | WO 2004096225 | A2 | 20041111 | WO 2004-IB1874 | 20040428 |
| | WO 2004096225 | A3 | 20050310 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2523852. | AA | 20041111 | CA 2004-2523852 | 20040428 |
| | EP 1624873 | A2 | 20060215 | EP 2004-729952 | 20040428 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-465789P | P | 20030428 | | |
| | WO 2004-IB1874 | W | 20040428 | | |
| OS | MARPAT | 141:406114 | | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | tyrosine kinase inhibitors for treating cerebral ischemia | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) | (CA INDEX NAME) | | | |



L5 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:965067 CAPLUS
 DN 141:406039
 TI Combinations for the treatment of diseases involving cell proliferation,
 migration or apoptosis of myeloma cells, or angiogenesis
 IN Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke;
 Munzert, Gerd; Van Meel, Jacobus C. A.
 PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim
 Pharma G.m.b.H. & Co. K.-G.
 SO PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004096224 | A2 | 20041111 | WO 2004-EP4363 | 20040424 |
| | WO 2004096224 | A3 | 20041216 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | EP 1473043 | A1 | 20041103 | EP 2003-9587 | 20030429 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | AU 2004233576 | A1 | 20041111 | AU 2004-233576 | 20040424 |
| | CA 2523868 | AA | 20041111 | CA 2004-2523868 | 20040424 |
| | EP 1622619 | A2 | 20060208 | EP 2004-729366 | 20040424 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | BR 2004009919 | A | 20060425 | BR 2004-9919 | 20040424 |
| | NO 2005005605 | A | 20051128 | NO 2005-5605 | 20051128 |
| PRAI | EP 2003-9587 | A | 20030429 | | |
| | EP 2004-508 | A | 20040113 | | |
| | EP 2004-1171 | A | 20040121 | | |
| | WO 2004-EP4363 | W | 20040424 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (drug combinations for diseases involving cell proliferation and
migration or apoptosis or angiogenesis including protein tyrosine
kinase receptor antagonists and radiotherapy) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- | | | | |


(pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:878151 CAPLUS
 DN 141:366243
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamilus; Dwyer, Michael P.; Doll, Ronald J.;
 Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar,
 Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann,
 Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray
 Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
 PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2004209878 | A1 | 20041021 | US 2004-776988 | 20040211 |
| | AU 2005212409 | A1 | 20050825 | AU 2005-212409 | 20050208 |
| | WO 2005077954 | A2 | 20050825 | WO 2005-US3859 | 20050208 |
| | WO 2005077954 | A3 | 20051013 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | US 2006128725 | A1 | 20060615 | US 2005-245401 | 20051006 |
| PRAI | US 2002-408027P | P | 20020904 | | |
| | US 2002-421959P | P | 20021029 | | |
| | US 2003-654546 | A2 | 20030903 | | |
| | US 2004-776988 | A | 20040211 | | |
| | WO 2005-US3859 | W | 20050208 | | |
| OS | MARPAT 141:366243 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors for treating cancer in combination of other
anticancer agents) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O


CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756710 CAPLUS
 DN 141:277628
 TI Preparation of ureidophenoxycyanopyridines as anticancer drugs.
 IN Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004078747 | A1 | 20040916 | WO 2004-US6286 | 20040301 |
| | WO 2004078747 | C1 | 20041104 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004235829 | A1 | 20041125 | US 2004-788029 | 20040227 |
| | AU 2004217977 | A1 | 20040916 | AU 2004-217977 | 20040301 |
| | CA 2517361 | AA | 20040916 | CA 2004-2517361 | 20040301 |
| | US 2004229937 | A1 | 20041118 | US 2004-789446 | 20040301 |
| | US 2005032798 | A1 | 20050210 | US 2004-788405 | 20040301 |
| | US 2005038031 | A1 | 20050217 | US 2004-788426 | 20040301 |
| | EP 1599467 | A1 | 20051130 | EP 2004-716144 | 20040301 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 BR 2004007897 A 20060301 BR 2004-7897 20040301
 JP 2006519264 T2 20060824 JP 2006-508977 20040301
 PRAI US 2003-450323P P 20030228
 US 2003-450324P P 20030228
 US 2003-450348P P 20030228
 WO 2004-US6286 A 20040301
 OS MARPAT 141:277628
 IT 220127-57-1, Gleevec
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of ureidophenoxycyanopyridines as anticancer
 drugs)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl-, monomethanesulfonate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756044 CAPLUS
 DN 141:266048
 TI Medical implants with carbon-containing surfaces that are functionalized
 PA Blue Membranes GmbH, Germany
 SO Ger. Gebrauchsmusterschrift, 18 pp.
 CODEN: GGXXFR
 DT Patent
 LA German
 FAN.CNT 9


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|-------|-------|-----------------|-------|
| ----- | ----- | ----- | ----- | ----- |

PI DE 202004009061 U1 20040916 DE 2004-202004009061 20040528
 DE 10324415 A1 20041216 DE 2003-10324415 20030528
 DE 10333098 A1 20050210 DE 2003-10333098 20030721
 DE 10333099 A1 20050210 DE 2003-10333099 20030721
 PRAI DE 2003-10324415 A1 20030528
 DE 2003-10333098 A1 20030721
 DE 2003-10333099 A1 20030721
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medical implants with carbon-containing surfaces that are functionalized)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756043 CAPLUS
 DN 141:266047
 TI Medical implants coated with biocompatible carbon-containing layers
 PA Blue Membranes GmbH, Germany
 SO Ger. Gebrauchsmusterschrift, 23 pp.
 CODEN: GGXXFR
 DT Patent
 LA German
 FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|----------------------|----------|
| PI | DE 202004009060 | U1 | 20040916 | DE 2004-202004009060 | 20040510 |
| | DE 10322182 | A1 | 20041202 | DE 2003-10322182 | 20030516 |
| | DE 10324415 | A1 | 20041216 | DE 2003-10324415 | 20030528 |
| | DE 10333098 | A1 | 20050210 | DE 2003-10333098 | 20030721 |
| PRAI | DE 2003-10322182 | A1 | 20030516 | | |
| | DE 2003-10324415 | A1 | 20030528 | | |
| | DE 2003-10333098 | A1 | 20030721 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (medical implants coated with biocompatible carbon-containing layers) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



AN 2004:691283 CAPLUS

DN 141:207230

TI Preparation of imatinib and salts by reaction of N-(2-methyl-5-aminophenyl)-4-(3-pyridyl)-2-pyrimidinamine with 4-(4-methylpiperazinylmethyl)benzoyl halides.

IN Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra

PA Cipla Limited, India

SO Brit. UK Pat. Appl., 34 pp.


CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | GB 2398565 | A1 | 20040825 | GB 2003-3730 | 20030218 |
| | AU 2004213616 | A2 | 20040902 | AU 2004-213616 | 20040108 |
| | AU 2004213616 | A1 | 20040902 | | |
| | CA 2516370 | AA | 20040902 | CA 2004-2516370 | 20040108 |
| | WO 2004074502 | A2 | 20040902 | WO 2004-GB18 | 20040108 |
| | WO 2004074502 | A3 | 20041028 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1599462 | A2 | 20051130 | EP 2004-700728 | 20040108 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2004007672 | A | 20060301 | BR 2004-7672 | 20040108 |
| | JP 2006518360 | T2 | 20060810 | JP 2006-502181 | 20040108 |
| | US 2006173182 | A1 | 20060803 | US 2005-546193 | 20051031 |
| PRAI | GB 2003-3730 | A | 20030218 | | |
| | WO 2004-GB18 | A | 20040108 | | |
| OS | CASREACT 141:207230 | | | | |
| IT | 152459-95-5P, Imatinib 220127-57-1P, Imatinib mesylate
744256-04-0P 744256-05-1P 744256-06-2P | | | | |
| | RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(preparation of imatinib and salts by reaction of
methylaminophenylpyridylpyrimidinamine with
methylpiperazinylmethylbenzoyl halides) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA

10/519,722

INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 744256-04-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● x HBr

RN 744256-05-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 744256-06-2 CAPLUS

CN Benzamide, 4-[4-methyl-1-piperazinyl]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)



● 3 HCl

● H₂O

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:650874 CAPLUS
DN 141:167761
TI Sensitizing cells for apoptosis by selectively blocking cytokines
IN Stassi, Giorgio; Todaro, Matilde
PA Italy
SO Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | EP 1444989 | A1 | 20040811 | EP 2003-2603 | 20030207 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | AU 2004210432 | A1 | 20040819 | AU 2004-210432 | 20040209 |
| | CA 2515302 | AA | 20040819 | CA 2004-2515302 | 20040209 |
| | WO 2004069274 | A2 | 20040819 | WO 2004-EP1177 | 20040209 |
| | WO 2004069274 | A3 | 20041111 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

EP 1592449 A2 20051109 EP 2004-709222 20040209

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006519190 T2 20060824 JP 2006-501781 20040209

PRAI EP 2003-2603 A 20030207
 WO 2004-EP1177 W 20040209

IT 220127-57-1, STI571

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(CPG57148B; sensitizing cells for apoptosis by blocking cytokines)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:565086 CAPLUS

DN 141:123632

TI Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis


IN Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong; Kemnitzer, William E.

PA Cytovia, Inc., USA

SO PCT Int. Appl., 97 pp.


CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004058253 | A1 | 20040715 | WO 2003-US40308 | 20031218 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US | 2004127521 | A1 | 20040701 | US 2003-737865 | 20031218 |
| CA | 2509224 | AA | 20040715 | CA 2003-2509224 | 20031218 |
| AU | 2003303373 | A1 | 20040722 | AU 2003-303373 | 20031218 |
| EP | 1581213 | A1 | 20051005 | EP 2003-808469 | 20031218 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1756547 | A | 20060405 | CN 2003-80106440 | 20031218 |
| | JP 2006516250 | T2 | 20060629 | JP 2004-563731 | 20031218 |
| PRAI | US 2002-433953P | P | 20021218 | | |
| | WO 2003-US40308 | W | 20031218 | | |
| OS | MARPAT 141:123632 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-
oxadiazoles and analogs as activators of caspases and inducers of
apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
CMF C H4 O3 S



L5 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:559502 CAPLUS

DN 141:190802

TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors

IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-yu; James, Ray A.; Bishop, W. Robert; Wang, James J.-S.; Desai, Jagdish A.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 731 pp., Cont.-in-part of U.S. Ser. No. 85,896.
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| | US 2002198216 | A1 | 20021226 | US 2001-940811 | 20010828 |
| | US 2003229099 | A1 | 20031211 | US 2002-85896 | 20020227 |
| | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| PRAI | US 2001-940811 | A2 | 20010828 | | |
| | US 2002-85896 | A2 | 20020227 | | |
| | US 2002-325896 | A | 20021219 | | |
| | US 2000-229183P | P | 20000830 | | |

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of tricyclic antitumor agents as farnesyl protein transferase inhibitors for treatment of cancer and other proliferative diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S



L5 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:513393 CAPLUS
 DN 141:71544
 TI Preparation of substituted benzazoles as Raf kinase inhibitors
 IN Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
 PA USA
 SO U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2004122237 | A1 | 20040624 | US 2003-675927 | 20030929 |
| | US 2004087626 | A1 | 20040506 | US 2003-405945 | 20030331 |
| | US 7071216 | B2 | 20060704 | | |
| | AU 2004277405 | A1 | 20050414 | AU 2004-277405 | 20040929 |
| | CA 2539748 | AA | 20050414 | CA 2004-2539748 | 20040929 |
| | WO 2005032548 | A1 | 20050414 | WO 2004-US32161 | 20040929 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | EP 1675584 | A1 | 20060705 | EP 2004-789345 | 20040929 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | JP 2006193533 | A2 | 20060727 | JP 2006-96143 | 20060330 |
| PRAI | US 2002-369066P | P | 20020329 | | |
| | US 2003-405945 | A2 | 20030331 | | |
| | JP 2003-579810 | A3 | 20030331 | | |
| | US 2003-675927 | A | 20030929 | | |
| | WO 2004-US32161 | W | 20040929 | | |
| OS | MARPAT 141:71544 | | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted benzazoles as Raf kinase inhibitors for use in
combination with other antitumor agents) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- | | | | |


pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:467883 CAPLUS
 DN 141:38627
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 151 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004048365 | A1 | 20040610 | WO 2003-US37294 | 20031121 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2507100 | AA | 20040610 | CA 2003-2507100 | 20031121 |
| | AU 2003295776 | A1 | 20040618 | AU 2003-295776 | 20031121 |
| | US 2004176385 | A1 | 20040909 | US 2003-719896 | 20031121 |
| | EP 1575940 | A1 | 20050921 | EP-2003-786980 | 20031121 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003016485 | A | 20051011 | BR 2003-16485 | 20031121 |
| | CN 1735607 | A | 20060215 | CN 2003-80108239 | 20031121 |
| | JP 2006514118 | T2 | 20060427 | JP 2005-510381 | 20031121 |
| | NO 2005002927 | A | 20050708 | NO 2005-2927 | 20050615 |
| PRAI | US 2002-428473P | P | 20021121 | | |
| | US 2003-438568P | P | 20030107 | | |
| | US 2003-523081P | P | 20031119 | | |
| | WO 2003-US37294 | W | 20031121 | | |
| OS | MARPAT 141:38627 | | | | |
| IT | 152459-95-5, Imatinib 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:452964 CAPLUS

DN 141:1206

TI Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

IN Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.

PA Sugen, Inc., USA

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2004045523 | A2 | 20040603 | WO 2003-US36526 | 20031114 |
| | WO 2004045523 | A3 | 20040930 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 NL 1024779 A1 20040518 NL 2003-1024779 20031114
 NL 1024779 C2 20041109
 CA 2506308 AA 20040603 CA 2003-2506308 20031114
 AU 2003290943 A1 20040615 AU 2003-290943 20031114
 US 2004152759 A1 20040805 US 2003-712296 20031114
 EP 1562600 A2 20050817 EP 2003-783527 20031114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015630 A 20050823 BR 2003-15630 20031114
 CN 1711089 A 20051221 CN 2003-80103225 20031114
 JP 2006508981 T2 20060316 JP 2004-553729 20031114
 NO 2005002578 A 20050527 NO 2005-2578 20050527
 PRAI US 2002-426386P P 20021115
 WO 2003-US36526 W 20031114
 OS MARPAT 141:1206
 IT 152459-95-5, Imatinib
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as chemotherapeutic agent; cancer therapy using combination
 administration of indolinone compds. with chemotherapeutic agents for
 cell proliferation disorders)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:419904 CAPLUS
 DN 142:70669
 TI Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors
 AU Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyorgy; Ullrich, Axel; Daub, Henrik
 CS Axxima Pharmaceuticals AG, Munchen, 81377, Germany
 SO Chemistry & Biology (2004), 11(5), 691-701
 CODEN: CBOLE2; ISSN: 1074-5521
 PB Cell Press
 DT Journal
 LA English
 IT 220127-57-1, STI571
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (characterization of a conserved structural determinant controlling protein kinase inhibitor sensitivity)

10/519,722

RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:331787 CAPLUS
DN 140:350538
TI Treatment of tuberous sclerosis associated neoplasms with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase inhibitors, especially N-phenyl-2-pyrimidineamines

IN Arbiser, Jack

PA USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO


DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004077661 | A1 | 20040422 | US 2003-655407 | 20030904 |
| | CA 2439440 | AA | 20040305 | CA 2003-2439440 | 20030903 |
| PRAI | US 2002-408550P | P | 20020905 | | |
| OS | MARPAT 140:350538 | | | | |
| IT | 152459-95-5 152459-95-5D, acceptable salts
220127-57-1 | | | | |
| | RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tuberous sclerosis-associated neoplasms treatment with platelet-derived
growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase | | | | |

RN inhibitors, especially N-Ph-2-pyrimidineamines)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
 CMF C₂₉ H₃₁ N₇ O



CM 2

CRN 75-75-2
 CMF C₄ H₄ O₃ S



L5 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:269996 CAPLUS
 DN 140:303691
 TI Preparation and pharmaceutical compositions of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
 PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004026229 | A2 | 20040401 | WO 2003-US27491 | 20030903 |
| | WO 2004026229 | A3 | 20040617 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2497544 | AA | 20040401 | CA 2003-2497544 | 20030903 |
| | AU 2003298571 | A1 | 20040408 | AU 2003-298571 | 20030903 |
| | EP 1534712 | A2 | 20050601 | EP 2003-796321 | 20030903 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1701073 | A | 20051123 | CN 2003-824701 | 20030903 |
| | JP 2006502184 | T2 | 20060119 | JP 2004-537708 | 20030903 |
| | NZ 539161 | A | 20060526 | NZ 2003-539161 | 20030903 |
| | ZA 2005001846 | A | 20050912 | ZA 2005-1846 | 20050303 |
| PRAI | US 2002-408029P | P | 20020904 | | |
| | WO 2003-US27491 | W | 20030903 | | |
| OS | MARPAT 140:303691 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyrimidines) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 S


L5 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:268055 CAPLUS
 DN 140:385622
 TI Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro
 AU Houghton, Peter J.; Germain, Glen S.; Harwood, Franklin C.; Schuetz, John D.; Stewart, Clinton F.; Buchdunger, Elisabeth; Traxler, Peter
 CS Tennessee, Memphis, St. Jude Children's Research Hospital, Departments of Molecular Pharmacology, Memphis, TN, 38105-2794, USA
 SO Cancer Research (2004), 64(7), 2333-2337
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1, Imatinib Mesylate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (imatinib mesylate is a potent inhibitor of ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:267339 CAPLUS
 DN 140:303700
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan K.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004026877 | A1 | 20040401 | WO 2003-US29209 | 20030919 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499756 | AA | 20040401 | CA 2003-2499756 | 20030919 |
| | AU 2003272476 | A1 | 20040408 | AU 2003-272476 | 20030919 |
| | EP 1543008 | A1 | 20050622 | EP 2003-754658 | 20030919 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1694886 | A | 20051109 | CN 2003-825177 | 20030919 |
| | JP 2006507253 | T2 | 20060302 | JP 2004-537904 | 20030919 |
| | ZA 2005002375 | A | 20050927 | ZA 2005-2375 | 20050322 |
| PRAI | US 2002-412997P | P | 20020923 | | |
| | WO 2003-US29209 | W | 20030919 | | |
| OS | MARPAT 140:303700 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3- | | | | |

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267335 CAPLUS
DN 140:287379
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.
PA Schering Corporation, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004026872 | A1 | 20040401 | WO 2003-US29841 | 20030917 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA | 2499593 | AA | 20040401 | CA 2003-2499593 | 20030917 |
| AU | 2003270846 | A1 | 20040408 | AU 2003-270846 | 20030917 |

| | | | | |
|--|----|----------|----------------|----------|
| US 2004097516 | A1 | 20040520 | US 2003-664337 | 20030917 |
| EP 1539750 | A1 | 20050615 | EP 2003-752559 | 20030917 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1681816 | A | 20051012 | CN 2003-822011 | 20030917 |
| JP 2006503060 | T2 | 20060126 | JP 2004-538405 | 20030917 |
| NZ 538595 | A | 20060428 | NZ 2003-538595 | 20030917 |
| ZA 2005002271 | A | 20050919 | ZA 2005-2271 | 20050317 |
| PRAI US 2002-412138P | P | 20020919 | | |
| WO 2003-US29841 | W | 20030917 | | |
| OS MARPAT 140:287379 | | | | |
| IT 220127-57-1, Gleevec | | | | |
| RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin
dependent kinases in the presence of prepared pyrazolopyridines) | | | | |
| RN 220127-57-1 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM 1 | | | | |
| CRN 152459-95-5 | | | | |
| CMF C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267330 CAPLUS
DN 140:303698
TI Preparation and pharmaceutical compositions of novel imidazopyridines as cyclin dependent kinase inhibitors.
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.
PA Schering Corporation, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|---|----------|----------------|-----------------|----------|
| PI | WO 2004026867 | A2 | 20040401 | WO 2003-US29498 | 20030917 |
| | WO 2004026867 | A3 | 20040805 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499639 | AA | 20040401 | CA 2003-2499639 | 20030917 |
| | AU 2003295332 | A1 | 20040408 | AU 2003-295332 | 20030917 |
| | US 2004097517 | A1 | 20040520 | US 2003-664338 | 20030917 |
| | US 6992080 | B2 | 20060131 | | |
| | EP 1539756 | A2 | 20050615 | EP 2003-786514 | 20030917 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1703414 | A | 20051130 | CN 2003-825047 | 20030917 | |
| JP 2006507254 | T2 | 20060302 | JP 2004-538237 | 20030917 | |
| US 2006030555 | A1 | 20060209 | US 2005-238597 | 20050929 | |
| PRAI | US 2002-412063P | P | 20020919 | | |
| | US 2003-664338 | A3 | 20030917 | | |
| | WO 2003-US29498 | W | 20030917 | | |
| OS MARPAT 140:303698 | | | | | |
| IT 220127-57-1, Gleevec | | | | | |
| RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | | |
| RN 220127-57-1 CAPLUS | | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | | |


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




L5 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:267246 CAPLUS
 DN 140:303696
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004026310 | A1 | 20040401 | WO 2003-US29456 | 20030919 |
| | WO 2004026310 | C1 | 20050630 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499874 | AA | 20040401 | CA 2003-2499874 | 20030919 |
| | AU 2003275031 | A1 | 20040408 | AU 2003-275031 | 20030919 |
| | US 2004072835 | A1 | 20040415 | US 2003-666424 | 20030919 |
| | EP 1542693 | A1 | 20050622 | EP 2003-759300 | 20030919 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1694706 | A | 20051109 | CN 2003-825102 | 20030919 |
| | JP 2006503838 | T2 | 20060202 | JP 2004-538213 | 20030919 |
| | ZA 2005002380 | A | 20050927 | ZA 2005-2380 | 20050322 |
| PRAI | US 2002-412906P | P | 20020923 | | |
| | WO 2003-US29456 | W | 20030919 | | |
| OS | MARPAT 140:303696 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 SRE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:252622 CAPLUS
 DN 140:283386
 TI Crystal structure of human PIM-1 kinase and complexes with AMP-PNP and use
 in drug screening and design
 IN Bremer, Ryan; Ibrahim, Prabha; Kumar, Abhinav; Mandiyan, Valsan; Milburn,
 Michael V.
 PA Plexxxikon, Inc., USA
 SO PCT Int. Appl., 217 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004024895 | A2 | 20040325 | WO 2003-US29415 | 20030916 |
| | WO 2004024895 | A3 | 20050609 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2503905 | AA | 20040325 | CA 2003-2503905 | 20030916 |
| | AU 2003272548 | A1 | 20040430 | AU 2003-272548 | 20030916 |
| | US 2004142864 | A1 | 20040722 | US 2003-664421 | 20030916 |
| | EP 1558751 | A2 | 20050803 | EP 2003-754735 | 20030916 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1701122 | A | 20051123 | CN 2003-825157 | 20030916 |
| PRAI | US 2002-411398P | P | 20020916 | | |

US 2002-412341P P 20020920
 WO 2003-US29415 W 20030916
 IT 220127-57-1, Imatinib mesylate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystal structure of human PIM-1 kinase and complexes with AMP-PNP and
 use in drug screening and design)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



L5 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:252351 CAPLUS
 DN 140:264488
 TI Combination of a benzamide derivative and a histone deacetylase inhibitor
 for the treatment of leukemia
 IN Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong
 PA Virginia Commonwealth University, USA; McGuire Va Medical Center 111k
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|---|----------|-----------------|----------|
| PI | WO 2004024160 | A1 | 20040325 | WO 2003-IB4053 | 20030910 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT,
LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN,
YU, ZA, ZW | | | |

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR
 CA 2498210 AA 20040325 CA 2003-2498210 20030910
 AU 2003259521 A1 20040430 AU 2003-259521 20030910
 BR 2003014112 A 20050712 BR 2003-14112 20030910
 EP 1553948 A1 20050720 EP 2003-795175 20030910
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1681505 A 20051012 CN 2003-821763 20030910
 JP 2006501267 T2 20060112 JP 2004-535791 20030910
 US 2006100140 A1 20060511 US 2005-527553 20050909
 PRAI US 2002-410286P P 20020913
 US 2002-411344P P 20020918
 WO 2003-IB4053 W 20030910
 IT 152459-95-5 220127-57-1, Glivec
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of histone deacetylase inhibitor and antitumor benzamide
 derivative for treatment of leukemia)
 RN 152459-95-5 CAPPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:220336 CAPLUS
 DN 140:270873
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.;
 Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.;
 Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;
 Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min;
 James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs,
 Douglas Walsh

PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO PCT Int. Appl., 609 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004022561 | A1 | 20040318 | WO 2003-US27555 | 20030903 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE,
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2497440 | AA | 20040318 | CA 2003-2497440 | 20030903 |
| | AU 2003263071 | A1 | 20040329 | AU 2003-263071 | 20030903 |
| | EP 1537116 | A1 | 20050608 | EP 2003-794592 | 20030903 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003014001 | A | 20050705 | BR 2003-14001 | 20030903 |
| | JP 2006502163 | T2 | 20060119 | JP 2004-534487 | 20030903 |
| | CN 17335614 | A | 20060215 | CN 2003-824997 | 20030903 |
| | NO 2005001647 | A | 20050603 | NO 2005-1647 | 20050404 |
| PRAI | US 2002-408027P | P | 20020904 | | |
| | US 2002-421959P | P | 20021029 | | |
| | WO 2003-US27555 | W | 20030903 | | |
| OS | MARPAT 140:270873 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors for treating cancer in combination of other
anticancer agents) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:220335 CAPLUS
 DN 140:270872
 TI Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
 PA Schering Corporation, USA; Pharmacopeia, Inc.; Pharmacopeia Drug Discovery, Inc.
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2004022560 | A1 | 20040318 | WO 2003-US27502 | 20030903 |
| | WO 2004022560 | C2 | 20050707 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2497450 | AA | 20040318 | CA 2003-2497450 | 20030903 |

AU 2003268385 A1 20040329 AU 2003-268385 20030903
 US 2004116442 A1 20040617 US 2003-653868 20030903
 US 7074924 B2 20060711 EP 2003-749347 20030903
 EP 1534710 A1 20050601 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1701074 A 20051123 CN 2003-824779 20030903
 JP 2006502161 T2 20060119 JP 2004-534459 20030903
 NZ 539164 A 20060428 NZ 2003-539164 20030903
 ZA 2005001852 A 20050908 ZA 2005-1852 20050303
 US 2006173016 A1 20060803 US 2006-395824 20060331
 PRAI US 2002-407999P P 20020904
 US 2003-653868 A3 20030903
 WO 2003-US27502 W 20030903
 OS MARPAT 140:270872
 IT 220127-57-1, Gleevec
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticancer agent, combination therapy; preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents)
 RN 220127-57-1 CAPPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

 CRN 75-75-2
 CMF C H4 O3 S


RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:218528 CAPLUS
 DN 140:247038
 TI Use of specific inhibitors of tyrosine kinases for immunomodulation
 IN Zitvogel, Laurence; Auclair, Christian; Tursz, Thomas

PA Institut Gustave Roussy Igr, Fr.

SO Fr. Demande, 50 pp.

CODEN: FRXXBL

DT Patent

LA French


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI. | FR 2844452 | A1 | 20040319 | FR 2002-11545 | 20020918 |
| | WO 2004026311 | A2 | 20040401 | WO 2003-FR2744 | 20030917 |
| | WO 2004026311 | A3 | 20040812 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003276351 | A1 | 20040408 | AU 2003-276351 | 20030917 |
| PRAI | FR 2002-11545 | A | 20020918 | | |
| | WO 2003-FR2744 | W | 20030917 | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (use of specific inhibitors of tyrosine kinases for immunomodulation) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:100803 CAPLUS
 DN 140:139483
 TI Method for enhancing the effectiveness of therapies of hyperproliferative diseases
 IN Chang, Yan; Sasak, Vodek
 PA USA
 SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
 CODEN: USXXCO
 DT Patent
 LA English


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2004023925 | A1 | 20040205 | US 2003-408723 | 20030407 |
| | US 2003013681 | A1 | 20030116 | US 2002-176235 | 20020620 |
| | US 6680306 | B2 | 20040120 | | |
| | CN 1543351 | A | 20041103 | CN 2002-816003 | 20020621 |
| | US 2004043962 | A1 | 20040304 | US 2003-657383 | 20030908 |
| | AU 2004229399 | A1 | 20041028 | AU 2004-229399 | 20040407 |
| | CA 2521649 | AA | 20041028 | CA 2004-2521649 | 20040407 |
| | WO 2004091634 | A1 | 20041028 | WO 2004-US10675 | 20040407 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG | | | | |
| | EP 1617849 | A1 | 20060125 | EP 2004-759200 | 20040407 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | JP 2006522163 | T2 | 20060928 | JP 2006-509773 | 20040407 |
| PRAI | US 2001-299991P | P | 20010621 | | |
| | US 2002-176235 | A2 | 20020620 | | |
| | US 2003-408723 | A | 20030407 | | |
| | US 2003-461006P | P | 20030407 | | |
| | US 2003-474562P | P | 20030530 | | |
| | WO 2004-US10675 | W | 20040407 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method for enhancing effectiveness of therapies of hyperproliferative
diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




L5 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:20664 CAPLUS
 DN 140:77165
 TI Preparation of 4-[(4-methylpiperazin-1-yl)methyl]benzamide for treatment of leukemia
 IN Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004002963 | A1 | 20040108 | WO 2003-JP8192 | 20030627 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2490907 | AA | 20040108 | CA 2003-2490907 | 20030627 |
| | AU 2003246100 | A1 | 20040119 | AU 2003-246100 | 20030627 |
| | BR 2003012288 | A | 20050412 | BR 2003-12288 | 20030627 |
| | EP 1533304 | A1 | 20050525 | EP 2003-738555 | 20030627 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1678590 | A | 20051005 | CN 2003-820146 | 20030627 |
| | US 2006014742 | A1 | 20060119 | US 2004-519722 | 20041228 |
| PRAI | JP 2002-189269 | A | 20020628 | | |
| | JP 2002-305146 | A | 20021018 | | |
| | JP 2002-377937 | A | 20021226 | | |
| | WO 2003-JP8192 | W | 20030627 | | |
| OS | MARPAT 140:77165 | | | | |
| IT | 641614-84-8P 641614-88-2P 641614-92-8P
641614-95-1P 641615-19-2P | | | | |
| | RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia) | | | | |
| RN | 641614-84-8 CAPLUS | | | | |
| CN | Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 641614-88-2 CAPLUS
 CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-92-8 CAPLUS
 CN Benzamide, N-[3-[(4-(5-bromo-3-pyridinyl)-2-pyrimidinyl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 641614-95-1 CAPLUS
 CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 641615-19-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]amino]carbonyl]-2-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 641614-83-7P 641614-85-9P 641614-86-0P

641614-87-1P 641614-89-3P 641614-90-6P

641614-91-7P 641614-93-9P 641614-94-0P

641614-96-2P 641614-97-3P 641614-98-4P

641614-99-5P 641615-00-1P 641615-01-2P

641615-02-3P 641615-03-4P 641615-04-5P

641615-05-6P 641615-06-7P 641615-07-8P

641615-08-9P 641615-09-0P 641615-10-3P

641615-11-4P 641615-12-5P 641615-13-6P

641615-14-7P 641615-15-8P 641615-16-9P

641615-17-0P 641615-18-1P 641615-20-5P

641615-21-6P 641615-22-7P 641615-23-8P


641615-24-9P 641615-25-0P 641615-26-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)


RN 641614-83-7 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS

CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-86-0 CAPLUS

CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-87-1 CAPLUS

CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl}-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-89-3 CAPLUS

CN Benzamide, 3-bromo-4-[{(4-methyl-1-piperazinyl)methyl}-N-[4-methyl-3-[(4-pyrazinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-90-6 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[{(4-methyl-1-piperazinyl)methyl}- (9CI) (CA INDEX NAME)




RN 641614-91-7 CAPLUS


CN Benzamide, 3-bromo-N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[{(4-methyl-1-piperazinyl)methyl}- (9CI) (CA INDEX NAME)




RN 641614-93-9 CAPLUS
 CN Benzamide, 3-bromo-N-[3-[(4-(1,2-dihydro-4-pyridazinyl)-2-pyrimidinyl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-94-0 CAPLUS
 CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridazinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-96-2 CAPLUS
 CN Benzamide, N-[3-[(3,4'-bipyridin)-2'-ylamino]-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-97-3 CAPLUS
 CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(5-pyridinyl)-2-pyridinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-98-4 CAPLUS

CN Benzamide, N-[3-({[2,3'-bipyridin]-6-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-99-5 CAPLUS

CN Benzamide, N-[3-({[3,3'-bipyridin]-5-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-00-1 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[3-(3-pyridinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-01-2 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[6-(3-pyridinyl)pyrazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-02-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-1,2,4-triazin-3-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-03-4 CAPLUS

CN Benzamide, 3-methyl-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-04-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 641615-05-6 CAPLUS

CN Benzamide, 3-methoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-06-7 CAPLUS

CN Benzamide, 3,5-dibromo-4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-07-8 CAPLUS

CN Benzamide, 3,5-dimethoxy-4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-08-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N3,N3-dimethyl-4-[{(4-methyl-1-piperazinyl)methyl]-N1-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-09-0 CAPLUS


CN Benzamide, 3-bromo-4-[{(4-ethyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-10-3 CAPLUS
 CN Benzamide, 3-bromo-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-propyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-11-4 CAPLUS
 CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-12-5 CAPLUS
 CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-13-6 CAPLUS
 CN Benzamide, 3-bromo-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-14-7 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-15-8 CAPLUS


CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-16-9 CAPLUS


CN Benzamide, 3-bromo-4-[[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 641615-17-0 CAPLUS

CN Benzamide, 3-bromo-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-18-1 CAPLUS

CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-3-bromo-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-20-5 CAPLUS

CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-4-(1-piperazinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641615-21-6 CAPLUS

CN Benzoic acid, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 641615-22-7 CAPLUS

CN Benzamide, 3-cyano-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-23-8 CAPLUS


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 641615-24-9 CAPLUS


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 641615-25-0 CAPLUS

CN Benzamide, N-[3-[(4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 641615-26-1 CAPLUS

CN Benzamide, N-[3-[(4,5'-bipyrimidinyl-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 641614-88-2


CMF C29 H29 F3 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:971730 CAPLUS
 DN 140:27844
 TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors
 IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu; James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.
 PA USA
 SO U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S. Pat. Appl. 2002 198,216.
 CODEN: USXXCO
 DT Patent
 LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2003229099 | A1 | 20031211 | US 2002-85896 | 20020227 |
| | US 2002198216 | A1 | 20021226 | US 2001-940811 | 20010828 |
| | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| | CA 2477328 | AA | 20030904 | CA 2003-2477328 | 20030225 |
| | WO 2003072549 | A1 | 20030904 | WO 2003-US5479 | 20030225 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003215389 | A1 | 20030909 | AU 2003-215389 | 20030225 |
| | BR 2003008071 | A | 20041221 | BR 2003-8071 | 20030225 |
| | EP 1492772 | A1 | 20050105 | EP 2003-711214 | 20030225 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1630641 | A | 20050622 | CN 2003-804720 | 20030225 |
| | JP 2005525356 | T2 | 20050825 | JP 2003-571255 | 20030225 |
| | ZA 2004006807 | A | 20050829 | ZA 2004-6807 | 20040826 |
| | NO 2004004053 | A | 20041126 | NO 2004-4053 | 20040924 |
| PRAI | US 2000-229183P | P | 20000830 | | |
| | US 2001-940811 | A2 | 20010828 | | |
| | US 2002-85896 | A2 | 20020227 | | |
| | US 2002-325896 | A | 20021219 | | |
| | WO 2003-US5479 | W | 20030225 | | |
| OS | MARPAT 140:27844 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |

10/519,722

(co-administration; preparation of tricyclic compds. as farnesyl protein transferase inhibitors for treating cancer in combination with other agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:917665 CAPLUS

DN 140:156958

TI Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

AU Nimmanapalli, Ramadevi; Bali, Purva; O'Bryan, Erica; Fuino, Lianne; Guo, Fei; Wu, Jie; Houghton, Peter; Bhalla, Kapil

CS Interdisciplinary Oncology Program, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, FL, USA

SO Cancer Research (2003), 63(22), 7950-7958

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

IT 220127-57-1, Imatinib mesylate


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells)

RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:912990 CAPLUS
DN 139:375014
TI Methods and compositions with N-phenyl-2-pyrimidine compounds inhibiting platelet derived growth factor receptor for the treatment of graft failure
IN Sukhatme, Vikas P.
PA Beth Israel Deaconess Medical Center, USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|------------------|----------|
| PI | WO 2003094904 | A1 | 20031120 | WO 2003-US314916 | 20030513 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003232115 | A1 | 20031111 | AU 2003-232115 | 20030513 |
| | CA 2490989 | AA | 20031120 | CA 2003-2490989 | 20030513 |
| | EP 1509219 | A1 | 20050302 | EP 2003-750120 | 20030513 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |

10/519,722


JP 2005533019 T2 20051104 JP 2004-502990 20030513
US 2005261283 A1 20051124 US 2005-514322 20050719
PRAI US 2002-380180P P 20020513
US 2003-464023P P 20030418
WO 2003-US14916 W 20030513
OS MARPAT 139:375014
IT 152459-95-5 220127-57-1, Imatinib mesylate
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth
factor receptor for treatment of graft failure)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:892800 CAPLUS
 DN 139:395950
 TI Preparation of substituted pyrazines as protein kinase modulators
 IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Thimothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy
 PA Exelixis, Inc., USA
 SO PCT Int. Appl., 468 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003093297 | A2 | 20031113 | WO 2003-US13869 | 20030502 |
| | WO 2003093297 | A3 | 20040701 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2484209 | AA | 20031113 | CA 2003-2484209 | 20030502 |
| | AU 2003234464 | A1 | 20031117 | AU 2003-234464 | 20030502 |
| | EP 1501514 | A2 | 20050202 | EP 2003-728690 | 20030502 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005530760 | T2 | 20051013 | JP 2004-501436 | 20030502 |
| | US 2006211709 | A1 | 20060921 | US 2005-513081 | 20050727 |
| PRAI | US 2002-377933P | P | 20020503 | | |
| | WO 2003-US13869 | W | 20030502 | | |
| OS | MARPAT 139:395950 | | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



TI Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis

IN Debatin, Klaus Michael; Fulda, Simone

PA Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany

SO Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 1354952 | A1 | 20031022 | EP 2002-8199 | 20020417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | EP 1354953 | A1 | 20031022 | EP 2002-15499 | 20020712 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | WO 2003086470 | A2 | 20031023 | WO 2003-EP4039 | 20030417 |
| | WO 2003086470 | A3 | 20040506 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003236211 | A1 | 20031027 | AU 2003-236211 | 20030417 |
| | EP 1495124 | A2 | 20050112 | EP 2003-722503 | 20030417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005536457 | T2 | 20051202 | JP 2003-583486 | 20030417 |
| | US 2005222387 | A1 | 20051006 | US 2005-511037 | 20050119 |
| PRAI | EP 2002-8199 | A | 20020417 | | |
| | EP 2002-15499 | A | 20020712 | | |
| | WO 2003-EP4039 | W | 20030417 | | |
| IT | 220127-57-1, STI571 | | | | |
| | RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) | | | | |
| | (therapeutic combination with SMAC peptide; Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:809105 CAPLUS
 DN 140:122306
 TI Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine
 -Type Small Molecule Kinase Inhibitors
 AU von Bubnoff, Nikolas; Veach, Darren R.; Miller, W. Todd; Li, Wanqing;
 Saenger, Jana; Peschel, Christian; Bornmann, William G.; Clarkson, Bayard;
 Duyster, Justus
 CS Department of Internal Medicine III, Technical University of Munich,
 Munich, Germany
 SO Cancer Research (2003), 63(19), 6395-6404
 CODEN: CNREAB; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1, Glivec
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibition of wild-type and mutant Bcr-Abl by pyrido-
 pyrimidine-type small mol. kinase inhibitors in relation to
 leukemia treatment)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 SRE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:796477 CAPLUS
 DN 139:307759
 TI Preparation of substituted benzazoles as Raf kinase inhibitors
 IN Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry
 Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl,
 Wendy
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 259 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2003082272 | A1 | 20031009 | WO 2003-US10117 | 20030331 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2480638 | AA | 20031009 | CA 2003-2480638 | 20030331 |
| | AU 2003226211 | A1 | 20031013 | AU 2003-226211 | 20030331 |
| | EP 1499311 | A1 | 20050126 | EP 2003-745683 | 20030331 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003008854 | A | 20050222 | BR 2003-8854 | 20030331 |
| | CN 1655779 | A | 20050817 | CN 2003-812193 | 20030331 |
| | JP 2005529089 | T2 | 20050929 | JP 2003-579810 | 20030331 |
| | NO 2004004617 | A | 20041228 | NO 2004-4617 | 20041026 |

JP 2006193533 A2 20060727 JP 2006-96143 20060330
 PRAI US 2002-369066P P 20020329
 JP 2003-579810 A3 20030331
 WO 2003-US10117 W 20030331
 OS MARPAT 139:307759
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of substituted benzazoles as Raf kinase inhibitors for use in
 combination with other antitumor agents)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:696780 CAPLUS
 DN 139:219397
 TI N-[5-{4-(4-methyl-piperazino-methyl)-benzoylamido}-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine coated stents
 IN Prescott, Margaret Forney; Feldman, David Louis
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003072159 | A1 | 20030904 | WO 2003-EP2028 | 20030227 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE,
SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR | | | | |
| | CA 2477558 | AA | 20030904 | CA 2003-2477558 | 20030227 |
| | AU 2003214079 | A1 | 20030909 | AU 2003-214079 | 20030227 |
| | EP 1480688 | A1 | 20041201 | EP 2003-709729 | 20030227 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003008053 | A | 20041228 | BR 2003-8053 | 20030227 |
| | JP 2005519080 | T2 | 20050630 | JP 2003-570902 | 20030227 |
| | CN 1638823 | A | 20050713 | CN 2003-804788 | 20030227 |
| | NO 2004004093 | A | 20041124 | NO 2004-4093 | 20040927 |
| | US 2005209244 | A1 | 20050922 | US 2005-505398 | 20050429 |
| PRAI | US 2002-360254P | P | 20020228 | | |
| | WO 2003-EP2028 | W | 20030227 | | |
| IT | 152459-95-5 | | | | |


10/519,722

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(piperazino-methylbenzoylamido pyridylpyrimidineamine coated stents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:696536 CAPLUS

DN 139:207765

TI Combinations comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one telomerase inhibitor for treating proliferative diseases

IN Tauchi, Tetsuzo

PA Novartis AG, Switz.

SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 2003166660 | A1 | 20030904 | US 2002-272837 | 20021017 |
| | US 7045523 | B2 | 20060516 | | |
| | US 2006111365 | A1 | 20060525 | US 2006-332406 | 20060113 |
| PRAI | GB 2001-25105 | A | 20011018 | | |
| | GB 2002-15583 | A | 20020704 | | |
| | US 2002-272837 | A3 | 20021017 | | |

IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, salts
220127-57-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising imatinib and at least one telomerase inhibitor for treating proliferative diseases)

RN 152459-95-5 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

(pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:639686 CAPLUS

DN 140:139030

TI Leflunomide analogue FK778 is vaso protective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection

AU Savikko, Johanna; von Willebrand, Eva; Haeyry, Pekka

CS Transplantation Laboratory, Haartman Institute, Helsinki Univ. Central Hospital, Helsinki, Finland


SO Transplantation (2003), 76(3), 455-458
CODEN: TRPLAU; ISSN: 0041-1337

PB Lippincott Williams & Wilkins

DT Journal

LA English

IT 152459-95-5, Imatinib
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (leflunomide analog FK778 is vasculoprotective independent of its
 immunosuppressive effect in relation to imatinib)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:633685 CAPLUS
 DN 139:180080
 TI Preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivatives
 IN Loiseleur, Olivier; Kaufmann, Daniel; Abel, Stephan; Buerger, Hans Michael; Meisenbach, Mark; Schmitz, Beat; Sedelmeier, Gottfried
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003066613 | A1 | 20030814 | WO 2003-EP1188 | 20030206 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| | CA 2474738 | AA | 20030814 | CA 2003-2474738 | 20030206 |
| | AU 2003244444 | A1 | 20030902 | AU 2003-244444 | 20030206 |
| | EP 1474408 | A1 | 20041110 | EP 2003-737319 | 20030206 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003007529 | A | 20041221 | BR 2003-7529 | 20030206 |
| | CN 1630648 | A | 20050622 | CN 2003-803556 | 20030206 |
| | JP 2005528340 | T2 | 20050922 | JP 2003-565987 | 20030206 |
| | NO 2004003685 | A | 20041105 | NO 2004-3685 | 20040903 |
| | US 2006142580 | A1 | 20060629 | US 2005-503538 | 20050120 |
| PRAI | GB 2002-2873 | A | 20020207 | | |
| | WO 2003-EP1188 | W | 20030206 | | |
| OS | MARPAT 139:180080 | | | | |
| IT | 152459-95-5P | | | | |

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610246 CAPLUS

DN 139:154937

TI Treatment of rheumatoid arthritis

IN Joensuu, Heikki

PA Hyks-Instituutti Oy, Finland

SO PCT Int. Appl., 16 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003063844 | A2 | 20030807 | WO 2003-EP802 | 20030127 |
| | WO 2003063844 | A3 | 20040401 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | | |
| | RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| | CA 2473158 | AA | 20030807 | CA 2003-2473158 | 20030127 |
| | EP 1471916 | A2 | 20041103 | EP 2003-704474 | 20030127 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003007286 | A | 20041228 | BR 2003-7286 | 20030127 |
| | CN 1646130 | A | 20050727 | CN 2003-802880 | 20030127 |
| | JP 2005526022 | T2 | 20050902 | JP 2003-563538 | 20030127 |
| | ZA 2004005323 | A | 20050620 | ZA 2004-5323 | 20040705 |
| | NO 2004003585 | A | 20041021 | NO 2004-3585 | 20040827 |
| PRAI | GB 2002-1882 | A | 20020128 | | |
| | WO 2003-EP802 | W | 20030127 | | |
| IT | 152459-95-5 220127-57-1 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (treatment of rheumatoid arthritis with piperazinylmethylpyridinylpyrimidinylaminophenylbenzamide) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
 CMF C₂₉ H₃₁ N₇ O



CM 2

CRN 75-75-2
 CMF C H₄ O₃ S



L5 ANSWER 91 OF 106. CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:355612 CAPLUS
 DN 138:362649
 TI Treatment of cancer with anti-ErbB2 antibodies
 IN Sliwkowski, Mark X.
 PA Genentech, Inc., USA
 SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2003086924 | A1 | 20030508 | US 2002-268501 | 20021010 |
| | US 6949245 | B1 | 20050927 | US 2000-602812 | 20000623 |
| | US 2004013667 | A1 | 20040122 | US 2003-608626 | 20030627 |
| | US 2005208043 | A1 | 20050922 | US 2005-44749 | 20050127 |
| | US 2005238640 | A1 | 20051027 | US 2005-154465 | 20050616 |

| | | | | |
|---|----|----------|----------------|----------|
| US 2006034842 | A1 | 20060216 | US 2005-223361 | 20050909 |
| US 2006073143 | A1 | 20060406 | US 2005-222587 | 20050909 |
| AU 2005242195 | A1 | 20060112 | AU 2005-242195 | 20051207 |
| US 2006193854 | A1 | 20060831 | US 2006-429361 | 20060505 |
| US 2006198843 | A1 | 20060907 | US 2006-429043 | 20060505 |
| US 2006216285 | A1 | 20060928 | US 2006-429363 | 20060505 |
| PRAI US 1999-141316P | P | 19990625 | | |
| US 2000-602812 | A2 | 20000623 | | |
| AU 2000-57632 | A3 | 20000623 | | |
| US 2002-268501 | A2 | 20021010 | | |
| US 2005-44749 | A1 | 20050127 | | |
| IT 220127-57-1, Imatinib mesylate | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (as tyrosine kinase inhibitor in combination with anti-ErbB2
antibodies; cancer treatment with anti-ErbB2 antibodies) | | | | |
| RN 220127-57-1 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:334888 CAPLUS
 DN 138:358163
 TI Use of tyrosine kinase inhibitors for promoting hair growth
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 13

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2003035050 | A2 | 20030501 | WO 2002-IB4290 | 20020920 |
| WO 2003035050 | A3 | 20040527 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2461182 | AA | 20030501 | CA 2002-2461182 | 20020920 |
| EP 1461032 | A2 | 20040929 | EP 2002-801980 | 20020920 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2005507917 | T2 | 20050324 | JP 2003-537617 | 20020920 |
| US 2004242612 | A1 | 20041202 | US 2004-490334 | 20040322 |
| PRAI US 2001-323314P | P | 20010920 | | |
| WO 2002-IB4290 | W | 20020920 | | |
| OS MARPAT 138:358163 | | | | |
| IT 152459-95-5 | | | | |
| RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| (use of tyrosine kinase inhibitors for promoting hair growth) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:273844 CAPLUS
 DN 139:345426
 TI A Novel Pyridopyrimidine Inhibitor of Ab1 Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants
 AU Huron, David R.; Gorre, Mercedes E.; Kraker, Alan J.; Sawyers, Charles L.; Rosen, Neal; Moasser, Mark M.
 CS Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA
 SO Clinical Cancer Research (2003), 9(4), 1267-1273
 CODEN: CCREF4; ISSN: 1078-0432
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1, STI571
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel pyridopyrimidine inhibitor (PD166326) of Bcr-abl tyrosine kinase

10/519,722

is effective against ST1571-resistant Bcr-abl mutants in chronic myelogenous leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242116 CAPLUS

DN 138:265640

TI Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 13

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2003024386 | A2 | 20030327 | WO 2002-IB4236 | 20020920 |
| | WO 2003024386 | A3 | 20040205 | | |
| | WO 2003024386 | C1 | 20040624 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2460845 AA 20030327 CA 2002-2460845 20020920
 EP 1427379 A2 20040616 EP 2002-767812 20020920
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005511506 T2 20050428 JP 2003-528285 20020920
 US 2004242601 A1 20041202 US 2004-490348 20040322
 PRAI US 2001-323315P P 20010920
 WO 2002-IB4236 W 20020920
 OS MARPAT 138:265640
 IT 152459-95-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of potent, selective and non toxic c-kit inhibitors for treating
 interstitial cystitis)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:133053 CAPLUS
 DN 138:163522
 TI Use of c-Src inhibitors alone or in combination with ST1571 for the treatment of leukaemia
 IN Donato, Nicholas J.; Fabbro, Doriano; Manley, Paul William; Mestan, Juergen; Warmuth, Markus; Hallek, Michael; Talpaz, Moshe; Wu, Ji
 PA Novartis AG, Switz.; Novartis Pharma GmbH; GSF-National Research Institute for Environment and Health; The University of Texas System
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2003013540 | A1 | 20030220 | WO 2002-EP8941 | 20020809 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR | | | | |
| | CA 2450777 | AA | 20030220 | CA 2002-2450777 | 20020809 |
| | EP 1418917 | A1 | 20040519 | EP 2002-794592 | 20020809 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | CN 1523991 | A | 20040825 | CN 2002-813696 | 20020809 |

| | | | | |
|--|----|----------|----------------|----------|
| JP 2005502643 | T2 | 20050127 | JP 2003-518549 | 20020809 |
| US 2004248906 | A1 | 20041209 | US 2004-485803 | 20040729 |
| US 2006074094 | A1 | 20060406 | US 2005-285664 | 20051122 |
| PRAI US 2001-311690P | P | 20010810 | | |
| WO 2002-EP8941 | W | 20020809 | | |
| US 2004-485803 | A3 | 20040729 | | |
| IT 152459-95-5 220127-57-1 | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (use of c-Src inhibitors alone or in combination with STI571 for
leukemia treatment) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S


RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/519,722

AN 2003:10878 CAPLUS
DN 138:395641
TI Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)
AU La Rosee, Paul; Corbin, Amie S.; Stoffregen, Eric P.; Deininger, Michael W.; Druker, Brian J.
CS Division of Hematology and Medical Oncology, Oregon Health and Sciences University Cancer Institute, Portland, OR, 97239, USA
SO Cancer Research (2002), 62(24), 7149-7153
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activity of Bcr-Abl kinase inhibitor PD180970 against Abl kinase domain mutations that cause resistance to imatinib mesylate)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:977959 CAPLUS
DN 138:51923
TI Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
IN Sawyers, Charles L.; Gorre, Mercedes E.; Shah, Neil Pravin; Nicoll, John

PA The Regents of the University of California, USA
 SO PCT Int. Appl., 129 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002102976 | A2 | 20021227 | WO 2002-US18729 | 20020614 |
| | WO 2002102976 | A3 | 20040805 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2450473 | AA | 20021227 | CA 2002-2450473 | 20020614 |
| | US 2003158105 | A1 | 20030821 | US 2002-171889 | 20020614 |
| | EP 1466174 | A2 | 20041013 | EP 2002-744318 | 20020614 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004537992 | T2 | 20041224 | JP 2003-506431 | 20020614 |
| PRAI | US 2001-298728P | P | 20010614 | | |
| | US 2001-331709P | P | 20011120 | | |
| | WO 2002-US18729 | W | 20020614 | | |
| IT | 220127-57-1, STI-571 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| | CM 1 | | | | |
| | CRN 152459-95-5 | | | | |
| | CMF C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2

CMF C H4 O3 S




LS ANSWER 98 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:946113 CAPLUS
 DN 138:24647
 TI Preparation of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and
 analogs as activators of caspases and inducers of apoptosis for treatment
 of cancer and other proliferative disorders
 IN Cai, Sui Xiong; Zhang, Han-Zhong; Drewe, John; Kasibhatla, Shailaja
 PA Cytovia, Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2002098425 | A1 | 20021212 | WO 2002-US17486 | 20020604 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1404329 | A1 | 20040407 | EP 2002-741817 | 20020604 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2005165053 | A1 | 20050728 | US 2003-477953 | 20031118 |
| PRAI | US 2001-295007P | P | 20010604 | | |
| | WO 2002-US17486 | W | 20020604 | | |
| OS | MARPAT 138:24647 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration agent; coadministration of (arylpropenoyl)-2(1H)-
quinolinone caspases activators with known cancer therapeutic agents
for treatment of cancer) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:946109 CAPLUS
 DN 138:24718
 TI Preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases and inducers of apoptosis
 IN Cai, Sui Xiong; Nguyen, Bao Ngoc; Drewe, John; Reddy, P. Sanjeева; Kasibhatla, Shailaja; Pervin, Azra
 PA Cytovia, Inc., USA
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002098420 | A1 | 20021212 | WO 2002-US17108 | 20020531 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1399159 | A1 | 20040324 | EP 2002-734605 | 20020531 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2003045581 | A1 | 20030306 | US 2002-158827 | 20020603 |
| | US 6794400 | B2 | 20040921 | | |
| PRAI | US 2001-294641P | P | 20010601 | | |
| | WO 2002-US17108 | W | 20020531 | | |
| OS | MARPAT 138:24718 | | | | |
| IT | 220127-57-1, Gleevec | | | | |

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of 4-substituted-1-(aryl methylidene)thiosemicarbazides and
 4-substituted-1-(aryl carbonyl)thiosemicarbazides for treating cancer in
 combination with)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:778718 CAPLUS

DN 137:289046

TI Methods and compositions for enhancing pharmaceutical treatments

IN Newman, Michael J.; Dixon, William Ross

PA USA

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|------|----------|-----------------|----------|
| PI US 2002147197 | A1 | 20021010 | US 2002-104549 | 20020320 |
| PRAI US 1999-158322P | P | 19991008 | | |
| US 2000-684293 | A2 | 20001006 | | |

OS MARPAT 137:289046


IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, derivs.,
 analogs, and metabolites

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(methods and compns. for enhancing pharmaceutical treatments)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:675840 CAPLUS

DN 137:226590

TI Use of epothilone derivatives and a signal transduction inhibitor for the treatment of cancer

IN Buchdunger, Elisabeth; Heldin, Carl-Henrik; Oestman, Arne; Pietras, Kristian; O'Reilly, Terence; Rothermel, John David; Traxler, Peter; Wartmann, Markus

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Brandt, Ralf

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2002067941 | A2 | 20020906 | WO 2002-EP2049 | 20020226 |
| | WO 2002067941 | A3 | 20031120 | | |
| | WO 2002067941 | C1 | 20031218 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| | CA 2439268 | AA | 20020906 | CA 2002-2439268 | 20020226 |
| | EP 1385522 | A2 | 20040204 | EP 2002-744903 | 20020226 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | BR 2002007649 | A | 20040309 | BR 2002-7649 | 20020226 |
| | CN 1511036 | A | 20040707 | CN 2002-805608 | 20020226 |

JP 2004527493 T2 20040909 JP 2002-567308 20020226
 NZ 527764 A 20060127 NZ 2002-527764 20020226
 ZA 2003006404 A 20040607 ZA 2003-6404 20030818
 NO 2003003769 A 20030825 NO 2003-3769 20030825
 US 2004132754 A1 20040708 US 2004-469367 20040218
 PRAI GB 2001-4840 A 20010227
 US 2001-339040P P 20011030
 WO 2002-EP2049 W 20020226
 OS MARPAT 137:226590
 IT 220127-57-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (STI 571; use of epothilone derivs. and a signal transduction inhibitor
 for the treatment of cancer)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O




CM 2

 CRN 75-75-2
 CMF C H4 O3 S


L5 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:593669 CAPLUS
 DN 138:198235
 TI Characterization of potent inhibitors of the Bcr-Abl and the c-kit
 receptor tyrosine kinases
 AU Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel;
 Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas;
 Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard
 CS Molecular Pharmacology and Chemistry Program, New York, NY, 10021, USA
 SO Cancer Research (2002), 62(15), 4244-4255
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal


10/519,722

LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of potent inhibitors of Bcr-Abl and the c-kit receptor tyrosine kinases and their antitumor effect)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:465821 CAPLUS
DN 137:47211
TI Substituted 2-aryl-4-arylaminoypyrimidines and analogs as activators of caspases and inducers of apoptosis, their preparation, and the use thereof as, e.g., anticancer agents
IN Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin, Azra
PA Cytovia, Inc., USA
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2002047690 | A1 | 20020620 | WO 2001-US47498 | 20011212 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002028922 A5 20020624 AU 2002-28922 20011212
 US 2003069239 A1 20030410 US 2001-12444 20011212
 US 6716851 B2 20040406
 EP 1351691 A1 20031015 EP 2001-990048 20011212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004097503 A1 20040520 US 2003-704448 20031110
 PRAI US 2000-254581P P 20001212
 US 2001-12444 A3 20011212
 WO 2001-US47498 W 20011212
 OS MARPAT 137:47211
 IT 438248-82-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(2-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)
 RN 438248-82-9 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(2-(4-pyridinyl)-6-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:686951 CAPLUS
 DN 136:111944
 TI Bcr-Abl inhibition as a modality of CML therapeutics
 AU Buchdunger, E.; Matter, A.; Druker, B. J.
 CS Research Oncology, Novartis Pharma AG, Basel, CH-4002, Switz.
 SO Biochimica et Biophysica Acta, Reviews on Cancer (2001), 1551(1), M11-M18
 CODEN: BBACEU; ISSN: 0304-419X
 PB Elsevier B.V.
 DT Journal; General Review
 LA English
 IT 220127-57-1
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (STI 571; Bcr-Abl inhibition as modality of chronic myelogenous leukemia therapeutics)

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

379.57

547.16

STN INTERNATIONAL LOGOFF AT 13:50:07 ON 29 SEP 2006


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:380210 CAPLUS

DN 125:114681

TI Pyrimidine derivatives and processes for the preparation thereof

IN Zimmermann, Juerg

PA Ciba-Geigy Corporation, USA

SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------|------|----------|-----------------|----------|
| PI US 5521184 | A | 19960528 | US 1994-234889 | 19940428 |
| CA 2148477 | AA | 19950413 | CA 1994-2148477 | 19940921 |
| PRAI CH 1992-1083 | A | 19920403 | | |
| US 1993-42322 | B2 | 19930402 | | |
| CH 1993-2966 | A | 19931001 | | |

OS MARPAT 125:114681

IT 152459-93-3P 152459-95-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidine derivs. as antitumor agents)

RN 152459-93-3 CAPLUS



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:CLASS17:Atom 18:Atom 21:CLASS22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

18:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

O,O0

S,S0



N,N0-3

Node 18: Limited

O,O0

S,S0

N,N1-2



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:CLASS17:Atom 18:Atom 21:CLASS22:CLASS

Generic attributes :

17:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

18:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

O,O0
S,S0
N,N0-3

Node 18: Limited

O,O0
S,S0
N,N1-2

10/519,722

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 19 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 20 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 x 25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10/519,722

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:44:50 ON 29 SEP 2006

=> file reg
COST IN U.S. DOLLARS

| | SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:44:58 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7
DICTIONARY FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10519722.str



chain nodes :
 7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom 21:CLASS
 22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

10/519,722

18:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 17: Limited
O,OO
S,SO
N,N0-3

Node 18: Limited
O,OO
S,SO
N,N1-2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:45:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 336 TO ITERATE

100.0% PROCESSED 336 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5621 TO 7819
PROJECTED ANSWERS: 132 TO 668

L2 20 SEA SSS SAM L1

=> d scan
L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[(methyl-3-pyrrolidinylamino)methyl]- (9CI)
MF C29 H31 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):19

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)
 MF C29 H31 N7 O . x C5 H8 O4

CM 1




CM 2

HO2C-(CH2)3-CO2H

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(*(3S)*-3-(dimethylamino)-1-pyrrolidinyl)methyl]-3-(trifluoromethyl)- (9CI)
 MF C32 H35 F3 N8 O
 CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(*(3S)*-3-(dimethylamino)-1-piperidinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
 MF C31 H33 F3 N8 O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI)
 MF C32 H33 F3 N6 O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI)
 MF C30 H33 N7 O . C2 H4 O2


CM 1



CM 2




L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)
 MF C30 H31 Br N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[4-chloro-3-[(1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)-
 (9CI)
 MF C29 H28 Cl F3 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (1:2)
 (9CI)
 MF C29 H31 N7 O . 1/2 C5 H8 O4

CM 1




CM 2

HO₂C-(CH₂)₃-CO₂H

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(2R,4S)-
 4-(dimethylamino)-2-methyl-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-
 (9CI)
 MF C31 H33 F3 N8 O
 CI COM


Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-(2-
 hydroxyethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI)
 MF C30 H31 F3 N8 O2
 CI COM


PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-ethyl-4-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI)
 MF C₃₀ H₃₄ N₈ O . Cl H



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI)
 MF C₂₉ H₃₁ N₇ O
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


10/519, 722

IN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI)
MF C26 H24 F3 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI)
MF C30 H31 F3 N8 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI)
MF C29 H31 N7 O . Cl H




● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3-
 (dimethylamino)-1-azetidinyl)methyl]-3-(trifluoromethyl)-,
 monohydrochloride (9CI)
 MF C29 H29 F3 N8 O . Cl H



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-6-ylamino)-4-methylphenyl]-4-[(4-
 methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
 MF C29 H29 F3 N8 O . Cl H



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[(4-[(3-aminopropyl)amino]butyl)amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI)

MF C29 H31 N7 O . C17 H37 N7 O3


CI MXS

CM 1



CM 2


Absolute stereochemistry. Rotation (-).



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-nitro- (9CI)

MF C29 H30 N8 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful

FULL SEARCH INITIATED 13:45:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6526 TO ITERATE

100.0% PROCESSED 6526 ITERATIONS
SEARCH TIME: 00.00.01

325 ANSWERS

L3 325 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 167.38 | 167.59 |

FILE 'CAPLUS' ENTERED AT 13:46:03 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 2002 L3

=> l4 and (pyridine or pyrimidine or pyrazine or pyridazine)
L4 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.

10/519,722


For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 14 and (pyridine or pyridazine or pyrazine or pyrimidine)
211669 PYRIDINE
6728 PYRIDAZINE
12811 PYRAZINE
54368 PYRIMIDINE
L5 106 L4 AND (PYRIDINE OR PYRIDAZINE OR PYRAZINE OR PYRIMIDINE)

=> d 15 1-105 bib hitstr

L5 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:817911 CAPLUS
DN 145:249188
TI Preparation of tetrahydropyrido thiophenes as antiproliferative agents for
the treatment of cancer
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,
Bjoern
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 158pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006084904 | A1 | 20060817 | WO 2006-EP50859 | 20060210 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-101007 | A | 20050211 | | |
| | EP 2005-104493 | A | 20050525 | | |
| | EP 2005-112159 | A | 20051214 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of tetrahydropyrido thiophenes as antiproliferative and
apoptosis-inducing agents useful in treatment of cancer) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




10/519,722

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:817524 CAPLUS
DN 145:249187
TI Preparation of tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels, Bjoern
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 154pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006084869 | A1 | 20060817 | WO 2006-EP50782 | 20060208 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI EP 2005-100895 | A | 20050209 | | |
| EP 2005-104488 | A | 20050525 | | |
| EP 2005-112158 | A | 20051214 | | |
| IT 152459-95-5, Imatinib | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (preparation of tetrahydropyridothiophenes with cell-cycle dependent,
antiproliferative and apoptosis-inducing activity useful in treatment
of hyperproliferative diseases such as cancer) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:768666 CAPLUS
DN 145:188880
TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and their preparation, pharmaceutical compositions and antiproliferative and

10/519,722

apoptosis inducing activity
IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra;
Beckers, Thomas; Schmidt, Mathias; Ciossek, Thomas; Nappe, Sandra

PA Altana Pharma AG, Germany
SO PCT Int. Appl., 56pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006079644 | A1 | 20060803 | WO 2006-EP50465 | 20060126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-100594 | A | 20050128 | | |
| | EP 2005-100913 | A | 20050209 | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of indolopyridines, benzofuranopyridines, and
benzothienopyridines with antiproliferative and apoptosis inducing
activity) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768650 CAPLUS

DN 145:211060

TI Preparation of substituted phenylaminopyrimidines as B-Raf inhibitors

IN Aquila, Brian; Lyne, Paul; Pontz, Timothy

PA AstraZeneca AB, Swed.; AstraZeneca UK Limited

SO PCT Int. Appl., 59pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
| | | | | |

PI WO 2006079791 A1 20060803 WO 2006-GB223 20060124
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI US 2005-646820P P 20050125

OS MARPAT 145:211060


IT 904326-67-6P 904326-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted phenylaminopyrimidines as B-Raf inhibitors for treating cancer)


RN 904326-67-6 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[dimethylamino]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 904326-68-7 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[4-methyl-1-piperazinylmethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768370 CAPLUS

DN 145:188879

TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and their preparation, pharmaceutical compositions and antiproliferative and apoptosis inducing activity

IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra
 PA Altana Pharma AG, Germany

10/519,722

SO PCT Int. Appl., 61pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006079645 | A1 | 20060803 | WO 2006-EP50467 | 20060126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | EP 2005-100526 | A | 20050127 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of indolopyridines, benzofuranopyridines, and
benzothienopyridines with antiproliferative and apoptosis inducing
activity) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:729704 CAPLUS

DN 145:159791

TI 2-Phenylquinoxalines as inhibitors of MPP1 for treatment of proliferative diseases

IN Nigg, Erich A.; Mayer, Thomas U.; Huemmer, Stefan; Barr, Francis; Bormann, Jenny

PA Max-Planck-Gesellschaft Zur Foerderung der Wissenschaften e.v., Germany

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | EP 1683523 | A1 | 20060726 | EP 2005-1419 | 20050125 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,


BA, HR, IS, YU
 WO 2006079478 A1 20060803 WO 2006-EP459 20060119
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 PRAI EP 2005-1419 A 20050125
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination with; phenylquinoxalines as inhibitors of human
 phosphoprotein MPPI for treatment of cancer and proliferative diseases)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:657352 CAPLUS
 DN 145:124614
 TI Multi-step process for preparing imatinib
 IN Huang, Anli; Xing, Liu; Zelikovitch, Lior; Kaspi, Joseph
 PA Peop. Rep. China
 SO U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2006149061 | A1 | 20060706 | US 2005-318455 | 20051228 |
| PRAI | US 2004-640013P | P | 20041230 | | |
| OS | CASREACT 145:124614 | | | | |
| IT | 152459-95-5P, Imatinib | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation)
(multi-step process for preparing imatinib) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:655575 CAPLUS

DN 145:124558

TI Preparation of pyrazolyl phenyl ureas as enzyme modulators

IN Flynn, Daniel L.; Petillo, Peter A.

PA Deciphera Pharmaceuticals, LLC, USA

SO PCT Int. Appl., 974 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------------|----------|-----------------|----------|
| PI | WO 2006071940 | A2 | 20060706 | WO 2005-US47270 | 20051223 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-638968P | P | 20041223 | | |
| | US 2004-638986P | P | 20041223 | | |
| | US 2004-638987P | P | 20041223 | | |
| | US 2004-639087P | P | 20041223 | | |
| OS | MARPAT | 145:124558 | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (co-drug; preparation of pyrazolyl Ph ureas as enzyme modulators for treating cancer and hyperproliferative diseases) | | | | |
| RN | 220127-57-1 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) | (CA INDEX NAME) | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2


CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:513267 CAPLUS
 DN 145:21160
 TI Methods and compositions for the treatment of graft failure
 IN Sukhatme, Vikas P.
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|----------|-----------------|----------|
| PI WO 2006057951 | A2 | 20060601 | WO 2005-US42111 | 20051121 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI US 2004-630242P | P | 20041122 | | |
| IT 220127-57-1, Gleevec | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(compns. for treatment of graft failure) | | | | |
| RN 220127-57-1 | CAPLUS | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S




L5 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:463553 CAPLUS
DN 144:488677
TI Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2006106023 | A1 | 20060518 | US 2005-272392 | 20051110 |
| | US 2004063715 | A1 | 20040401 | US 2003-665005 | 20030919 |
| | US 6919341 | B2 | 20050719 | | |
| | US 2005130980 | A1 | 20050616 | US 2005-47524 | 20050131 |
| PRAI | US 2002-412997P | P | 20020923 | | |
| | US 2003-665005 | A3 | 20030919 | | |
| | US 2005-47524 | A2 | 20050131 | | |
| OS | MARPAT 144:488677 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2


CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:412038 CAPLUS
 DN 144:450735
 TI Preparation of novel aminopyridine derivatives having selective Aurora-A protein kinase inhibitory effect
 IN Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi;
 Shimomura, Toshiyasu
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006046734 | A2 | 20060504 | WO 2005-JP19957 | 20051025 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006106029 | A1 | 20060518 | US 2005-258447 | 20051025 |
| PRAI | JP 2004-315152 | A | 20041029 | | |
| | JP 2005-161156 | A | 20050601 | | |

10/519,722

US 2005-692537P P 20050621
OS MARPAT 144:450735
IT 152459-95-5, Imatinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(novel aminopyridine derivs. having selective Aurora-A inhibitory
effect)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:372184 CAPLUS
DN 145:34047
TI Anticancer implant compositions containing vasoinhibitor/
pyrimidine derivative composite implant
IN Kong, Qingzhong; Sun, Juan; Liu, Enxiang
PA Peop. Rep. China
SO Faming Zhanli Shengqing Gongkai Shuomingshu, 18 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|------|----------|------------------|----------|
| PI CN 1733300 | A | 20060215 | CN 2005-10044377 | 20050805 |
| PRAI CN 2005-10044377 | | 20050805 | | |

IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(vasoinhibitor/pyrimidine derivative antitumor composite implant)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)

CM 1
CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:333442 CAPLUS
 DN 144:370121
 TI Preparation of pyrimidine derivatives as phosphatase and kinase inhibitors for treating a variety of diseases
 IN Klebl, Bert; Baumann, Matthias; Hoppe, Edmund; Brehmer, Dirk; Daub, Henrik; Keri, Gyoergy; Varga, Zoltan; Marosfalvi, Jenoe; Oerfi, Laszlo
 PA GPC Biotech A.-G., Germany
 SO PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2006021458 | A2 | 20060302 | WO 2005-EP9291 | 20050829 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-604685P | P | 20040827 | | |
| OS | MARPAT 144:370121 | | | | |
| IT | 152459-93-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 152459-95-5P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 475587-66-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-2-yl)pyrimidin-2-yl)amino]phenyl]benzamide 872672-74-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-2-yl)pyrimidin-2-yl)amino]phenyl]benzamide 881676-19-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-4-yl)pyrimidin-2-yl)amino]phenyl]benzamide 881677-62-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[(4-(pyridin-4-yl)pyrimidin-2-yl)amino]phenyl]benzamide | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidine derivs. as phosphatase and kinase inhibitors for treating a variety of diseases) | | | | |
| RN | 152459-93-3 CAPLUS | | | | |


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-66-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 872672-74-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 881676-19-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 881677-62-9 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:333345 CAPLUS

DN 144:350709

TI Pyrazolopyrimidines as protein kinase B inhibitors, their preparation, pharmaceutical compositions, and use in therapy

IN Maier, Thomas; Zuelch, Armin; Ciossek, Thomas; Baer, Thomas; Beckers, Thomas

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006027346 | A2 | 20060316 | WO 2005-EP54366 | 20050905 |
| | WO 2006027346 | A3 | 20060803 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |

PRAI EP 2004-104283 A 20040906

OS MARPAT 144:350709

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(novel pyrazolopyrimidine compds. useful in therapy of
hyper-proliferative diseases and disorders responsive to induction of
apoptosis)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318488 CAPLUS

DN 144:369909

TI Preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors

IN Bold, Guido; Caravatti, Giorgio; Floersheimer, Andreas; Furet, Pascal;
Manley, Paul W.; Pissot Soldermann, Carole; Vaupel, Andrea

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|-----------------|----------|
| PI | WO 2006034833 | A1 | 20060406 | WO 2005-EP10408 | 20050927 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | GB 2004-21525 | A | 20040928 | | |
| OS | MARPAT | 144:369909 | | | |
| IT | 220127-57-1, Glivec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(claimed drug for co-administration; preparation of cyclic diaryl ureas
suitable as tyrosine kinase inhibitors) | | | | |
| RN | 220127-57-1 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:196073 CAPLUS
 DN 144:274310
 TI Preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use
 IN Wrasidlo, Wolfgang; Dneprovskaya, Elena
 PA Targegen, Inc., USA
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2


DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006024034 | A1 | 20060302 | WO 2005-US30614 | 20050824 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006079526 | A1 | 20060413 | US 2005-212064 | 20050824 |
| PRAI | US 2004-604298P | P | 20040825 | | |
| | US 2005-696168P | P | 20050701 | | |
| OS | MARPAT 144:274310 | | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (codrug; preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use) | | | | |

10/519,722

RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:176834 CAPLUS

DN 144:370108

TI Preparation and application of phenylamino pyrimidine derivatives

IN Chen, Guoqing

PA Chen Guoqing, Peop. Rep. China

SO Faming Zhanli Shengqing Gongkai Shuomingshu, 41 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|------------------|----------|
| PI | CN 1560050 | A | 20050105 | CN 2004-10014093 | 20040218 |
| PRAJ | CN 2004-10014093 | | | | |



IT 791609-82-OP 791609-84-2P 791609-85-3P

882166-67-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and application of phenylamino pyrimidine derivs.)


RN 791609-82-0 CAPLUS

CN Benzamide, 4-[(methyl(1-methyl-3-pyrrolidinyl)amino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 791609-84-2 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[[[(1-methyl-3-pyrrolidinyl)amino]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 791609-85-3 CAPLUS
CN Benzamide, N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
Me

RN 882166-67-8 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-4-[(methyl-3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:167936 CAPLUS
 DN 144:254145
 TI Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.
 PA Schering Corporation, USA
 SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2006041131 | A1 | 20060223 | US 2005-244772 | 20051006 |
| | US 2004106624 | A1 | 20040603 | US 2003-653776 | 20030903 |
| | US 7067661 | B2 | 20060627 | | |
| | US 2006178371 | A1 | 20060810 | US 2006-395676 | 20060331 |
| PRAI | US 2002-408029P | P | 20020904 | | |
| | US 2003-653776 | A2 | 20030903 | | |
| OS | MARPAT 144:254145 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (preparation of novel pyrazolopyrimidines as cyclin dependent kinase | | | | |

10/519,722

inhibitors for treatment and prevention of diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:167588 CAPLUS

DN 144:254148

TI Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy

IN Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2006018182 | A1 | 20060223 | WO 2005-EP8623 | 20050809 |
| | WO 2006018182 | C1 | 20060608 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, | | | |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

US 2006058311 A1 20060316 US 2005-189540 20050726
 PRAI EP 2004-19361 A 20040814
 EP 2004-19448 A 20040817
 OS MARPAT 144:254148
 IT 152459-95-5, Imatinib
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of aminopteridinones for use in combination therapy for
 treatment of cell proliferative diseases)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:117065 CAPLUS
 DN 144:184657
 TI Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide
 IN Breedveld, Pauline; Cipriani, Greta; Pluim, Dick; Schellens, Johannes Henricus Matthias; Van Tellingen, Olaf; Wielinga, Pieter Roeland
 PA The Netherlands Cancer Institute, Neth.
 SO PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2006012958 | A2 | 20060209 | WO 2005-EP7090 | 20050630 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM | | | | |

PRAI US 2004-584825P P 20040701

IT 152459-95-5 220127-57-1


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)

10/519,722

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 874946-80-2 874946-81-3 874946-82-4

874946-83-5 874946-84-6 874946-85-7

875128-64-6 875128-67-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)


RN 874946-80-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 102625-70-7
CMF C16 H15 F2 N3 O4 S




RN 874946-81-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with (3S,8aS)-hexahydro-3-[[6-methoxy-2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]pyrrolo[1,2-a]pyrazine-1,4-dione (9CI) (CA INDEX NAME)

CM 1


CRN 171864-80-5
CMF C22 H27 N3 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




RN 874946-82-4 CAPLUS

CN Benzamide, 4-[[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (5aS,12S,14aS)-1,2,3,5a,6,11,12,14a-octahydro-9-methoxy-12-(2-methyl-1-propenyl)-5H,14H-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,14-dione (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 118974-02-0

CMF C22 H25 N3 O3

Absolute stereochemistry.

RN 874946-83-5 CAPLUS


CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid, 1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxo-, 1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 461054-93-3

CMF C26 H35 N3 O5


Absolute stereochemistry. Rotation (-).



CM 2


CRN 152459-95-5
CMF C29 H31 N7 ORN 874946-84-6 CAPLUS
CN 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2


CRN 143664-11-3
CMF C34 H33 N3 O5



RN 874946-85-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride (9CI) (CA INDEX NAME)


CM 1

CRN 289499-45-2
 CMF C24 H25 Cl F N5 O3 . 2 Cl H



●2 HCl

CM 2


CRN 152459-95-5
CMF C29 H31 N7 O

RN 875128-64-6 CAPLUS
 CN Carbamic acid, [4-[(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl]butyl]-, 1,1-dimethylethyl ester, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 329356-42-5
CMF C27 H38 N4 O4


Absolute stereochemistry.



10/519,722

CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




RN 875128-67-9 CAPLUS
CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid,
1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxo-,
1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-
pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 329356-45-8
CMF C25 H33 N3 O4

Absolute stereochemistry.




CM 2

CRN 152459-95-5
CMF C29 H31 N7 O




L5 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:87941 CAPLUS
DN 144:331390
TI Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl
kinase inhibitors
AU Asaki, Tetsuo; Sugiyama, Yukiteru; Hamamoto, Taisuke; Higashioka, Masaya;

Umehara, Masato; Naito, Haruna; Niwa, Tomoko
 CS Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Minami-ku,
 Kyoto, Kisshoin, 601-8550, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1421-1425
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:331390
 IT 641614-88-2P 859212-07-0P 859212-16-1P, NS-187
 859212-47-8P 859212-49-0P 859212-51-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation N-[(bipyrimidinyl)amino](methyl)phenyl](trifluoromethyl)benzamide
 ide derivs. and study of their activity as Bcr-Abl kinase inhibitors)
 RN 641614-88-2 CAPLUS
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-
 methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 859212-07-0 CAPLUS
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3R)-3-
 (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 859212-16-1 CAPLUS

10/519,722


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859212-47-8 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-(dimethylamino)-1-azetidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 859212-49-0 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3R)-3-[(dimethylamino)methyl]-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 859212-51-4 CAPLUS
CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(3S)-3-((dimethylamino)methyl)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 641614-83-7P 641614-84-8P 641614-85-9P

641614-86-0P 641614-87-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)


(preparation halo[(piperazinyl)methyl][methyl[(pyridinyl)pyrimidinyl]amino]phenyl]benzamide derivs. and study of their activity as Bcr-Abl kinase inhibitors)

10/519, 722


RN 641614-83-7 CAPLUS
CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-84-8 CAPLUS
CN Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS
CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-86-0 CAPLUS
CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-87-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 220127-57-1, STI-571

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation substituted benzamide derivs., study of their activity as gene
 Bcr-Abl fusion protein- phosphorylating kinase (Bcr-Abl kinase)
 inhibitors and their activity against STI-571-resistant chronic myeloid
 leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:15086 CAPLUS

DN 144:108347

TI Preparation of pyrimidine urea derivatives as kinase inhibitors
 for use against proliferative diseasesIN Ding, Qiang; Gray, Nathanael Schiander; Li, Bing; Liu, Yi; Sim, Taebo;
 Uno, Tetsuo; Zhang, Guobao; Pissot Soldermann, Carole; Breitenstein,
 Werner; Bold, Guido; Caravatti, Giorgio; Furet, Pascal; Guagnano, Vito;
 Lang, Marc; Manley, Paul W.; Schoepfer, Joseph; Spanka, Carsten

10/519,722

PA Novartis AG, Switz.
SO PCT Int. Appl., 327 pp.
CODEN: PIXXD2


DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006000420 | A1 | 20060105 | WO 2005-EP6815 | 20050623 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-582425P | P | 20040624 | | |
| | GB 2005-12324 | A | 20050616 | | |
| OS | MARPAT 144:108347 | | | | |
| IT | 220127-57-1, Glivec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of pyrimidine urea derivs. as kinase
inhibitors for use against proliferative diseases) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



10/519,722

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1329776 CAPLUS
DN 144:45462
TI Pharmacologically active substances in combination with radio waves for
the treatment of cancer
IN Kalbe, Jochen; Ludwig, Georg
PA Germany
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|----------------------|----------|
| PI | WO 2005120638 | A1 | 20051222 | WO 2005-DE1028 | 20050609 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | DE 102004028156 | A1 | 20060105 | DE 2004-102004028156 | 20040609 |
| PRAI | DE 2004-102004028156 A | | 20040609 | | |
| | US 2004-585061P | P | 20040706 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug-radio wave combination for treatment of cancer) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1289902 CAPLUS
DN 144:17212
TI Use of c-kit inhibitors for treating fibrodysplasia
IN Moussy, Alain; Kinet, Jean-Pierre
PA Ab Science, Fr.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2005115304 | A2 | 20051208 | WO 2005-IB1371 | 20050419 |
| | WO 2005115304 | A3 | 20060406 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2004-573345P | P | 20040524 | | |
| OS | MARPAT 144:17212 | | | | |
| IT | 152459-95-5 | | | | |
| | RL: | PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | |
| | | (c-kit inhibitors for treating fibrodysplasia) | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1289861 CAPLUS

DN 144:17211

TI Use of c-kit inhibitors for treating acne

IN Moussy, Alain; Kinet, Jean-Pierre

PA Ab Science, Fr.

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005115385 | A1 | 20051208 | WO 2005-IB1366 | 20050419 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | | | |

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRAI US 2004-573351P P 20040524


OS MARPAT 144:17211

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treating acne)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1262399 CAPLUS

DN 144:22712

TI Triaryl compounds as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

IN Epple, Robert; Azimioara, Mihai

PA Irm LLC, Bermuda

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005113506 | A1 | 20051201 | WO 2005-US16747 | 20050513 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRAI US 2004-571004P P 20040514

OS MARPAT 144:22712


IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(preparation of triaryl compds. as PPAR modulators and their use for treatment and prevention of diseases associated with PPAR δ activity)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1239173 CAPLUS
DN 143:477963
TI Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer
IN Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum
PA Bayer Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|-----------------|----------|
| PI | WO 2005110994 | A2 | 20051124 | WO 2005-US15106 | 20050502 |
| | WO 2005110994 | A3 | 20060202 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| PRAI | US 2004-566445P | P | 20040430 | | |
| OS | MARPAT | 143:477963 | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(substituted pyrazolylurea derivs. useful for cancer treatment) | | | | |
| RN | 220127-57-1 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1170688 CAPLUS
 DN 143:432622
 TI Use of c-kit inhibitors for treating HIV-related diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005102318 | A1 | 20051103 | WO 2005-IB1433 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |

PRAI US 2004-563442P P 20040420


OS MARPAT 143:432622

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (c-kit inhibitors for treatment of HIV-related diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170667 CAPLUS

DN 143:432692

TI / Use of c-kit inhibitors for treating fibrosis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 67 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|---|----------|
| PI | WO 2005102346 | A2 | 20051103 | WO 2005-IB1391 | 20050419 |
| | WO 2005102346 | A3 | 20060330 | | |
| | | | | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | |
| PRAI | US 2004-564569P | P | 20040423 | | |
| OS | MARPAT | 143:432692 | | | |
| IT | 152459-95-5 | | | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treatment of fibrosis) | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170651 CAPLUS

10/519,722

DN 143:432621
TI Use of c-kit inhibitors for treating plasmodium-related diseases
IN Moussy, Alain; Kinet, Jean-Pierre
PA Ab Science, Fr.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005102455 | A1 | 20051103 | WO 2005-IB1390 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |

PRAI US 2004-564599P P 20040423


OS MARPAT 143:432621

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(c-kit inhibitors for treating plasmodium-related diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170633 CAPLUS

DN 143:432657

TI Use of c-kit inhibitors for treating renal diseases

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2005102326 | A2 | 20051103 | WO 2005-IB1370 | 20050419 |
| | WO 2005102326 | A3 | 20060330 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
 SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
 ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRAI US 2004-564586P P 20040423


OS MARPAT 143:432657

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (c-kit inhibitors for treatment of renal disease)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4'-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170607 CAPLUS

DN 143:432650

TI Use of c-kit inhibitors for treating inflammatory muscle disorders
 including myositis and muscular dystrophy

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005102325 | A1 | 20051103 | WO 2005-IB1367 | 20050419 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |

PRAI US 2004-563460P P 20040420

OS MARPAT 143:432650


IT 152459-95-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (c-kit inhibitors for treatment of inflammatory muscle disorders
 including myositis and muscular dystrophy)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1006008 CAPLUS
 DN 143:260361
 TI Leptomycin B combination with chemotherapeutic agents for the treatment of proliferative diseases
 IN Santi, Daniel V.; Zhou, Yiqing
 PA Kosan Biosciences, Inc., USA
 SO U.S. Pat. Appl. Publ., 4 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|--|-----------------|----------|
| PI | US 2005203174 | A1 | 20050915 | US 2005-58447 | 20050214 |
| | WO 2005086944 | A2 | 20050922 | WO 2005-US8124 | 20050309 |
| | WO 2005086944 | A3 | 20051215 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: | | |
| | | | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | |
| PRAI | US 2004-551970P | P | 20040309 | | |
| | US 2005-58447 | A | 20050214 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(leptomycin B combination with chemotherapeutic agents for treatment of
proliferative diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:823686 CAPLUS

DN 143:216705

TI Preparation of salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide (imatinib)

IN Buerger, Hans Michael; Manley, Paul William; Mutz, Michael

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 16 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|---|----------|-----------------|----------|
| PI | WO 2005075454 | A2 | 20050818 | WO 2005-EP1077 | 20050203 |
| | WO 2005075454 | A3 | 20060727 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005211514 | A1 | 20050818 | AU 2005-211514 | 20050203 |
| PRAI | US 2004-541817P | P | 20040204 | | |
| | WO 2005-EP1077 | W | 20050203 | | |
| IT | 152459-95-5DP, Imatinib, salts | 862366-24-3P
862366-25-4P 862366-26-5P 862366-27-6P
862366-28-7P 862366-30-1P 862366-31-2P
862366-32-3P 862366-33-4P 862366-34-5P
862366-35-6P 862366-36-7P 862366-37-8P
862366-38-9P 862366-39-0P 862366-40-3P
862366-41-4P 862366-42-5P 862366-43-6P
862366-44-7P 862366-45-8P 862366-46-9P
862366-47-0P 862366-48-1P 862366-49-2P
862366-50-5P 862366-51-6P | | | |
| | RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of salt forms of imatinib) | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) | (CA INDEX NAME) | | | |




RN 862366-24-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.

RN 862366-25-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 862366-26-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 862366-27-6 CAPLUS

CN Butanedioic acid, hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 6915-15-7
CMF C4 H6 O5

RN 862366-28-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2E)-2-butenedioate (1:1) (9CI)
 (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 862366-30-1 CAPLUS
 CN Butanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 862366-31-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 862366-32-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 98-11-3
CMF C6 H6 O3 S



RN 862366-33-4 CAPLUS
CN 2-Naphthalene carboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 130-85-8
CMF C23 H16 O6




RN 862366-34-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 862366-35-6 CAPLUS


CN Benzoic acid, 4-hydroxy-3-methoxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O

10/519,722



CM 2


CRN 121-34-6
CMF C8 H8 O4



RN 862366-36-7 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 100-88-9
CMF C6 H13 N O3 S




RN 862366-37-8 CAPLUS
CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 110-94-1
CMF C5 H8 O4

HO₂C—(CH₂)₃—CO₂H

RN 862366-38-9 CAPLUS
CN Propanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 141-82-2
CMF C3 H4 O4

HO₂C—CH₂—CO₂H


RN 862366-39-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

10/519, 722


CMF C29 H31 N7 O



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 862366-40-3 CAPLUS

CN Hexanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 124-04-9

CMF C6 H10 O4

HO₂C-(CH₂)₄-CO₂H


RN 862366-41-4 CAPLUS

CN Benzeneacetic acid, α -hydroxy-, (αR)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

10/519,722


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 611-71-2
CMF C8 H8 O3


Absolute stereochemistry. Rotation (-).



RN 862366-42-5 CAPLUS
CN Butanedioic acid, hydroxy-, (2R)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 636-61-3
CMF C4 H6 O5

Absolute stereochemistry.




RN 862366-43-6 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2S,3S)-2,3-dihydroxybutanedioate
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 147-71-7
CMF C4 H6 O6


Absolute stereochemistry.



RN 862366-44-7 CAPLUS
CN Formic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

10/519, 722


RN 862366-45-8 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




RN 862366-46-9 CAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 862366-47-0 CAPLUS

CN Propanoic acid, 2-hydroxy-, (2S)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 79-33-4

CMF C3 H6 O3

Absolute stereochemistry. Rotation (+).




RN 862366-48-1 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

10/519,722


CRN 110-94-1
CMF C5 H8 O4



RN 862366-49-2 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, compd. with 3,4-dihydroxy-3-cyclobutene-1,2-dione (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 2892-51-5
CMF C4 H2 O4



RN 862366-50-5 CAPLUS
CN Butanedioic acid, oxo-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



10/519,722

CM 2

CRN 328-42-7
CMF C4 H4 05




RN 862366-51-6 CAPIUS

KN 362666-31-1
CN L-Ascorbic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.




IT 152459-95-5, Imatinib

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of salt forms of imatinib)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:729564 CAPLUS
 DN 143:186693
 TI Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
 IN Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene
 PA Emory University, USA
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005072826 | A2 | 20050811 | WO 2005-US1710 | 20050120 |
| | WO 2005072826 | A3 | 20060420 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | AU 2005209231 | A1 | 20050811 | AU 2005-209231 | 20050120 |
| | CA 2554201 | AA | 20050811 | CA 2005-2554201 | 20050120 |
| PRAI | US 2004-537960P | P | 20040121 | | |
| | US 2004-553681P | P | 20040316 | | |
| | US 2004-614203P | P | 20040929 | | |
| | WO 2005-US1710 | W | 20050120 | | |
| OS | MARPAT 143:186693 | | | | |
| IT | 152459-95-5 152459-95-5D, derivs. 220127-57-1,
Imatinib mesylate 220127-57-1D, Imatinib mesylate, derivs.
593281-61-9, STI-X 593281-61-9D, derivs. | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(tyrosine kinase inhibitors for treatment of pathogenic infection) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 593281-61-9 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 593281-61-9 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:567125 CAPLUS
DN 143:90993
TI Combination of N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and at least one

hypusination inhibitor for the treatment of proliferative diseases,
including leukemia
 IN Bruemmendorf, Tim H.; Balabanov, Stefan; Hartmann, Ulrike; Kammer,
Winfried; Nordheim, Alfred
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|-------------|-------------|-----------------|----------|
| PI | WO 2005058320 | A1 | 20050630 | WO 2004-EP14439 | 20041217 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| | AU 2004298761 | A1 | 20050630 | AU 2004-298761 | 20041217 |
| | CA 2547196 | AA | 20050630 | CA 2004-2547196 | 20041217 |
| | EP 1696917 | A1 | 20060906 | EP 2004-804040 | 20041217 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| PRAI | US 2003-531563P | P | 20031219 | | |
| | WO 2004-EP14439 | W | 20041217 | | |
| IT | 152459-95-5 220127-57-1 | 855843-70-8 | | | |
| | 855843-71-9 | 855843-72-0 | 855843-73-1 | | |
| | 855843-74-2 | 855843-75-3 | 855843-76-4 | | |
| | 855843-77-5 | 855843-78-6 | 855843-79-7 | | |
| | 855843-80-0 | 855843-81-1 | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | | | | | |
| | | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 855843-70-8 CAPLUS
CN Butanediamide, N'-[5-[[4-[[5-(acetylhydroxymethyl)pentyl]amino]-1,4-dioxobutyl]hydroxymethyl]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 70-51-9
CMF C25 H48 N6 O8

PAGE 1-A



— (CH₂)₅—NH₂


RN 855843-71-9 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C₂₉ H₃₁ N₇ O



CM 2

CRN 29342-05-0

CMF C₁₂ H₁₇ N₂O₂




RN 855843-72-0 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C₂₉ H₃₁ N₇ O




CM 2

CRN 89149-10-0
CMF C17 H37 N7 O3


Absolute stereochemistry. Rotation (-).

RN 855843-73-1 CAPLUS
CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 30652-11-0
CMF C7 H9 N O2

10/519,722


RN 855843-74-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 150333-69-0

CMF C8 H20 N4



RN 855843-75-3 CAPLUS


CN Butanediamide, N'-(5-[[4-[(5-acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino)pentyl-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 70-51-9

CMF C25 H48 N6 O8

PAGE 1-A



PAGE 1-B

—(CH₂)₅-NH₂


CM 2

10/519,722

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4


CRN 75-75-2
CMF C H4 O3 S



RN 855843-76-4 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 29342-05-0
CMF C12 H17 N O2




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S

CM 3


10/519,722

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4

CRN 75-75-2
CMF C H4 O3 S




RN 855843-77-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 89149-10-0
CMF C17 H37 N7 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4


CRN 75-75-2
CMF C H4 O3 S



RN 855843-78-6 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 30652-11-0
CMF C7 H9 N O2




CM 2


CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S

CM 3


CRN 152459-95-5
CMF C29 H31 N7 O



CM 4

CRN 75-75-2
CMF C H4 O3 SRN 855843-79-7 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)


CM 1

CRN 150333-69-0
CMF C8 H20 N4

CM 2


CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5
CMF C29 H31 N7 O

CM 4


CRN 75-75-2
 CMF C H4 O3 S



RN 855843-80-0 CAPLUS
 CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.
 with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 201530-41-8
 CMF C21 H15 N3 O4



CM 2

CRN 152459-95-5
 CMF C29 H31 N7 O




RN 855843-81-1 CAPLUS
 CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.
 with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 201530-41-8
CMF C21 H15 N3 O4




CM 2

CRN 220127-57-1
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5
CMF C29 H31 N7 O



CM 4

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:369277 CAPLUS
 DN 142:430271
 TI Preparation of substituted benzazoles as inhibitors of raf kinase
 IN Ramurthy, Savithri; Subramanian, Sharadha; Verhagen, Joelle; Poon, Daniel J.; Hansen, Teresa; Shafer, Cynthia; McBride, Christopher; Levine, Barry H.; Costales, Abran; Renhowe, Paul A.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 185 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005037273 | A1 | 20050428 | WO 2004-US34179 | 20041015 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004281151 | A1 | 20050428 | AU 2004-281151 | 20041015 |
| | CA 2542653 | AA | 20050428 | CA 2004-2542653 | 20041015 |
| | US 2005192287 | A1 | 20050901 | US 2004-967089 | 20041015 |
| | EP 1682126 | A1 | 20060726 | EP 2004-795357 | 20041015 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-511966P | P | 20031016 | | |
| | WO 2004-US34179 | W | 20041015 | | |
| OS | MARPAT 142:430271 | | | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of substituted benzazoles as inhibitors of raf kinase) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:369221 CAPLUS
 DN 142:430024
 TI Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
 IN Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc

PA Cytovia, Inc., USA
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2


DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005037196 | A2 | 20050428 | WO 2004-US32570 | 20041005 |
| | WO 2005037196 | A3 | 20051013 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| PRAI | US 2003-508290P | P | 20031006 | | |
| OS | MARPAT 142:430024 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 2-arylmethylene-N,N'-diarylmalonamides
and analogs as activators of caspases and inducers of apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



L5 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:324144 CAPLUS
 DN 142:392431
 TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation
 IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia; Liu, Yi; Schoepfer, Joseph; Steensma, Ruo
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005033086 | A1 | 20050414 | WO 2004-US32473 | 20040930 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004278413 | A1 | 20050414 | AU 2004-278413 | 20040930 |
| | CA 2539339 | AA | 20050414 | CA 2004-2539339 | 20040930 |
| | US 2005171105 | A1 | 20050804 | US 2004-956412 | 20040930 |
| | EP 1670771 | A1 | 20060621 | EP 2004-789483 | 20040930 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-507592P | P | 20030930 | | |
| | WO 2004-US32473 | W | 20040930 | | |
| OS | MARPAT 142:392431 | | | | |
| IT | 850087-62-6P, N-[3-[(2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl)amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide
850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[(2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl)amino]phenyl]benzamide
850087-74-0P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[(2-(pyrimidin-4-yl)phenyl)amino]phenyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors) | | | | |
| RN | 850087-62-6 CAPLUS | | | | |
| CN | Benzamide, N-[3-[(2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME) | | | | |

PAGE 1-A




PAGE 1-B

Me

RN 850087-68-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[(4-trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 850087-74-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-(4-pyrimidinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:323779 CAPLUS
DN 142:397824
TI Biocompatibly coated medical implants
IN Rathenow, Jorg; Ban, Andreas; Kunstmann, Jurgen; Mayer, Bernhard; Asgari,
Soheil
PA Germany
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of Appl. No. PCT/EP04/04985.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | US 2005079200 | A1 | 20050414 | US 2004-938995 | 20040910 |
| | DE 10322182 | A1 | 20041202 | DE 2003-10322182 | 20030516 |
| | DE 10324415 | A1 | 20041216 | DE 2003-10324415 | 20030528 |
| | DE 10333098 | A1 | 20050210 | DE 2003-10333098 | 20030721 |
| | WO 2004101017 | A2 | 20041125 | WO 2004-EP4985 | 20040510 |
| | WO 2004101017 | A3 | 20050303 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| PRAI | DE 2003-10322182 | A | 20030516 | | |
| | DE 2003-10324415 | A | 20030528 | | |
| | DE 2003-10333098 | A | 20030721 | | |
| | WO 2004-EP4985 | A2 | 20040510 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatibly coated medical implants) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:158528 CAPLUS

DN 142:254620

TI Use of c-kit inhibitors for treating type II diabetes

IN Moussy, Alain; Kinet, Jean-Pierre

PA Ab Science, Fr.

SO PCT Int. Appl., 126 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005016323 | A2 | 20050224 | WO 2004-IB2934 | 20040816 |
| | WO 2005016323 | A3 | 20050407 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | CA 2535242 | AA | 20050224 | CA 2004-2535242 | 20040816 |
| | EP 1653934 | A2 | 20060510 | EP 2004-769332 | 20040816 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-495088P | P | 20030815 | | |
| | WO 2004-IB2934 | W | 20040816 | | |
| OS | MARPAT 142:254620 | | | | |
| IT | 152459-95-5P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (c-kit inhibitor; use of potent, selective and non-toxic c-kit inhibitors for treating type diabetes, obesity and related diseases) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 42 OF 106 CAPIUS COPYRIGHT 2006 ACS on STN
 AN 2005:99470 CAPIUS
 DN 142:197889
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf,
 VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
 IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005009961 | A2 | 20050203 | WO 2004-US23500 | 20040722 |
| | WO 2005009961 | A3 | 20050331 | | |
| | WO 2005009961 | B1 | 20050602 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004259760 | A1 | 20050203 | AU 2004-259760 | 20040722 |
| | CA 2532865 | AA | 20050203 | CA 2004-2532865 | 20040722 |
| | US 2005038080 | A1 | 20050217 | US 2004-895985 | 20040722 |
| | EP 1663978 | A2 | 20060607 | EP 2004-786091 | 20040722 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | NO 2006000870 | A | 20060407 | NO 2006-870 | 20060222 |
| PRAI | US 2003-489102P | P | 20030723 | | |
| | US 2004-540326P | P | 20040202 | | |
| | WO 2004-US23500 | W | 20040722 | | |
| IT | 220127-57-1, STI-571 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph
urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated
diseases) | | | | |
| RN | 220127-57-1 CAPIUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


10/519,722

CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S




L5 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:17705 CAPLUS
DN 142:148113
TI Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations
AU Wong, S.; McLaughlin, J.; Cheng, D.; Zhang, C.; Shokat, K. M.; Witte, O. N.
CS Molecular Biology Interdepartmental Ph.D. Program, University of California, Los Angeles, CA, 90095, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2004), 101(50), 17456-17461
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H₄ O₃ SRE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| L5 | ANSWER 44 OF 106 CAPLUS | COPYRIGHT 2006 ACS on STN | | |
|--|---|---------------------------|------------------|----------|
| AN | 2004:1127387 | CAPLUS | | |
| DN | 142:74600 | | | |
| TI | Heteroaryl-fused pyrimidinyl compounds, including thieno[3,2-d]pyrimidine derivatives, with KSP-inhibiting activity, and their preparation, pharmaceutical compositions, and use as anticancer agents | | | |
| IN | Wang, Weibo; Lagniton, Liana M.; Constantine, Ryan N.; Burger, Matthew T. | | | |
| PA | Chiron Corporation, USA | | | |
| SO | PCT Int. Appl., 59 pp. | | | |
| | CODEN: PIXXD2 | | | |
| DT | Patent | | | |
| LA | English | | | |
| FAN.CNT 1 | | | | |
| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| ----- | ----- | ----- | ----- | ----- |
| PI WO 2004111058 | A1 | 20041223 | WO 2004-US16954 | 20040527 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| US 2005065169 | A1 | 20050324 | US 2004-850429 | 20040521 |
| AU 2004247650 | A1 | 20041223 | AU 2004-247650 | 20040527 |
| CA 2526217 | AA | 20041223 | CA 2004-2526217 | 20040527 |
| EP 1636238 | A1 | 20060322 | EP 2004-753729 | 20040527 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1798749 | A | 20060705 | CN 2004-80014819 | 20040527 |
| PRAI US 2003-474684P | P | 20030530 | | |

10/519,722


WO 2004-US16954 W 20040527
OS MARPAT 142:74600
IT 152459-95-5, Imatinib 220127-57-1, Gleevec
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic coadministration with; preparation of thieno[3,2-d]
pyrimidine derivs. as KSP inhibitors for use as anticancer
agents)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1080793 CAPLUS
DN 142:32971
TI Methods and compounds for the treatment of vascular stenosis using a
combination of N-phenyl-2-pyrimidine derivatives and PI3K

inhibitors


IN Sukhatme, Vikas P.
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004108130 | A1 | 20041216 | WO 2004-US17273 | 20040601 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | CA 2528032 | AA | 20041216 | CA 2004-2528032 | 20040601 |
| | EP 1635815 | A1 | 20060322 | EP 2004-753981 | 20040601 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-475295P | P | 20030603 | | |
| | WO 2004-US17273 | W | 20040601 | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (Imatinib mesylate; methods and compds. for treatment of vascular
stenosis using combination of N-phenyl-2-pyrimidine derivs.
and PI3K inhibitors) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| | CM 1 | | | | |
| | CRN 152459-95-5 | | | | |
| | CMF C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 46 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1060780 CAPLUS
 DN 142:38275
 TI Preparation of N-phenyl-2-pyrimidine-amine derivatives as anticancer agents and process for the preparation thereof
 IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-Chul; Lee, Sun-Ahe; Han, Byoung-Cheol
 PA Il Yang Pharm. Co., Ltd., S. Korea
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 446,446, abandoned.
 CODEN: USXXCO
 DT Patent
 LA English

FAN.CNT 3


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2004248918 | A1 | 20041209 | US 2004-806834 | 20040322 |
| PRAI | KR 2003-28669 | A | 20030506 | | |
| | US 2003-446446 | B2 | 20030528 | | |
| OS | MARPAT 142:38275 | | | | |
| IT | 796738-20-OP, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-23-3P, 4-[(4-Methylhomopiperazin-1-ylamino)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-25-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-28-8P, 4-(4-Methylhomopiperazin-1-ylaminomethyl)-N-[2-methyl-5-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-32-4P
, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P, 4-(4-Methylhomopiperazin-1-ylaminomethyl)-N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-40-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
796738-42-6P, 4-(4-Methylhomopiperazin-1-ylaminomethyl)-N-[4-methoxy-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide 796738-44-8P
, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,
4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P, 4-(4-Methylhomopiperazin-1-ylaminomethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P, 4-(Piperidin-1-ylmethyl)-N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
804554-75-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
804554-76-5P, 4-[(4-Methylhomopiperazin-1-ylamino)methyl]-N-[4-methyl- | | | | |

3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-77-6P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-78-7P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-methyl-
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-80-1P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-81-2P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-84-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-85-6P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methoxy-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-86-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-87-8P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[2-fluoro-5-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-88-9P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-fluoro-
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-90-3P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-fluoro-3-[[4-
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-91-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-92-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-
 yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 804554-94-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-95-8P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 804554-98-1P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)


RN 796738-20-0 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-
 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-23-3 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-25-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-28-8 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-32-4 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-34-6 CAPLUS


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS

CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




10/519,722


RN 796738-47-1 CAPLUS
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[([(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 796738-54-0 CAPLUS
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-56-2 CAPLUS
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

10/519,722

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 804554-75-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-76-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3

CMF C29 H32 N8 O




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 804554-77-6 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl-, monomethanesulfonate
 (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5
CMF C30 H33 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S

10/519,722


RN 804554-78-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-80-1 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4


CMF C29 H31 N7 O



CM 2

10/519,722


CRN 75-75-2
CMF C H4 O3 S



RN 804554-81-2 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6
CMF C28 H30 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-84-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-40-4
CMF C30 H33 N7 O2



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-85-6 CAPLUS
CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-42-6
CMF C29 H32 N8 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 804554-86-7 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]-4-

10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl] -, monomethanesulfonate
(9CI) (CA INDEX NAME)


CM 1

CRN 796738-44-8
CMF C29 H30 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-87-8 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-47-1
CMF C28 H28 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-88-9 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-50-6
CMF C28 H29 F N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-90-3 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-54-0
CMF C28 H28 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 804554-91-4 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-56-2
CMF C29 H30 F N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



10/519,722


RN 804554-92-5 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-58-4


CMF C28 H28 N6 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-94-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0

CMF C30 H33 N7 O




CM 2

CRN 64-19-7

10/519, 722


CMF C2 H4 O2



RN 804554-95-8 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 804554-98-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

AN 2004:1036851 CAPLUS
 DN 142:696
 TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
 IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
 PA Hybridon, Inc., USA
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|---------|----------|-----------------|----------|
| PI | WO 2004103301 | A2 | 20041202 | WO 2004-US15313 | 20040514 |
| | WO 2004103301 | A3 | 20051103 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | AU 2004241093 | A1 | 20041202 | AU 2004-241093 | 20040514 |
| | CA 2526212 | AA | 20041202 | CA 2004-2526212 | 20040514 |
| | US 2005009773 | A1 | 20050113 | US 2004-846167 | 20040514 |
| | EP 1628531 | A2 | 20060301 | EP 2004-752345 | 20040514 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| PRAI | US 2003-471247P | P | 20030516 | | |
| | WO 2004-US15313 | W | 20040514 | | |
| OS | MARPAT | 142:696 | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (immunostimulatory oligonucleotide and/or immunomer combination with
chemotherapeutic agent for synergistic cancer treatment) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| | CM 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |




CRN 75-75-2
 CMF C H4 O3 S




L5 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:996162 CAPLUS
 DN 141:424205
 TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for their preparation
 IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Cheol
 PA Il Yang Pharm. Co. Ltd., S. Korea
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004099187 | A1 | 20041118 | WO 2004-KR611 | 20040319 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | KR 2004095155 | A | 20041112 | KR 2004-17594 | 20040316 |
| OS | KR 2003-28669 | A | 20030506 | | |
| IT | MARPAT 141:424205 | | | | |
| | 796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide
796738-23-3P, 4-[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[(4-(pyridin-3-yl)pyrimidin-2-yl)amino]phenyl]benzamide | | | | |
| RL | ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents) | | | | |
| RN | 796738-20-0 CAPLUS | | | | |
| CN | Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 796738-23-3 CAPLUS


CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
796738-24-4P, 4-[[[4-Methylhomopiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonateRL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)RN 796738-22-2 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-24-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2

CRN 75-75-2


CMF C H4 O3 S



IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-28-8P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P
 , 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,
 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,
 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS


CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[([(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS
 CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-29-9P, 4-[[4-Methylhomopiperazin-1-yl]amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-35-7P, 4-[[4-Methylhomopiperazin-1-yl]amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-43-7P, 4-[[4-Methylhomopiperazin-1-yl]amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-51-7P, 4-[[4-Methylhomopiperazin-1-yl]amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-55-1P, 4-[(4-Methylhomopiperazin-1-

yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-62-0P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-65-3P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 796738-28-8
CMF C29 H32 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-33-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-32-4
CMF C29 H31 N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-35-7 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6
 CMF C28 H30 N8 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 796738-41-5 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-40-4
 CMF C30 H33 N7 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-
[[[(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-

10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 796738-44-8
CMF C29 H30 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-48-2 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-47-1
CMF C28 H28 F N7 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-51-7 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-50-6
 CMF C28 H29 F N8 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 796738-55-1 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-54-0
 CMF C28 H28 F N7 O



10/519,722

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-57-3 CAPLUS
CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)
(CA INDEX NAME)


CM 1

CRN 796738-56-2
CMF C29 H30 F N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-59-5 CAPLUS
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-58-4
CMF C28 H28 N6 O

10/519,722



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-61-9 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0
CMF C30 H33 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[(4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 796738-65-3 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs.
related to imatinib mesylate as antitumor agents)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


10/519,722

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:996161 CAPLUS
DN 141:424204
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib mesylate, useful as antitumor agents, and process for the preparation thereof
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jn; Lee, Gong-Yeal; Kim, Hong-Youb; Woo, Seok-Hun; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Ceol
PA Il Yang Pharm Co., Ltd., S. Korea
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004099186 | A1 | 20041118 | WO 2003-KR1029 | 20030526 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003232650 | A1 | 20041126 | AU 2003-232650 | 20030526 |
| | KR 2004095155 | A | 20041112 | KR 2004-17594 | 20040316 |
| PRAI | KR 2003-28669 | A | 20030506 | | |
| | WO 2003-KR1029 | W | 20030526 | | |
| OS | MARPAT 141:424204 | | | | |
| IT | 796738-20-OP, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3- | | | | |

[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-23-3P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-24-4P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-22-2 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-24-4 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2


CRN 75-75-2

CMF C H4 O3 S




IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-28-8P, 4-[[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P
 (4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,
 4-[[4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,
 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-25-5 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS
 CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-32-4 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS
CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS
CN Benzamide, N-[4-methoxy-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS
 CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS
 CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS
 CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)




IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-29-9P, 4-[[[4-Methylpiperazin-1-yl]amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-35-7P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-43-7P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
 methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P,
 4-[[4-Methylpiperazin-1-yl]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-51-7P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-62-0P, 4-[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate
 796738-65-3P, 4-[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-27-7 CAPLUS
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)
 (CA INDEX NAME)


CM 1

CRN 796738-25-5
 CMF C30 H33 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 796738-29-9 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 796738-28-8
CMF C29 H32 N8 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-33-5 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-32-4
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 796738-35-7 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6


CMF C28 H30 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-41-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4


CMF C30 H33 N7 O2



10/519, 722

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-43-7 CAPLUS
CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[[(4-methyl-1-piperazinyl)amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-42-6
CMF C29 H32 N8 O2



CM 2


CRN 75-75-2
CMF C H4 O3 S




RN 796738-45-9 CAPLUS
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-44-8
CMF C29 H30 F N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 796738-48-2 CAPLUS
CN Benzamide, N-[2-fluoro-5-[(4-(3-pyridinyl)-2-pyrimidinylamino)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1
CMF C28 H28 F N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S

10/519,722


RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)amino]methyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-55-1 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-54-0


CMF C28 H28 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-57-3 CAPIUS

CN Benzamide, N-[4-fluoro-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-59-5 CAPIUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-58-4

CMF C28 H28 N6 O



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 796738-61-9 CAPLUS
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0
CMF C30 H33 N7 O



CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 796738-62-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[4-(3-

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3
CMF C29 H32 N8 O




CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 796738-65-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)amino]methyl-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs.
related to imatinib mesylate as antitumor agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:995984 CAPLUS
 DN 141:389290
 TI New calcitriol analogs and therapeutic use in treating mast cell associated diseases
 IN Moussy, Alain; Kinet, Jean-Pierre
 PA AB Science, Fr.
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2004098612 | A2 | 20041118 | WO 2004-IB1871 | 20040507 |
| | WO 2004098612 | A3 | 20050210 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI US 2003-468295P P 20030507
 US 2003-480224P P 20030623

OS MARPAT 141:389290


IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new calcitriol analogs and therapeutic use in treating mast cell associated diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965068 CAPLUS

DN 141:406114

TI Use of tyrosine kinase inhibitors for treating cerebral ischemia

IN Kinet, Jean-Pierre; Moussy, Alain

PA AB Science, Fr.

SO PCT Int. Appl., 117 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------------|----------|-----------------|----------|
| PI | WO 2004096225 | A2 | 20041111 | WO 2004-IB1874 | 20040428 |
| | WO 2004096225 | A3 | 20050310 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2523852 | AA | 20041111 | CA 2004-2523852 | 20040428 |
| | EP 1624873 | A2 | 20060215 | EP 2004-729952 | 20040428 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | US 2003-465789P | P | 20030428 | | |
| | WO 2004-IB1874 | W | 20040428 | | |
| OS | MARPAT | 141:406114 | | | |
| IT | 152459-95-5 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (tyrosine kinase inhibitors for treating cerebral ischemia) | | | | |
| RN | 152459-95-5 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) | (CA INDEX NAME) | | | |



L5 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:965067 CAPLUS
 DN 141:406039
 TI Combinations for the treatment of diseases involving cell proliferation,
 migration or apoptosis of myeloma cells, or angiogenesis
 IN Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke;
 Munzert, Gerd; Van Meel, Jacobus C. A.
 PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim
 Pharma G.m.b.H. & Co. K.-G.
 SO PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004096224 | A2 | 20041111 | WO 2004-EP4363 | 20040424 |
| | WO 2004096224 | A3 | 20041216 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG | | | | |
| | EP 1473043 | A1 | 20041103 | EP 2003-9587 | 20030429 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | AU 2004233576 | A1 | 20041111 | AU 2004-233576 | 20040424 |
| | CA 2523868 | AA | 20041111 | CA 2004-2523868 | 20040424 |
| | EP 1622619 | A2 | 20060208 | EP 2004-729366 | 20040424 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | BR 2004009919 | A | 20060425 | BR 2004-9919 | 20040424 |
| | NO 2005005605 | A | 20051128 | NO 2005-5605 | 20051128 |
| PRAI | EP 2003-9587 | A | 20030429 | | |
| | EP 2004-508 | A | 20040113 | | |
| | EP 2004-1171 | A | 20040121 | | |
| | WO 2004-EP4363 | W | 20040424 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (drug combinations for diseases involving cell proliferation and
migration or apoptosis or angiogenesis including protein tyrosine
kinase receptor antagonists and radiotherapy) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3- | | | | |

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878151 CAPLUS

DN 141:366243

TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
IN Guzi, Timothy J.; Paruch, Kamilus; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh Schering Corporation, USA; Pharmacopeia, Inc.PA SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004209878 | A1 | 20041021 | US 2004-776988 | 20040211 |
| | AU 2005212409 | A1 | 20050825 | AU 2005-212409 | 20050208 |
| | WO 2005077954 | A2 | 20050825 | WO 2005-US3859 | 20050208 |
| | WO 2005077954 | A3 | 20051013 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

| | | | | | |
|------|-----------------|----|----------|----------------|----------|
| | US 2006128725 | A1 | 20060615 | US 2005-245401 | 20051006 |
| PRAI | US 2002-408027P | P | 20020904 | | |
| | US 2002-421959P | P | 20021029 | | |
| | US 2003-654546 | A2 | 20030903 | | |
| | US 2004-776988 | A | 20040211 | | |
| | WO 2005-US3859 | W | 20050208 | | |

OS MARPAT 141:366243


IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors for treating cancer in combination of other
anticancer agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 S


| L5 | ANSWER 54 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN | | | |
|---|--|----------|-----------------|----------|
| AN | 2004:756710 CAPLUS | | | |
| DN | 141:277628 | | | |
| TI | Preparation of ureidophenoxycyanopyridines as anticancer drugs. | | | |
| IN | Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming | | | |
| PA | Bayer Pharmaceuticals Corporation, USA | | | |
| SO | PCT Int. Appl., 127 pp. | | | |
| | CODEN: PIXXD2 | | | |
| DT | Patent | | | |
| LA | English | | | |
| FAN.CNT | 4 | | | |
| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| ----- | ----- | ----- | ----- | ----- |
| PI WO 2004078747 | A1 | 20040916 | WO 2004-US6286 | 20040301 |
| WO 2004078747 | C1 | 20041104 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004235829 | A1 | 20041125 | US 2004-788029 | 20040227 |
| AU 2004217977 | A1 | 20040916 | AU 2004-217977 | 20040301 |
| CA 2517361 | AA | 20040916 | CA 2004-2517361 | 20040301 |
| US 2004229937 | A1 | 20041118 | US 2004-789446 | 20040301 |
| US 2005032798 | A1 | 20050210 | US 2004-788405 | 20040301 |
| US 2005038031 | A1 | 20050217 | US 2004-788426 | 20040301 |
| EP 1599467 | A1 | 20051130 | EP 2004-716144 | 20040301 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 BR 2004007897 A 20060301 BR 2004-7897 20040301
 JP 2006519264 T2 20060824 JP 2006-508977 20040301
 PRAI US 2003-450323P P 20030228
 US 2003-450324P P 20030228
 US 2003-450348P P 20030228
 WO 2004-US6286 A 20040301
 OS MARPAT 141:277628
 IT 220127-57-1, Gleevec
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of ureidophenoxycyanopyridines as anticancer
 drugs)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756044 CAPLUS
 DN 141:266048
 TI Medical implants with carbon-containing surfaces that are functionalized
 PA Blue Membranes GmbH, Germany
 SO Ger. Gebrauchsmusterschrift, 18 pp.
 CODEN: GGXXFR
 DT Patent
 LA German
 FAN.CNT 9


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

PI DE 202004009061 U1 20040916 DE 2004-202004009061 20040528
 DE 10324415 A1 20041216 DE 2003-10324415 20030528
 DE 10333098 A1 20050210 DE 2003-10333098 20030721
 DE 10333099 A1 20050210 DE 2003-10333099 20030721
 PRAI DE 2003-10324415 A1 20030528
 DE 2003-10333098 A1 20030721
 DE 2003-10333099 A1 20030721
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medical implants with carbon-containing surfaces that are functionalized)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:756043 CAPLUS
 DN 141:266047
 TI Medical implants coated with biocompatible carbon-containing layers
 PA Blue Membranes GmbH, Germany
 SO Ger. Gebrauchsmusterschrift, 23 pp.
 CODEN: GGXXFR
 DT Patent
 LA German
 FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|----------------------|----------|
| PI | DE 202004009060 | U1 | 20040916 | DE 2004-202004009060 | 20040510 |
| | DE 10322182 | A1 | 20041202 | DE 2003-10322182 | 20030516 |
| | DE 10324415 | A1 | 20041216 | DE 2003-10324415 | 20030528 |
| | DE 10333098 | A1 | 20050210 | DE 2003-10333098 | 20030721 |
| PRAI | DE 2003-10322182 | A1 | 20030516 | | |
| | DE 2003-10324415 | A1 | 20030528 | | |
| | DE 2003-10333098 | A1 | 20030721 | | |
| IT | 152459-95-5, Imatinib | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (medical implants coated with biocompatible carbon-containing layers) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



AN 2004:691283 CAPLUS
 DN 141:207230
 TI Preparation of imatinib and salts by reaction of N-(2-methyl-5-aminophenyl)-4-(3-pyridyl)-2-pyrimidinamine with 4-(4-methylpipеразинylmethyl)benzoyl halides.

IN Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra
 PA Cipla Limited, India
 SO Brit. UK Pat. Appl., 34 pp.
 CODEN: BAXXDU

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | GB 2398565 | A1 | 20040825 | GB 2003-3730 | 20030218 |
| | AU 2004213616 | A2 | 20040902 | AU 2004-213616 | 20040108 |
| | AU 2004213616 | A1 | 20040902 | | |
| | CA 2516370 | AA | 20040902 | CA 2004-2516370 | 20040108 |
| | WO 2004074502 | A2 | 20040902 | WO 2004-GB18 | 20040108 |
| | WO 2004074502 | A3 | 20041028 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1599462 | A2 | 20051130 | EP 2004-700728 | 20040108 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2004007672 | A | 20060301 | BR 2004-7672 | 20040108 |
| | JP 2006518360 | T2 | 20060810 | JP 2006-502181 | 20040108 |
| | US 2006173182 | A1 | 20060803 | US 2005-546193 | 20051031 |

PRAI GB 2003-3730 A 20030218
 WO 2004-GB18 A 20040108

OS CASREACT 141:207230


IT 152459-95-5P, Imatinib 220127-57-1P, Imatinib mesylate

744256-04-0P 744256-05-1P 744256-06-2P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (preparation of imatinib and salts by reaction of
 methylaminophenylpyridylpyrimidinamine with
 methylpipеразинylmethylbenzoyl halides)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA

10/519,722

INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 744256-04-0 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● x HBr


RN 744256-05-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 744256-06-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)




● 3 HCl


● H₂ORE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| | | | | |
|---------------|--|----------|-----------------|----------|
| L5 | ANSWER 58 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN | | | |
| AN | 2004:650874 CAPLUS | | | |
| DN | 141:167761 | | | |
| TI | Sensitizing cells for apoptosis by selectively blocking cytokines | | | |
| IN | Stassi, Giorgio; Todaro, Matilde | | | |
| PA | Italy | | | |
| SO | Eur. Pat. Appl., 30 pp. | | | |
| | CODEN: EPXXDW | | | |
| DT | Patent | | | |
| LA | English | | | |
| FAN.CNT 1 | | | | |
| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| ----- | ---- | ----- | ----- | ----- |
| PI EP 1444989 | A1 | 20040811 | EP 2003-2603 | 20030207 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| AU 2004210432 | A1 | 20040819 | AU 2004-210432 | 20040209 |
| CA 2515302 | AA | 20040819 | CA 2004-2515302 | 20040209 |
| WO 2004069274 | A2 | 20040819 | WO 2004-EP1177 | 20040209 |
| WO 2004069274 | A3 | 20041111 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1592449 A2 20051109 EP 2004-709222 20040209
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006519190 T2 20060824 JP 2006-501781 20040209
 PRAI EP 2003-2603 A 20030207
 WO 2004-EP1177 W 20040209
 IT 220127-57-1, STI571
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (CPG57148B; sensitizing cells for apoptosis by blocking cytokines)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O




CM 2

 CRN 75-75-2
 CMF C H4 O3 S


L5 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:565086 CAPLUS
 DN 141:123632
 TI Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as
 activators of caspases and inducers of apoptosis
 IN Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong;
 Kemnitzer, William E.
 PA Cytovia, Inc., USA
 SO PCT Int. Appl., 97 pp.


CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004058253 | A1 | 20040715 | WO 2003-US40308 | 20031218 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004127521 | A1 | 20040701 | US 2003-737865 | 20031218 |
| | CA 2509224 | AA | 20040715 | CA 2003-2509224 | 20031218 |
| | AU 2003303373 | A1 | 20040722 | AU 2003-303373 | 20031218 |
| | EP 1581213 | A1 | 20051005 | EP 2003-808469 | 20031218 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1756547 | A | 20060405 | CN 2003-80106440 | 20031218 |
| | JP 2006516250 | T2 | 20060629 | JP 2004-563731 | 20031218 |
| PRAI | US 2002-433953P | P | 20021218 | | |
| | WO 2003-US40308 | W | 20031218 | | |
| OS | MARPAT 141:123632 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
CMF C H4 O3 S



L5 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:559502 CAPLUS

DN 141:190802

TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors

IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-yu; James, Ray A.; Bishop, W. Robert; Wang, James J.-S.; Desai, Jagdish A.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 731 pp., Cont.-in-part of U.S. Ser. No. 85,896.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| | US 2002198216 | A1 | 20021226 | US 2001-940811 | 20010828 |
| | US 2003229099 | A1 | 20031211 | US 2002-85896 | 20020227 |
| | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| PRAI | US 2001-940811 | A2 | 20010828 | | |
| | US 2002-85896 | A2 | 20020227 | | |
| | US 2002-325896 | A | 20021219 | | |
| | US 2000-229183P | P | 20000830 | | |

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of tricyclic antitumor agents as farnesyl protein transferase inhibitors for treatment of cancer and other proliferative diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S



L5 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:513393 CAPLUS
 DN 141:71544
 TI Preparation of substituted benzazoles as Raf kinase inhibitors
 IN Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard
 PA USA
 SO U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.

CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004122237 | A1 | 20040624 | US 2003-675927 | 20030929 |
| | US 2004087626 | A1 | 20040506 | US 2003-405945 | 20030331 |
| | US 7071216 | B2 | 20060704 | | |
| | AU 2004277405 | A1 | 20050414 | AU 2004-277405 | 20040929 |
| | CA 2539748 | AA | 20050414 | CA 2004-2539748 | 20040929 |
| | WO 2005032548 | A1 | 20050414 | WO 2004-US32161 | 20040929 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1675584 | A1 | 20060705 | EP 2004-789345 | 20040929 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRAI | JP 2006193533 | A2 | 20060727 | JP 2006-96143 | 20060330 |
| | US 2002-369066P | P | 20020329 | | |
| | US 2003-405945 | A2 | 20030331 | | |
| | JP 2003-579810 | A3 | 20030331 | | |
| | US 2003-675927 | A | 20030929 | | |
| | WO 2004-US32161 | W | 20040929 | | |

OS MARPAT 141:71544


IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of substituted benzazoles as Raf kinase inhibitors for use in combination with other antitumor agents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(3-

(9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:467883 CAPLUS

DN 141:38627

TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.

PA Chiron Corporation, USA

SO PCT Int. Appl., 151 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004048365 | A1 | 20040610 | WO 2003-US37294 | 20031121 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2507100 | AA | 20040610 | CA 2003-2507100 | 20031121 |
| | AU 2003295776 | A1 | 20040618 | AU 2003-295776 | 20031121 |
| | US 2004176385 | A1 | 20040909 | US 2003-719896 | 20031121 |
| | EP 1575940 | A1 | 20050921 | EP 2003-786980 | 20031121 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003016485 | A | 20051011 | BR 2003-16485 | 20031121 |
| | CN 1735607 | A | 20060215 | CN 2003-80108239 | 20031121 |
| | JP 2006514118 | T2 | 20060427 | JP 2005-510381 | 20031121 |
| | NO 2005002927 | A | 20050708 | NO 2005-2927 | 20050615 |
| PRAI | US 2002-428473P | P | 20021121 | | |
| | US 2003-438568P | P | 20030107 | | |
| | US 2003-523081P | P | 20031119 | | |
| | WO 2003-US37294 | W | 20031121 | | |
| OS | MARPAT 141:38627 | | | | |
| IT | 152459-95-5, Imatinib 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:452964 CAPLUS

DN 141:1206

TI Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

IN Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.

PA Sugen, Inc., USA

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2004045523 | A2 | 20040603 | WO 2003-US36526 | 20031114 |
| | WO 2004045523 | A3 | 20040930 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 NL 1024779 A1 20040518 NL 2003-1024779 20031114
 NL 1024779 C2 20041109
 CA 2506308 AA 20040603 CA 2003-2506308 20031114
 AU 2003290943 A1 20040615 AU 2003-290943 20031114
 US 2004152759 A1 20040805 US 2003-712296 20031114
 EP 1562600 A2 20050817 EP 2003-783527 20031114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015630 A 20050823 BR 2003-15630 20031114
 CN 1711089 A 20051221 CN 2003-80103225 20031114
 JP 2006508981 T2 20060316 JP 2004-553729 20031114
 NO 2005002578 A 20050527 NO 2005-2578 20050527
 PRAI US 2002-426386P P 20021115
 WO 2003-US36526 W 20031114
 OS MARPAT 141:1206
 IT 152459-95-5, Imatinib
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as chemotherapeutic agent; cancer therapy using combination
 administration of indolinone compds. with chemotherapeutic agents for
 cell proliferation disorders)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:419904 CAPLUS
 DN 142:70669
 TI Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors
 AU Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik
 CS Axxima Pharmaceuticals AG, Munchen, 81377, Germany
 SO Chemistry & Biology (2004), 11(5), 691-701
 CODEN: CBOLE2; ISSN: 1074-5521
 PB Cell Press
 DT Journal
 LA English
 IT 220127-57-1, STI571
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (characterization of a conserved structural determinant controlling protein kinase inhibitor sensitivity)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:331787 CAPLUS

DN 140:350538

TI Treatment of tuberous sclerosis associated neoplasms with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase inhibitors, especially N-phenyl-2-pyrimidineamines

IN Arbiser, Jack

PA USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004077661 | A1 | 20040422 | US 2003-655407 | 20030904 |
| | CA 2439440 | AA | 20040305 | CA 2003-2439440 | 20030903 |
| PRAI | US 2002-408550P | P | 20020905 | | |
| OS | MARPAT 140:350538 | | | | |
| IT | 152459-95-5 152459-95-5D, acceptable salts
220127-57-1 | | | | |
| | RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tuberous sclerosis-associated neoplasms treatment with platelet-derived
growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase | | | | |

inhibitors, especially N-Ph-2-pyrimidineamines)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:269996 CAPLUS
 DN 140:303691
 TI Preparation and pharmaceutical compositions of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyvoor Moopil; Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
 PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2004026229 | A2 | 20040401 | WO 2003-US27491 | 20030903 |
| WO 2004026229 | A3 | 20040617 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2497544 | AA | 20040401 | CA 2003-2497544 | 20030903 |
| AU 2003298571 | A1 | 20040408 | AU 2003-298571 | 20030903 |
| EP 1534712 | A2 | 20050601 | EP 2003-796321 | 20030903 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1701073 | A | 20051123 | CN 2003-824701 | 20030903 |
| JP 2006502184 | T2 | 20060119 | JP 2004-537708 | 20030903 |
| NZ 539161 | A | 20060526 | NZ 2003-539161 | 20030903 |
| ZA 2005001846 | A | 20050912 | ZA 2005-1846 | 20050303 |
| PRAI US 2002-408029P | P | 20020904 | | |
| WO 2003-US27491 | W | 20030903 | | |
| OS MARPAT 140:303691 | | | | |
| IT 220127-57-1, Gleevec | | | | |
| RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin
dependent kinases in the presence of prepared pyrazolopyrimidines) | | | | |
| RN 220127-57-1 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM 1 | | | | |
| CRN 152459-95-5 | | | | |
| CMF C29 H31 N7 O | | | | |




CM 2


CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:268055 CAPLUS
 DN 140:385622
 TI Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro
 AU Houghton, Peter J.; Germain, Glen S.; Harwood, Franklin C.; Schuetz, John D.; Stewart, Clinton F.; Buchdunger, Elisabeth; Traxler, Peter
 CS Tennessee, Memphis, St. Jude Children's Research Hospital, Departments of Molecular Pharmacology, Memphis, TN, 38105-2794, USA
 SO Cancer Research (2004), 64(7), 2333-2337
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1; Imatinib Mesylate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (imatinib mesylate is a potent inhibitor of ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[4-(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:267339 CAPLUS
 DN 140:303700
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan K.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English


FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004026877 | A1 | 20040401 | WO 2003-US29209 | 20030919 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499756 | AA | 20040401 | CA 2003-2499756 | 20030919 |
| | AU 2003272476 | A1 | 20040408 | AU 2003-272476 | 20030919 |
| | EP 1543008 | A1 | 20050622 | EP 2003-754658 | 20030919 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1694886 | A | 20051109 | CN 2003-825177 | 20030919 |
| | JP 2006507253 | T2 | 20060302 | JP 2004-537904 | 20030919 |
| | ZA 2005002375 | A | 20050927 | ZA 2005-2375 | 20050322 |
| PRAI | US 2002-412997P | P | 20020923 | | |
| | WO 2003-US29209 | W | 20030919 | | |
| OS | MARPAT 140:303700 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3- | | | | |

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267335 CAPLUS
DN 140:287379
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.
PA Schering Corporation, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004026872 | A1 | 20040401 | WO 2003-US29841 | 20030917 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499593 | AA | 20040401 | CA 2003-2499593 | 20030917 |
| | AU 2003270846 | A1 | 20040408 | AU 2003-270846 | 20030917 |

| | | | | |
|--|--------|----------|----------------|----------|
| US 2004097516 | A1 | 20040520 | US 2003-664337 | 20030917 |
| EP 1539750 | A1 | 20050615 | EP 2003-752559 | 20030917 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1681816 | A | 20051012 | CN 2003-822011 | 20030917 |
| JP 2006503060 | T2 | 20060126 | JP 2004-538405 | 20030917 |
| NZ 538595 | A | 20060428 | NZ 2003-538595 | 20030917 |
| ZA 2005002271 | A | 20050919 | ZA 2005-2271 | 20050317 |
| PRAI US 2002-412138P | P | 20020919 | | |
| WO 2003-US29841 | W | 20030917 | | |
| OS MARPAT 140:287379 | | | | |
| IT 220127-57-1, Gleevec | | | | |
| RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin
dependent kinases in the presence of prepared pyrazolopyridines) | | | | |
| RN 220127-57-1 | CAPIUS | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 70 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267330 CAPLUS
DN 140:303698
TI Preparation and pharmaceutical compositions of novel imidazopyridines as
cyclin dependent kinase inhibitors
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.;
Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.
PA Schering Corporation, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXDD

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004026867 | A2 | 20040401 | WO 2003-US29498 | 20030917 |
| | WO 2004026867 | A3 | 20040805 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499639 | AA | 20040401 | CA 2003-2499639 | 20030917 |
| | AU 2003295332 | A1 | 20040408 | AU 2003-295332 | 20030917 |
| | US 2004097517 | A1 | 20040520 | US 2003-664338 | 20030917 |
| | US 6992080 | B2 | 20060131 | | |
| | EP 1539756 | A2 | 20050615 | EP 2003-786514 | 20030917 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1703414 | A | 20051130 | CN 2003-825047 | 20030917 |
| | JP 2006507254 | T2 | 20060302 | JP 2004-538237 | 20030917 |
| | US 2006030555 | A1 | 20060209 | US 2005-238597 | 20050929 |
| PRAI | US 2002-412063P | P | 20020919 | | |
| | US 2003-664338 | A3 | 20030917 | | |
| | WO 2003-US29498 | W | 20030917 | | |
| OS | MARPAT 140:303698 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




L5 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:267246 CAPLUS
 DN 140:303696
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--------|----------|-----------------|----------|
| PI | WO 2004026310 | A1 | 20040401 | WO 2003-US29456 | 20030919 |
| | WO 2004026310 | C1 | 20050630 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499874 | AA | 20040401 | CA 2003-2499874 | 20030919 |
| | AU 2003275031 | A1 | 20040408 | AU 2003-275031 | 20030919 |
| | US 2004072835 | A1 | 20040415 | US 2003-666424 | 20030919 |
| | EP 1542693 | A1 | 20050622 | EP 2003-759300 | 20030919 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1694706 | A | 20051109 | CN 2003-825102 | 20030919 |
| | JP 2006503838 | T2 | 20060202 | JP 2004-538213 | 20030919 |
| | ZA 2005002380 | A | 20050927 | ZA 2005-2380 | 20050322 |
| PRAI | US 2002-412906P | P | 20020923 | | |
| | WO 2003-US29456 | W | 20030919 | | |
| OS | MARPAT 140:303696 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines) | | | | |
| RN | 220127-57-1 | CAPLUS | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S





RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:252622 CAPLUS
DN 140:283386
TI Crystal structure of human PIM-1 kinase and complexes with AMP-PNP and use
in drug screening and design
IN Bremer, Ryan; Ibrahim, Prabha; Kumar, Abhinav; Mandiyan, Valsan; Milburn,
Michael V.
PA Plexxikon, Inc., USA
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English

| FAN.CNT 2 | | KIND | DATE | APPLICATION NO. | DATE |
|-----------|--|--|----------|-----------------|----------|
| PI | PATENT NO. | A2 | 20040325 | WO 2003-US29415 | 20030916 |
| | WO 2004024895 | A3 | 20050609 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA | 2503905 | AA | 20040325 | CA 2003-2503905 | 20030916 |
| AU | 2003272548 | A1 | 20040430 | AU 2003-272548 | 20030916 |
| US | 2004142864 | A1 | 20040722 | US 2003-664421 | 20030916 |
| EP | 1558751 | A2 | 20050803 | EP 2003-754735 | 20030916 |
| R: | AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK, | GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| CN | 1701122 | A | 20051123 | CN 2003-825157 | 20030916 |
| PRAT | US 2002-411398P | P | 20020916 | | |


US 2002-412341P P 20020920
 WO 2003-US29415 W 20030916
 IT 220127-57-1, Imatinib mesylate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystal structure of human PIM-1 kinase and complexes with AMP-PNP and
 use in drug screening and design)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



L5 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:252351 CAPLUS
 DN 140:264488
 TI Combination of a benzamide derivative and a histone deacetylase inhibitor for the treatment of leukemia
 IN Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong
 PA Virginia Commonwealth University, USA; McGuire Va Medical Center 111k
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2004024160 | A1 | 20040325 | WO 2003-IB4053 | 20030910 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | |


RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR
CA 2498210 AA 20040325 CA 2003-2498210 20030910
AU 2003259521 A1 20040430 AU 2003-259521 20030910
BR 2003014112 A 20050712 BR 2003-14112 20030910
EP 1553948 A1 20050720 EP 2003-795175 20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1681505 A 20051012 CN 2003-821763 20030910
JP 2006501267 T2 20060112 JP 2004-535791 20030910
US 2006100140 A1 20060511 US 2005-527553 20050909
PRAI US 2002-410286P P 20020913
US 2002-411344P P 20020918
WO 2003-IB4053 W 20030910
IT 152459-95-5 220127-57-1, Glivec
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of histone deacetylase inhibitor and antitumor benzamide
derivative for treatment of leukemia)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:220336 CAPLUS
 DN 140:270873
 TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.;
 Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.;
 Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;
 Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min;
 James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs,
 Douglas Walsh
 PA Schering Corporation, USA; Pharmacopeia, Inc.
 SO PCT Int. Appl., 609 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004022561 | A1 | 20040318 | WO 2003-US27555 | 20030903 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE,
SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2497440 | AA | 20040318 | CA 2003-2497440 | 20030903 |
| | AU 2003263071 | A1 | 20040329 | AU 2003-263071 | 20030903 |
| | EP 1537116 | A1 | 20050608 | EP 2003-794592 | 20030903 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003014001 | A | 20050705 | BR 2003-14001 | 20030903 |
| | JP 2006502163 | T2 | 20060119 | JP 2004-534487 | 20030903 |
| | CN 1735614 | A | 20060215 | CN 2003-824997 | 20030903 |
| | NO 2005001647 | A | 20050603 | NO 2005-1647 | 20050404 |
| PRAI | US 2002-408027P | P | 20020904 | | |
| | US 2002-421959P | P | 20021029 | | |
| | WO 2003-US27555 | W | 20030903 | | |
| OS | MARPAT 140:270873 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
kinase inhibitors for treating cancer in combination of other
anticancer agents) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:220335 CAPLUS
 DN 140:270872
 TI Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
 PA Schering Corporation, USA; Pharmacopeia, Inc.; Pharmacopeia Drug Discovery, Inc.
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2004022560 | A1 | 20040318 | WO 2003-US27502 | 20030903 |
| | WO 2004022560 | C2 | 20050707 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2497450 | AA | 20040318 | CA 2003-2497450 | 20030903 |

AU 2003268385 A1 20040329 AU 2003-268385 20030903
 US 2004116442 A1 20040617 US 2003-653868 20030903
 US 7074924 B2 20060711 EP 2003-749347 20030903
 EP 1534710 A1 20050601 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1701074 A 20051123 CN 2003-824779 20030903
 JP 2006502161 T2 20060119 JP 2004-534459 20030903
 NZ 539164 A 20060428 NZ 2003-539164 20030903
 ZA 2005001852 A 20050908 ZA 2005-1852 20050303
 US 2006173016 A1 20060803 US 2006-395824 20060331
 PRAI US 2002-407999P P 20020904
 US 2003-653868 A3 20030903
 WO 2003-US27502 W 20030903
 OS MARPAT 140:270872
 IT 220127-57-1, Gleevec
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticancer agent, combination therapy; preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents)
 RN 220127-57-1 CAPPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:218528 CAPLUS
 DN 140:247038
 TI Use of specific inhibitors of tyrosine kinases for immunomodulation
 IN Zitvogel, Laurence; Auclair, Christian; Tursz, Thomas


PA Institut Gustave Roussy Igr, Fr.
 SO Fr. Demande, 50 pp.
 CODEN: FRXXBL

DT Patent
 LA French
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|---|-----------------|----------|
| PI- | FR 2844452 | A1 | 20040319 | FR 2002-11545 | 20020918 |
| | WO 2004026311 | A2 | 20040401 | WO 2003-FR2744 | 20030917 |
| | WO 2004026311 | A3 | 20040812 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | AU 2003276351 | A1 | 20040408 | AU 2003-276351 | 20030917 |
| PRAI | FR 2002-11545 | A | 20020918 | | |
| | WO 2003-FR2744 | W | 20030917 | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| | (use of specific inhibitors of tyrosine kinases for immunomodulation) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:100803 CAPLUS
 DN 140:139483
 TI Method for enhancing the effectiveness of therapies of hyperproliferative diseases
 IN Chang, Yan; Sasak, Vodek
 PA USA
 SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|--------|----------|-----------------|----------|
| PI US 2004023925 | A1 | 20040205 | US 2003-408723 | 20030407 |
| US 2003013681 | A1 | 20030116 | US 2002-176235 | 20020620 |
| US 6680306 | B2 | 20040120 | | |
| CN 1543351 | A | 20041103 | CN 2002-816003 | 20020621 |
| US 2004043962 | A1 | 20040304 | US 2003-657383 | 20030908 |
| AU 2004229399 | A1 | 20041028 | AU 2004-229399 | 20040407 |
| CA 2521649 | AA | 20041028 | CA 2004-2521649 | 20040407 |
| WO 2004091634 | A1 | 20041028 | WO 2004-US10675 | 20040407 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG | | | | |
| EP 1617849 | A1 | 20060125 | EP 2004-759200 | 20040407 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| JP 2006522163 | T2 | 20060928 | JP 2006-509773 | 20040407 |
| PRAI US 2001-299991P | P | 20010621 | | |
| US 2002-176235 | A2 | 20020620 | | |
| US 2003-408723 | A | 20030407 | | |
| US 2003-461006P | P | 20030407 | | |
| US 2003-474562P | P | 20030530 | | |
| WO 2004-US10675 | W | 20040407 | | |
| IT 152459-95-5, Imatinib | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method for enhancing effectiveness of therapies of hyperproliferative
diseases) | | | | |
| RN 152459-95-5 | CAPLUS | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




L5 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:20664 CAPLUS
 DN 140:77165
 TI Preparation of 4-[[(4-methyl-1-piperazinyl)methyl]benzamide for treatment of leukemia
 IN Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru
 PA Nippon Shinyaku Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--------------|--------------|-----------------|----------|
| PI | WO 2004002963 | A1 | 20040108 | WO 2003-JP8192 | 20030627 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2490907 | AA | 20040108 | CA 2003-2490907 | 20030627 |
| | AU 2003246100 | A1 | 20040119 | AU 2003-246100 | 20030627 |
| | BR 2003012288 | A | 20050412 | BR 2003-12288 | 20030627 |
| | EP 1533304 | A1 | 20050525 | EP 2003-738555 | 20030627 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1678590 | A | 20051005 | CN 2003-820146 | 20030627 |
| | US 2006014742 | A1 | 20060119 | US 2004-519722 | 20041228 |
| PRAI | JP 2002-189269 | A | 20020628 | | |
| | JP 2002-305146 | A | 20021018 | | |
| | JP 2002-377937 | A | 20021226 | | |
| | WO 2003-JP8192 | W | 20030627 | | |
| OS | MARPAT | 140:77165 | | | |
| IT | 641614-84-8P | 641614-88-2P | 641614-92-8P | | |
| | 641614-95-1P | 641615-19-2P | | | |
| | RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia) | | | | |
| RN | 641614-84-8 | CAPLUS | | | |
| CN | Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 641614-88-2 CAPLUS
 CN Benzamide, N-[3-((4,5'-bipyrimidin)-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-92-8 CAPLUS
 CN Benzamide, N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 641614-95-1 CAPLUS
 CN Benzamide, N-[3-((4,5'-bipyrimidin)-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 641615-19-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[[3-((4,5'-bipyrimidin)-2-ylamino)-4-methylphenyl]amino]carbonyl]-2-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




| | | | |
|----|--------------|--------------|--------------|
| IT | 641614-83-7P | 641614-85-9P | 641614-86-0P |
| | 641614-87-1P | 641614-89-3P | 641614-90-6P |
| | 641614-91-7P | 641614-93-9P | 641614-94-0P |
| | 641614-96-2P | 641614-97-3P | 641614-98-4P |
| | 641614-99-5P | 641615-00-1P | 641615-01-2P |
| | 641615-02-3P | 641615-03-4P | 641615-04-5P |
| | 641615-05-6P | 641615-06-7P | 641615-07-8P |
| | 641615-08-9P | 641615-09-0P | 641615-10-3P |
| | 641615-11-4P | 641615-12-5P | 641615-13-6P |
| | 641615-14-7P | 641615-15-8P | 641615-16-9P |
| | 641615-17-0P | 641615-18-1P | 641615-20-5P |
| | 641615-21-6P | 641615-22-7P | 641615-23-8P |
| | 641615-24-9P | 641615-25-0P | 641615-26-1P |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


BN 641614-83-7 CAPIUS

AN 041614-83-7 CAFILED
CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS

CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-86-0 CAPLUS

CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-87-1 CAPLUS

CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl}-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-89-3 CAPLUS

CN Benzamide, 3-bromo-4-[{(4-methyl-1-piperazinyl)methyl}-N-[4-methyl-3-[(4-pyrazinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-90-6 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[{(4-methyl-1-piperazinyl)methyl}- (9CI) (CA INDEX NAME)




RN 641614-91-7 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[{(4-methyl-1-piperazinyl)methyl}- (9CI) (CA INDEX NAME)




RN 641614-93-9 CAPLUS

CN Benzamide, 3-bromo-N-[3-[(4-(1,2-dihydro-4-pyridazinyl)-2-pyrimidinyl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-94-0 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridazinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-96-2 CAPLUS

CN Benzamide, N-[3-[(3,4'-bipyridin)-2'-ylamino]-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-97-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(5-pyridinyl)-2-pyridinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-98-4 CAPLUS

CN Benzamide, N-[3-(3,3'-bipyridin)-5-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-99-5 CAPLUS

CN Benzamide, N-[3-(3,3'-bipyridin)-5-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-00-1 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[3-(3-pyridinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-01-2 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[6-(3-pyridinyl)pyrazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-02-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(5-(3-pyridinyl)-1,2,4-triazin-3-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-03-4 CAPLUS

CN Benzamide, 3-methyl-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-04-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 641615-05-6 CAPLUS


CN Benzamide, 3-methoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-06-7 CAPLUS
 CN Benzamide, 3,5-dibromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-07-8 CAPLUS
 CN Benzamide, 3,5-dimethoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-08-9 CAPLUS
 CN 1,3-Benzenedicarboxamide, N3,N3-dimethyl-4-[(4-methyl-1-piperazinyl)methyl]-N1-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-09-0 CAPLUS
 CN Benzamide, 3-bromo-4-[(4-ethyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-10-3 CAPIUS
 CN Benzamide, 3-bromo-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-[(4-propyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-11-4 CAPIUS
 CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-12-5 CAPIUS
 CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-13-6 CAPIUS
 CN Benzamide, 3-bromo-4-[(1-pyrrolidinylmethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-14-7 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-15-8 CAPLUS


CN Benzamide, 3-bromo-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-16-9 CAPLUS

CN Benzamide, 3-bromo-4-[(3R,5S)-3,5-dimethyl-1-piperazinylmethyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 641615-17-0 CAPLUS
 CN Benzamide, 3-bromo-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-18-1 CAPLUS
 CN Benzamide, N-[3-[[4,5'-bipyrimidin]-2-ylamino]-4-methylphenyl]-3-bromo-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-20-5 CAPLUS
 CN Benzamide, N-[3-[[4,5'-bipyrimidin]-2-ylamino]-4-methylphenyl]-4-(1-piperazinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641615-21-6 CAPLUS

CN Benzoic acid, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]amino]carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 641615-22-7 CAPLUS

CN Benzamide, 3-cyano-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-23-8 CAPLUS


CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 641615-24-9 CAPLUS


CN Benzamide, N-[3-[(4,5'-bipyrimidin)-2-ylamino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 641615-25-0 CAPLUS

CN Benzamide, N-[3-[(4-(5-bromo-3-pyridinyl)-2-pyrimidinyl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 641615-26-1 CAPLUS

CN Benzamide, N-[3-((4,5'-bipyrimidinyl)-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 641614-88-2


CMF C29 H29 F3 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:971730 CAPLUS
 DN 140:27844
 TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors
 IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu; James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.
 PA USA
 SO U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S. Pat. Appl. 2002 198,216.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2003229099 | A1 | 20031211 | US 2002-85896 | 20020227 |
| | US 2002198216 | A1 | 20021226 | US 2001-940811 | 20010828 |
| | US 2004122018 | A1 | 20040624 | US 2002-325896 | 20021219 |
| | CA 2477328 | AA | 20030904 | CA 2003-2477328 | 20030225 |
| | WO 2003072549 | A1 | 20030904 | WO 2003-US5479 | 20030225 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003215389 | A1 | 20030909 | AU 2003-215389 | 20030225 |
| | BR 2003008071 | A | 20041221 | BR 2003-8071 | 20030225 |
| | EP 1492772 | A1 | 20050105 | EP 2003-711214 | 20030225 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1630641 | A | 20050622 | CN 2003-804720 | 20030225 |
| | JP 2005525356 | T2 | 20050825 | JP 2003-571255 | 20030225 |
| | ZA 2004006807 | A | 20050829 | ZA 2004-6807 | 20040826 |
| | NO 2004004053 | A | 20041126 | NO 2004-4053 | 20040924 |
| PRAI | US 2000-229183P | P | 20000830 | | |
| | US 2001-940811 | A2 | 20010828 | | |
| | US 2002-85896 | A2 | 20020227 | | |
| | US 2002-325896 | A | 20021219 | | |
| | WO 2003-US5479 | W | 20030225 | | |
| OS | MARPAT 140:27844 | | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |

10/519,722

(co-administration; preparation of tricyclic compds. as farnesyl protein transferase inhibitors for treating cancer in combination with other agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:917665 CAPLUS

DN 140:156958

TI Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

AU Nimmanapalli, Ramadevi; Bali, Purva; O'Bryan, Erica; Fuino, Lianne; Guo, Fei; Wu, Jie; Houghton, Peter; Bhalla, Kapil

CS Interdisciplinary Oncology Program, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, FL, USA

SO Cancer Research (2003), 63(22), 7950-7958

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

IT 220127-57-1, Imatinib mesylate


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells)

RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:912990 CAPLUS
 DN 139:375014
 TI Methods and compositions with N-phenyl-2-pyrimidine compounds inhibiting platelet derived growth factor receptor for the treatment of graft failure
 IN Sukhatme, Vikas P.
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------|------|--|------------------|----------|
| PI WO 2003094904 | A1 | 20031120 | WO 2003-US314916 | 20030513 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| AU 2003232115 | A1 | 20031111 | AU 2003-232115 | 20030513 |
| CA 2490989 | AA | 20031120 | CA 2003-2490989 | 20030513 |
| EP 1509219 | A1 | 20050302 | EP 2003-750120 | 20030513 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | |

10/519,722


JP 2005533019 T2 20051104 JP 2004-502990 20030513
US 2005261283 A1 20051124 US 2005-514322 20050719
PRAI US 2002-380180P P 20020513
US 2003-464023P P 20030418
WO 2003-US14916 W 20030513
OS MARPAT 139:375014
IT 152459-95-5 220127-57-1, Imatinib mesylate
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth
factor receptor for treatment of graft failure)
RN 152459-95-5 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:892800 CAPLUS

DN 139:395950

TI Preparation of substituted pyrazines as protein kinase modulators

IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PA Exelixis, Inc., USA

SO PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003093297 | A2 | 20031113 | WO 2003-US13869 | 20030502 |
| | WO 2003093297 | A3 | 20040701 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2484209 | AA | 20031113 | CA 2003-2484209 | 20030502 |
| | AU 2003234464 | A1 | 20031117 | AU 2003-234464 | 20030502 |
| | EP 1501514 | A2 | 20050202 | EP 2003-728690 | 20030502 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005530760 | T2 | 20051013 | JP 2004-501436 | 20030502 |
| | US 2006211709 | A1 | 20060921 | US 2005-513081 | 20050727 |
| PRAI | US 2002-377933P | P | 20020503 | | |
| | WO 2003-US13869 | W | 20030502 | | |


OS MARPAT 139:395950

IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



TI Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis

IN Debatin, Klaus Michael; Fulda, Simone

PA Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany

SO Eur. Pat. Appl., 19 pp.


CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 1354952 | A1 | 20031022 | EP 2002-8199 | 20020417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | EP 1354953 | A1 | 20031022 | EP 2002-15499 | 20020712 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | WO 2003086470 | A2 | 20031023 | WO 2003-EP4039 | 20030417 |
| | WO 2003086470 | A3 | 20040506 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003236211 | A1 | 20031027 | AU 2003-236211 | 20030417 |
| | EP 1495124 | A2 | 20050112 | EP 2003-722503 | 20030417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005536457 | T2 | 20051202 | JP 2003-583486 | 20030417 |
| | US 2005222387 | A1 | 20051006 | US 2005-511037 | 20050119 |
| PRAI | EP 2002-8199 | A | 20020417 | | |
| | EP 2002-15499 | A | 20020712 | | |
| | WO 2003-EP4039 | W | 20030417 | | |
| IT | 220127-57-1, STI571 | | | | |
| | RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) | | | | |
| | (therapeutic combination with SMAC peptide; Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| | CM 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |




CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


- L5 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:809105 CAPLUS
 DN 140:122306
 TI Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine
 -Type Small Molecule Kinase Inhibitors
 AU von Bubnoff, Nikolas; Veach, Darren R.; Miller, W. Todd; Li, Wanqing;
 Saenger, Jana; Peschel, Christian; Bornmann, William G.; Clarkson, Bayard;
 Duyster, Justus
 CS Department of Internal Medicine III, Technical University of Munich,
 Munich, Germany
 SO Cancer Research (2003), 63(19), 6395-6404
 CODEN: CNREAB; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1, Glivec
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibition of wild-type and mutant Bcr-Abl by pyrido-
 pyrimidine-type small mol. kinase inhibitors in relation to
 leukemia treatment)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O




CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:796477 CAPLUS
 DN 139:307759
 TI Preparation of substituted benzazoles as Raf kinase inhibitors
 IN Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry
 Haskell, Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl,
 Wendy
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 259 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2003082272 | A1 | 20031009 | WO 2003-US10117 | 20030331 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2480638 | AA | 20031009 | CA 2003-2480638 | 20030331 |
| | AU 2003226211 | A1 | 20031013 | AU 2003-226211 | 20030331 |
| | EP 1499311 | A1 | 20050126 | EP 2003-745683 | 20030331 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003008854 | A | 20050222 | BR 2003-8854 | 20030331 |
| | CN 1655779 | A | 20050817 | CN 2003-812193 | 20030331 |
| | JP 2005529089 | T2 | 20050929 | JP 2003-579810 | 20030331 |
| | NO 2004004617 | A | 20041228 | NO 2004-4617 | 20041026 |

JP 2006193533 A2 20060727 JP 2006-96143 20060330
 PRAI US 2002-369066P P 20020329
 JP 2003-579810 A3 20030331
 WO 2003-US10117 W 20030331
 OS MARPAT 139:307759
 IT 152459-95-5, Imatinib
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of substituted benzazoles as Raf kinase inhibitors for use in
 combination with other antitumor agents)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:696780 CAPLUS
 DN 139:219397
 TI N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
 IN Prescott, Margaret Forney; Feldman, David Louis
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003072159 | A1 | 20030904 | WO 2003-EP2028 | 20030227 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | CA 2477558 | 20030227 |
| | CA 2477558 | AA | 20030904 | CA 2003-2477558 | 20030227 |
| | AU 2003214079 | A1 | 20030909 | AU 2003-214079 | 20030227 |
| | EP 1480688 | A1 | 20041201 | EP 2003-709729 | 20030227 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | BR 2003008053 | 20030227 |
| | BR 2003008053 | A | 20041228 | BR 2003-8053 | 20030227 |
| | JP 2005519080 | T2 | 20050630 | JP 2003-570902 | 20030227 |
| | CN 1638823 | A | 20050713 | CN 2003-804788 | 20030227 |
| | NO 2004004093 | A | 20041124 | NO 2004-4093 | 20040927 |
| | US 2005209244 | A1 | 20050922 | US 2005-505398 | 20050429 |
| PRAI | US 2002-360254P | P | 20020228 | | |
| | WO 2003-EP2028 | W | 20030227 | | |
| IT | 152459-95-5 | | | | |

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (piperazino-methylbenzoylamido pyridylpyrimidineamine coated stents)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:696536 CAPLUS
 DN 139:207765
 TI Combinations comprising N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and at least one telomerase inhibitor for treating proliferative diseases
 IN Tauchi, Tetsuzo
 PA Novartis AG, Switz.
 SO U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO
 DT Patent
 LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 2003166660 | A1 | 20030904 | US 2002-272837 | 20021017 |
| | US 7045523 | B2 | 20060516 | | |
| | US 2006111365 | A1 | 20060525 | US 2006-332406 | 20060113 |
| PRAI | GB 2001-25105 | A | 20011018 | | |
| | GB 2002-15583 | A | 20020704 | | |
| | US 2002-272837 | A3 | 20021017 | | |

IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, salts
 220127-57-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combinations comprising imatinib and at least one telomerase inhibitor
 for treating proliferative diseases)

RN 152459-95-5 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519, 722

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:639686 CAPLUS

DN 140:139030

TI Leflunomide analogue FK778 is vaso protective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection

AU Savikko, Johanna; von Willebrand, Eva; Haeyry, Pekka

CS Transplantation Laboratory, Haartman Institute, Helsinki Univ. Central Hospital, Helsinki, Finland

SO Transplantation (2003), 76(3), 455-458

CODEN: TRPLAU; ISSN: 0041-1337

PB Lippincott Williams & Wilkins

DT Journal


LA English

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (leflunomide analog FK778 is vaso protective independent of its
 immunosuppressive effect in relation to imatinib)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:633685 CAPLUS

DN 139:180080

TI Preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivatives

IN Loiseleur, Olivier; Kaufmann, Daniel; Abel, Stephan; Buerger, Hans Michael; Meisenbach, Mark; Schmitz, Beat; Sedelmeier, Gottfried

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003066613 | A1 | 20030814 | WO 2003-EP1188 | 20030206 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| | CA 2474738 | AA | 20030814 | CA 2003-2474738 | 20030206 |
| | AU 2003244444 | A1 | 20030902 | AU 2003-244444 | 20030206 |
| | EP 1474408 | A1 | 20041110 | EP 2003-737319 | 20030206 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003007529 | A | 20041221 | BR 2003-7529 | 20030206 |
| | CN 1630648 | A | 20050622 | CN 2003-803556 | 20030206 |
| | JP 2005528340 | T2 | 20050922 | JP 2003-565987 | 20030206 |
| | NO 2004003685 | A | 20041105 | NO 2004-3685 | 20040903 |
| | US 2006142580 | A1 | 20060629 | US 2005-503538 | 20050120 |
| PRAI | GB 2002-2873 | A | 20020207 | | |
| | WO 2003-EP1188 | W | 20030206 | | |
| OS | MARPAT 139:180080 | | | | |
| IT | 152459-95-5P | | | | |
| | RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) | | | | |
| | (preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.) | | | | |

RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610246 CAPLUS

DN 139:154937

TI Treatment of rheumatoid arthritis

IN Joensuu, Heikki

PA Hyks-Instituutti Oy, Finland

SO PCT Int. Appl., 16 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003063844 | A2 | 20030807 | WO 2003-EP802 | 20030127 |
| | WO 2003063844 | A3 | 20040401 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| | CA 2473158 | AA | 20030807 | CA 2003-2473158 | 20030127 |
| | EP 1471916 | A2 | 20041103 | EP 2003-704474 | 20030127 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003007286 | A | 20041228 | BR 2003-7286 | 20030127 |
| | CN 1646130 | A | 20050727 | CN 2003-802880 | 20030127 |
| | JP 2005526022 | T2 | 20050902 | JP 2003-563538 | 20030127 |
| | ZA 2004005323 | A | 20050620 | ZA 2004-5323 | 20040705 |
| | NO 2004003585 | A | 20041021 | NO 2004-3585 | 20040827 |
| PRAI | GB 2002-1882 | A | 20020128 | | |
| | WO 2003-EP802 | W | 20030127 | | |
| IT | 152459-95-5 220127-57-1 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of rheumatoid arthritis with piperazinylmethylpyridinylpyrimidinylaminophenylbenzamide) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[{(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C₂₉ H₃₁ N₇ O

CM 2

CRN 75-75-2

CMF C H₄ O₃ S

L5 ANSWER 91 OF 106. CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:355612 CAPLUS

DN 138:362649

TI Treatment of cancer with anti-ErbB2 antibodies

IN Sliwkowski, Mark X.

PA Genentech, Inc., USA

SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4.

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------|-------|----------|-----------------|----------|
| ----- | ----- | ----- | ----- | ----- |
| PI US 2003086924 | A1 | 20030508 | US 2002-268501 | 20021010 |
| US 6949245 | B1 | 20050927 | US 2000-602812 | 20000623 |
| US 2004013667 | A1 | 20040122 | US 2003-608626 | 20030627 |
| US 2005208043 | A1 | 20050922 | US 2005-44749 | 20050127 |
| US 2005238640 | A1 | 20051027 | US 2005-154465 | 20050616 |


10/519,722

| | | | | |
|---|----|----------|----------------|----------|
| US 2006034842 | A1 | 20060216 | US 2005-223361 | 20050909 |
| US 2006073143 | A1 | 20060406 | US 2005-222587 | 20050909 |
| AU 2005242195 | A1 | 20060112 | AU 2005-242195 | 20051207 |
| US 2006193854 | A1 | 20060831 | US 2006-429361 | 20060505 |
| US 2006198843 | A1 | 20060907 | US 2006-429043 | 20060505 |
| US 2006216285 | A1 | 20060928 | US 2006-429363 | 20060505 |
| PRAI US 1999-141316P | P | 19990625 | | |
| US 2000-602812 | A2 | 20000623 | | |
| AU 2000-57632 | A3 | 20000623 | | |
| US 2002-268501 | A2 | 20021010 | | |
| US 2005-44749 | A1 | 20050127 | | |
| IT 220127-57-1, Imatinib mesylate | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (as tyrosine kinase inhibitor in combination with anti-ErbB2
antibodies; cancer treatment with anti-ErbB2 antibodies) | | | | |
| RN 220127-57-1 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:334888 CAPLUS

DN 138:358163

TI Use of tyrosine kinase inhibitors for promoting hair growth

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 33 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|--|-----------------|----------|
| PI | WO 2003035050 | A2 | 20030501 | WO 2002-IB4290 | 20020920 |
| | WO 2003035050 | A3 | 20040527 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | CA 2461182 | AA | 20030501 | CA 2002-2461182 | 20020920 |
| | EP 1461032 | A2 | 20040929 | EP 2002-801980 | 20020920 |
| | | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | |
| | JP 2005507917 | T2 | 20050324 | JP 2003-537617 | 20020920 |
| | US 2004242612 | A1 | 20041202 | US 2004-490334 | 20040322 |
| PRAI | US 2001-323314P | P | 20010920 | | |
| | WO 2002-IB4290 | W | 20020920 | | |
| OS | MARPAT 138:358163 | | | | |
| IT | 152459-95-5 | | | | |
| | RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (use of tyrosine kinase inhibitors for promoting hair growth) | | | | |
| RN | 152459-95-5 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinylamino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



L5 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:273844 CAPLUS
 DN 139:345426
 TI A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against ST1571-resistant Bcr-abl Mutants
 AU Huron, David R.; Gorre, Mercedes E.; Kraker, Alan J.; Sawyers, Charles L.; Rosen, Neal; Moasser, Mark M.
 CS Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA
 SO Clinical Cancer Research (2003), 9(4), 1267-1273
 CODEN: CCREF4; ISSN: 1078-0432
 PB American Association for Cancer Research
 DT Journal
 LA English
 IT 220127-57-1, ST1571
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel pyridopyrimidine inhibitor (PD166326) of Bcr-abl tyrosine kinase

10/519, 722

is effective against STI571-resistant Bcr-abl mutants in chronic myelogenous leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242116 CAPLUS

DN 138:265640

TI Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 13

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2003024386 | A2 | 20030327 | WO 2002-IB4236 | 20020920 |
| | WO 2003024386 | A3 | 20040205 | | |
| | WO 2003024386 | C1 | 20040624 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2460845 AA 20030327 CA 2002-2460845 20020920
 EP 1427379 A2 20040616 EP 2002-767812 20020920
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005511506 T2 20050428 JP 2003-528285 20020920
 US 2004242601 A1 20041202 US 2004-490348 20040322
 PRAI US 2001-323315P P 20010920
 WO 2002-IB4236 W 20020920
 OS MARPAT 138:265640
 IT 152459-95-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of potent, selective and non toxic c-kit inhibitors for treating
 interstitial cystitis)
 RN 152459-95-5 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:133053 CAPLUS
 DN 138:163522
 TI Use of c-Src inhibitors alone or in combination with ST1571 for the treatment of leukaemia
 IN Donato, Nicholas J.; Fabbro, Doriano; Manley, Paul William; Mestan, Juergen; Warmuth, Markus; Hallek, Michael; Talpaz, Moshe; Wu, Ji
 PA Novartis AG, Switz.; Novartis Pharma GmbH; GSF-National Research Institute for Environment and Health; The University of Texas System
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|--|----------------|
| PI | WO 2003013540 | A1 | 20030220 | WO 2002-EP8941 | 20020809 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR | |
| | CA 2450777 | AA | 20030220 | CA 2002-2450777 | 20020809 |
| | EP 1418917 | A1 | 20040519 | EP 2002-794592 | 20020809 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | CN 1523991 | 20020809 |
| | | | | A 20040825 | CN 2002-813696 |


| | | | | |
|---|----|----------|----------------|----------|
| JP 2005502643 | T2 | 20050127 | JP 2003-518549 | 20020809 |
| US 2004248906 | A1 | 20041209 | US 2004-485803 | 20040729 |
| US 2006074094 | A1 | 20060406 | US 2005-285664 | 20051122 |
| PRAI US 2001-311690P | P | 20010810 | | |
| WO 2002-EP8941 | W | 20020809 | | |
| US 2004-485803 | A3 | 20040729 | | |
| IT 152459-95-5 220127-57-1 | | | | |
| RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses) | | | | |
| (use of c-Src inhibitors alone or in combination with ST1571 for
leukemia treatment) | | | | |
| RN 152459-95-5 CAPLUS | | | | |
| CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME) | | | | |



RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/519,722

AN 2003:10878 CAPLUS
DN 138:395641
TI Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)
AU La Rosee, Paul; Corbin, Amie S.; Stoffregen, Eric P.; Deininger, Michael W.; Druker, Brian J.
CS Division of Hematology and Medical Oncology, Oregon Health and Sciences University Cancer Institute, Portland, OR, 97239, USA
SO Cancer Research (2002), 62(24), 7149-7153
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activity of Bcr-Abl kinase inhibitor PD180970 against Abl kinase domain mutations that cause resistance to imatinib mesylate)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
CM 1
CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:977959 CAPLUS
DN 138:51923
TI Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
IN Sawyers, Charles L.; Gorre, Mercedes E.; Shah, Neil Pravin; Nicoll, John

PA The Regents of the University of California, USA
 SO PCT Int. Appl., 129 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002102976 | A2 | 20021227 | WO 2002-US18729 | 20020614 |
| | WO 2002102976 | A3 | 20040805 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2450473 | AA | 20021227 | CA 2002-2450473 | 20020614 |
| | US 2003158105 | A1 | 20030821 | US 2002-171889 | 20020614 |
| | EP 1466174 | A2 | 20041013 | EP 2002-744318 | 20020614 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004537992 | T2 | 20041224 | JP 2003-506431 | 20020614 |
| PRAI | US 2001-298728P | P | 20010614 | | |
| | US 2001-331709P | P | 20011120 | | |
| | WO 2002-US18729 | W | 20020614 | | |
| IT | 220127-57-1, STI-571 | | | | |
| | RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |




CM 2

CRN 75-75-2
 CMF C H4 O3 S




L5 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:946113 CAPLUS
DN 138:24647
TI Preparation of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs as activators of caspases and inducers of apoptosis for treatment of cancer and other proliferative disorders
IN Cai, Sui Xiong; Zhang, Han-Zhong; Drewe, John; Kasibhatla, Shailaja
PA Cytovia, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-----------|----------|-----------------|----------|
| PI | WO 2002098425 | A1 | 20021212 | WO 2002-US17486 | 20020604 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1404329 | A1 | 20040407 | EP 2002-741817 | 20020604 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2005165053 | A1 | 20050728 | US 2003-477953 | 20031118 |
| PRAI | US 2001-295007P | P | 20010604 | | |
| | WO 2002-US17486 | W | 20020604 | | |
| OS | MARPAT | 138:24647 | | | |
| IT | 220127-57-1, Gleevec | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (coadministration agent; coadministration of (arylpropenoyl)-2(1H)-quinolinone caspases activators with known cancer therapeutic agents for treatment of cancer) | | | | |
| RN | 220127-57-1 CAPLUS | | | | |
| CN | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 152459-95-5 | | | | |
| CMF | C29 H31 N7 O | | | | |



CM 2

CRN 75-75-2
CMF C H4 O3 SRE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 99 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:946109 CAPLUS
 DN 138:24718
 TI Preparation of 4-substituted-1-(arylmethyldene)thiosemicarbazides and 4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases and inducers of apoptosis
 IN Cai, Sui Xiong; Nguyen, Bao Ngoc; Drewe, John; Reddy, P. Sanjeева; Kasibhatla, Shailaja; Pervin, Azra
 PA Cytovia, Inc., USA
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002098420 | A1 | 20021212 | WO 2002-US17108 | 20020531 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1399159 | A1 | 20040324 | EP 2002-734605 | 20020531 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2003045581 | A1 | 20030306 | US 2002-158827 | 20020603 |
| | US 6794400 | B2 | 20040921 | | |
| PRAI | US 2001-294641P | P | 20010601 | | |
| | WO 2002-US17108 | W | 20020531 | | |
| OS | MARPAT 138:24718 | | | | |
| IT | 220127-57-1, Gleevec | | | | |

10/519,722

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and
4-substituted-1-(arylcarbonyl)thiosemicarbazides for treating cancer in
combination with)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:778718 CAPLUS
DN 137:289046
TI Methods and compositions for enhancing pharmaceutical treatments
IN Newman, Michael J.; Dixon, William Ross
PA USA
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|------|----------------|-----------------|----------|
| PI US 2002147197 | A1 | 20021010 | US 2002-104549 | 20020320 |
| PRAI US 1999-158322P | P | 19991008 | | |
| | | US 2000-684293 | A2 | 20001006 |

OS MARPAT 137:289046
IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, derivs.,
analogs, and metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(methods and compns. for enhancing pharmaceutical treatments)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:675840 CAPLUS

DN 137:226590

TI Use of epothilone derivatives and a signal transduction inhibitor for the treatment of cancer

IN Buchdunger, Elisabeth; Heldin, Carl-Henrik; Oestman, Arne; Pietras, Kristian; O'Reilly, Terence; Rothermel, John David; Traxler, Peter; Wartmann, Markus

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Brandt, Ralf

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|--|-----------------|----------|
| PI | WO 2002067941 | A2 | 20020906 | WO 2002-EP2049 | 20020226 |
| | WO 2002067941 | A3 | 2003I120 | | |
| | WO 2002067941 | C1 | 2003I218 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | |
| | CA 2439268 | AA | 20020906 | CA 2002-2439268 | 20020226 |
| | EP 1385522 | A2 | 20040204 | EP 2002-744903 | 20020226 |
| | | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | |
| | BR 2002007649 | A | 20040309 | BR 2002-7649 | 20020226 |
| | CN 1511036 | A | 20040707 | CN 2002-805608 | 20020226 |

JP 2004527493 T2 20040909 JP 2002-567308 20020226
 NZ 527764 A 20060127 NZ 2002-527764 20020226
 ZA 2003006404 A 20040607 ZA 2003-6404 20030818
 NO 2003003769 A 20030825 NO 2003-3769 20030825
 US 2004132754 A1 20040708 US 2004-469367 20040218
 PRAI GB 2001-4840 A 20010227
 US 2001-339040P P 20011030
 WO 2002-EP2049 W 20020226
 OS MARPAT 137:226590
 IT 220127-57-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (STI 571; use of epothilone derivs. and a signal transduction inhibitor
 for the treatment of cancer)
 RN 220127-57-1 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



L5 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:593669 CAPLUS
 DN 138:198235
 TI Characterization of potent inhibitors of the Bcr-Abl and the c-kit
 receptor tyrosine kinases
 AU Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel;
 Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas;
 Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard
 CS Molecular Pharmacology and Chemistry Program, New York, NY, 10021, USA
 SO Cancer Research (2002), 62(15), 4244-4255
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal


10/519,722

LA English
IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(characterization of potent inhibitors of Bcr-Abl and the c-kit
receptor tyrosine kinases and their antitumor effect)
RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA
INDEX NAME)
CM 1
CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S




RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:465821 CAPLUS
DN 137:47211
TI Substituted 2-aryl-4-arylaminoimidines and analogs as activators of caspases and inducers of apoptosis, their preparation, and the use thereof as, e.g., anticancer agents
IN Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin, Azra
PA Cytovia, Inc., USA
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2002047690 | A1 | 20020620 | WO 2001-US47498 | 20011212 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002028922 A5 20020624 AU 2002-28922 20011212
 US 2003069239 A1 20030410 US 2001-12444 20011212
 US 6716851 B2 20040406
 EP 1351691 A1 20031015 EP 2001-990048 20011212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004097503 A1 20040520 US 2003-704448 20031110
 PRAI US 2000-254581P P 20001212
 US 2001-12444 A3 20011212
 WO 2001-US47498 W 20011212
 OS MARPAT 137:47211
 IT 438248-82-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[2-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted aryl(arylarnino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)
 RN 438248-82-9 CAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[2-(4-pyridinyl)-6-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:686951 CAPLUS
 DN 136:111944
 TI Bcr-Abl inhibition as a modality of CML therapeutics
 AU Buchdunger, E.; Matter, A.; Druker, B. J.
 CS Research Oncology, Novartis Pharma AG, Basel, CH-4002, Switz.
 SO Biochimica et Biophysica Acta, Reviews on Cancer (2001), 1551(1), M11-M18
 CODEN: BBACEU; ISSN: 0304-419X
 PB Elsevier B.V.
 DT Journal; General Review
 LA English
 IT 220127-57-1
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (STI 571; Bcr-Abl inhibition as modality of chronic myelogenous leukemia therapeutics)

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

379.57

547.16


STN INTERNATIONAL LOGOFF AT 13:50:07 ON 29 SEP 2006

10/519,722

RN 220127-57-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:380210 CAPLUS
DN 125:114681
TI Pyrimidine derivatives and processes for the preparation thereof
IN Zimmermann, Juerg
PA Ciba-Geigy Corporation, USA
SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|----------|-----------------|----------|
| PI US 5521184 | A | 19960528 | US 1994-234889 | 19940428 |
| CA 2148477 | AA | 19950413 | CA 1994-2148477 | 19940921 |
| PRAI CH 1992-1083 | A | 19920403 | | |
| US 1993-42322 | B2 | 19930402 | | |
| CH 1993-2966 | A | 19931001 | | |
| OS MARPAT 125:114681 | | | | |
| IT 152459-93-3P 152459-95-5P | | | | |
| RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidine derivs. as antitumor agents) | | | | |
| RN 152459-93-3 | CAPLUS | | | |